Foxg1 and Emx2 control of cortico-cerebral astrogenesis and Emx2 as a novel tool to suppress glioblastoma multiforme by Mallamaci, Antonio
  
SCUOLA	  INTERNAZIONALE	  SUPERIORE	  STUDI	  AVANZATI	  (SISSA)	  
INTERNATIONAL	  SCHOOL	  FOR	  ADVANCED	  STUDIES	  









Foxg1	  and	  Emx2	  control	  of	  cortico-­‐cerebral	  astrogenesis	  and	  








THESIS	  SUBMITTED	  FOR	  THE	  DEGREE	  OF	  “DOCTOR	  PHILOSOPHIAE”	  








	  	  	  	  Candidate:	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  Supervisor:	  




	  	   Cortico-­‐cerebral	  astrogenesis	  is	  a	  tightly	  regulated	  process.	  Astrocytic	  outputs	  mainly	   depend	   on	   two	   factors:	   progression	   of	  multipotent	   precursors	   towards	   the	  astroglial	   lineage	   and	   sizing	   of	   the	   astrogenic	   proliferating	   pool.	   Uncontrolled	  proliferation	  of	  astroglial	   cells	   in	  adult	  may	  give	   rise	   to	   severe	  pathologies,	   such	  as	  glioblastoma	  multiforme	  (GBM),	  for	  which	  no	  cure	  is	  presently	  available.	  	  	   The	  aim	  of	  this	  study	  was	  to	  study	  the	  role	  of	  two	  transcription	  factors,	  Foxg1	  and	   Emx2,	   in	   the	   regulation	   of	   mouse	   corticocerebral	   astrogenesis	   and	   to	   employ	  
Emx2	  as	  a	  possible	  therapeutical	  tool	  to	  counteract	  GBM.	  We	  addressed	  this	  issue	  by	  combined	  gain-­‐	  and	  loss-­‐of-­‐function	  methods,	  in	  vivo	  as	  well	  as	  in	  primary	  cultures	  of	  cortico-­‐cerebral	  precursors	  and	  of	  patients’	  GBM	  cell	  lines.	  	   We	   found	   that	  Foxg1	   antagonizes	   the	  commitment	  of	  early	  neural	   stem	  cells	  toward	   glial	   fate,	   while	   Emx2	   suppress	   the	   proliferation	   of	   astrocyte-­‐committed	  progenitors.	  We	  showed	  that	  Foxg1	  inhibits	  the	  transcription	  of	  the	  well-­‐known	  glial	  gene	  
Gfap,	   possibly	   by	   impacting	   the	   regulation	   of	   the	   gliogenic	   transactive	   pathways.	  Then,	  we	   found	   that	  Emx2	  overexpression	   in	  cortico-­‐cerebral	   stem	  cells	   shrunk	   the	  proliferating	   astrogenic	   pool,	   resulting	   in	   a	   severe	   reduction	   of	   the	   astroglial	  outcome.	  We	  showed	  that	  this	  was	  caused	  by	  EgfR	  and	  Fgf9	  downregulation	  and	  that	  both	   phenomena	   originated	   from	   exaggerated	   Bmp	   signaling	   and	   Sox2	   repression.	  Furthermore,	  we	  provided	  evidence	  that	  in	  vivo	  temporal	  progression	  of	  Emx2	  levels	  in	   cortico-­‐cerebral	   multipotent	   precursors	   contributes	   to	   confine	   the	   bulk	   of	  astrogenesis	  to	  postnatal	  life.	  Finally,	  we	  translated	  our	  findings	  on	  Emx2	  role	  in	  the	  normal	  astrogenesis	  to	  a	  possible	  gene	  therapy	  to	  suppress	  glioblastoma	  multiforme	  tumor.	  As	   for	  this	   last	  part	   of	   the	   study,	   we	   investigated	   the	   impact	   of	   Emx2	   overexpression	   on	   patient	  malignant	  cells	  in	  vitro	  as	  well	  as	  upon	  transplantation	  into	  mouse	  recipient	  brains.	  We	  discovered	  that	  Emx2	  overexpression	  induced	  the	  collapse	  of	  seven	  out	  of	  seven	  
in	   vitro	   tested	   glioblastoma	   cell	   lines.	   Moreover,	   it	   suppressed	   four	   out	   of	   four	   of	  these	  lines	  in	  vivo	  in	  short-­‐term	  approaches	  and	  it	  also	  increased	  the	  survival	  of	  GBM-­‐
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1.	   INTRODUCTION	  
	  
1.1	   Cortico-­‐cerebral	  astrogenesis	  
	  
1.1.1	   Spatio-­‐temporal	  articulation	  	  Glia	  constitutes	  10-­‐20%	  of	  the	  cells	   in	  the	  Drosophila	  nervous	  system	  and	  at	  least	   50%	   of	   the	   cells	   in	   the	   human	   brain	   (Herculano-­‐Houzel,	   2011;	   Rowitch	   and	  Kriegstein,	   2010).	   This	   suggests	   that	   glial	   cells	   exhibit	   important	   roles	   in	   the	  increasing	  complexity	  of	   the	  nervous	  system.	  Glial	  cells	  can	  be	  very	  heterogeneous:	  some	  particular	  cells	   showing	  macrophage-­‐like	   functions	  constitute	   the	   “microglia”,	  while	  astrocytes	  and	  oligodendrocytes	  are	  part	  of	  what	  is	  called	  “macroglia”.	  	  In	   particular,	   astrocytes	   play	   a	   wide	   range	   of	   roles	   in	   the	   central	   nervous	   system.	  They	  provide	  structural	  support,	  modulate	  the	  chemical	  environment	  by	  influencing	  water	   balance	   and	   ion	   distribution,	   and	   participate	   in	   the	   blood-­‐brain	   barrier	  maintainance.	  Astrocytes	  are	  also	  crucial	  for	  the	  development	  of	  neural	  circuits	  and	  provide	   support	   to	   the	   dynamic	  machinery	   underlying	   synapse	   formation,	   function	  and	   elimination.	   Indeed,	   they	   regulate	   calcium	   flux	   and	   also	   release	   and	   reuptake	  neuropeptides	   (Rowitch	   and	   Kriegstein,	   2010;	   Sloan	   and	   Barres,	   2014).	   It	   is	   not	  surprising	  that	  dysfunction	  of	  astrocyte	  development	  may	  lead	  to	  severe	  pathological	  states	  such	  as	  autism,	  schizophrenia	  and	  epilepsy.	  	  In	   the	   developing	   embryo,	   neuroepithelial	   cells	   give	   origin	   to	   both	   neurons	  and	  glial	  cells.	  For	  long	  time,	  these	  two	  populations	  were	  considered	  to	  derive	  from	  distinct	  precursor	  pools	  diverging	  early	  during	  development.	  Conversely,	  the	  process	  is	  more	  complex	  and	  articulated	  with	  what	  previously	  thought.	  Studying	  the	  roles	  of	  astrocytes	   in	   development	   and	   disease	   will	   be	   crucial	   to	   clarify	   the	   relationship	  among	  neurons	  and	  glia	  in	  the	  maturing	  brain	  (Molofsky	  et	  al.,	  2012).	  	  Numerous	   studies	   have	   shown	   that,	   even	   if	   committed	   progenitors	   may	  emerge	   very	   early	   during	   development,	   there	   is	   one	   single	   precursor	   population	  called	   radial	  glia	   (RG).	   This	   is	   now	   also	   considered	   as	  neural	   stem	  cells	   population	  (NSCs).	  Moreover,	  NSCs	  give	  rise	  to	  transit	  amplifying	  intermediate	  progenitors	  (IPCs)	  before	   generating	   one	   of	   the	   different,	   specific	   neural	   subtypes.	   Intermediate	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progenitors	  are	  lineage	  restricted	  and	  coexist	  not	  only	  in	  the	  embryo	  but	  also	  in	  some	  germinal	  regions	  in	  the	  adult	  (Kriegstein	  and	  Alvarez-­‐Buylla,	  2009).	  Everything	   begins	   in	   the	   ventricular	   zone	   (VZ),	   a	   defined	   region	   next	   to	  cerebral	   ventricles	   (Fig.	   I.1).	   As	   anticipated	   above,	   around	   E9-­‐E10	   in	   mouse,	  neuroepithelial	  cells	  start	  transforming	  themselves	  into	  RG	  cells,	  with	  contacts	  with	  both	  pial	  and	  ventricular	  surfaces,	  but	  cell	  bodies	  within	  the	  VZ.	  The	   lengthening	  of	  the	   pia-­‐directed	   radial	   process	   is	   associated	  with	   the	   progressive	   thickening	   of	   the	  cortex	  throughout	  neurogenesis.	  RG	  cells	  retain	  the	  capability	  to	  undergo	  interkinetic	  nuclear	  migration	  (INM)	  (Del	  Bene,	  2011).	  Such	  peculiar	  mitotic	  behaviour	  consists	  in	  nuclear	  movement	  at	  different	  the	  cell	  cycle	  phases.	  Analyzing	  step	  by	  step	  RG	  cells	  mitotic	  behaviour,	  nuclei	  going	  through	  the	  S-­‐phase,	  lay	  on	  a	  layer	  quite	  distant	  from	  the	   ventricle,	   while	   nuclei	   in	   M	   phase,	   align	   themselves	   along	   the	   surface	   of	   the	  ventricle,	  and	  finally	  nuclei	  in	  G1	  and	  G2	  phases	  pass	  through	  the	  mid	  region	  of	  M	  and	  S	  phases.	  This	  behavioural	  pattern	  results	  in	  the	  formation	  of	  a	  pseudostratified	  layer	  of	   cells	   (Kriegstein	   and	  Alvarez-­‐Buylla,	   2009).	  RG	   cells	   also	  undergo	   some	   relevant	  cytoskeletal	   modifications	   and	   the	   conversion	   of	   tight	   junctional	   complexes	   to	  adherens	   junctions.	   Moreover,	   they	   start	   to	   express	   specific	   genetic	   markers	   (e.g.:	  GLAST,	  RC2,	  Pax6	  and	  BLBP	  protein),	  which	  witnesses	  a	  common	  origin	  for	  neurons	  and	  glia.	  Firing	  of	  the	  Notch	  pathway	  takes	  place	  at	  high	  level	  close	  to	  the	  apical	  side	  in	   RG	   cells	   and	   seems	   fundamental	   to	   maintain	   RG	   cell	   identity	   and	   self-­‐renewal	  (Zhang	  et	  al.,	  2008).	   In	  addition	  to	  proliferative	  activity,	  RG	  can	  directly	  give	  rise	  to	  neurons,	   or,	   more	   frequently,	   to	   different	   pools	   of	   intermediate	   progenitors	   (IPCs),	  which	   are	   characterized	   by	   a	   continual	   proliferative	   activity	   even	   though	   they	   are	  already	  addressed	   to	  one	  specific	  differentiated	  progeny.	  Most	  of	   these	   IPCs	  do	  not	  perform	   INM	   and	   place	   themselves	   in	   the	   subventricular	   zone	   (SVZ)	   with	   different	  regional	  distribution	  coherently	  with	  the	  different	  areas	  in	  the	  developing	  brain.	  Taking	   into	  account	   the	  prenatal	   temporal	  window,	  around	  E11,	  early	   radial	  glial	   cells	   within	   dorsal	   telencephalon	   mainly	   generate	   neuronal	   intermediate	  
progenitors	  (nIPCs)	  which	  in	  turn	  will	  originate	  the	  almost	  totality	  of	  cortico-­‐cerebral	  
glutamatergic	  neurons.	   (Cortico-­‐cerebral	  gabaergic	  neurons	   are	   born	   in	   rodents	   by	  progenitors	   located	   in	  ventral	   telencephalon	  and	  rostral	  hypothalamus;	  however	   in	  primates	   a	   substantial	   fraction	   (circa	   2/3)	   also	   originates	   from	   cortico-­‐cerebral	  autochtonous	  progenitors).	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Figure	  I.1.	  Neurogenesis	  during	  cortical	  development	  (adapted	  from	  Kriegstein	  and	  




1.1.2	   Clonal	  articulation	  As	  already	  mentioned	  above,	  at	  some	  point	  in	  the	  developing	  embryo,	  neural	  stem	   cells	  must	   face	   the	   option	   to	   remain	   in	   a	   pluripotent	   self-­‐renewing	   cell	   state,	  enter	   neurogenesis	   and	   become	   new	   neurons,	   or	   shift	   into	   gliogenesis.	   Complex	  genetic	  mechanisms	  underlie	  such	  big	  decision.	  Indeed,	  one	  of	  the	  main	  goals	  of	  the	  studies	   in	   progress	   in	   the	  modern	   developmental	   genetics	   is	   to	   understand	  which	  specific	   molecular	   mechanisms	   (cell-­‐autonomous	   or	   not),	   signaling	   molecules	   and	  effector	   pathways	   are	   involved	   in	   the	   regulation	   of	   this	   hard	   decision	   so	   finely	  restricted	  in	  time	  and	  space	  (Fig.	  I.2).	  	  	  
Figure	  I.2.	  	  Cortico-­‐cerebral	  histogenesis	  	  	   Astrocytes	   are	   no	   longer	   seen	   as	   a	   homogenous	   population	   of	   cells.	   Fibrous	  astrocytes	  with	  the	  classic	  ‘‘star-­‐like’’	  appearance	  are	  usually	  present	  in	  white	  matter	  where	  their	  dense	  glial	  filaments	  are	  stained	  with	  the	  intermediate	  filament	  marker	  GFAP.	   When	   they	   are	   in	   close	   proximity	   to	   capillaries	   they	   physically	   connect	   to	  capillary	   walls	   with	   their	   prolongations	   known	   as	   "vascular	   feet".	   	   The	   most	  numerous	   type	   of	   astrocytes	   are	   the	   protoplasmic	   glia,	   which	   are	   present	   in	   grey	  matter	  tissue	  and	  are	  mostly	  recognized	  with	  S100B	  labeling.	  It	  has	  been	  suggested	  that	   fibrous	   and	   protoplasmic	   astrocytes	   might	   be	   developmentally	   distinct	  (Nishiyama	  et	  al.,	  2009).	   In	  addition,	   there	  are	  at	   least	   two	  more	  subpopulations	  of	  astrocytes,	  known	  as	  specialized	  ‘‘radial’’	  astroglia:	  Bergmann	  glia,	  which	  is	  found	  in	  the	  cerebellum,	  and	  Muller	  cells,	  which	  are	  the	  primary	  glial	  cell	  in	  the	  retina.	  	  Astrocytes	  can	  be	  originated	   from	  RG	  cells	  directly. This	   is	   suggested	  by	   the	  fact	  that	  RG	  and	  astrocytes	  share	  the	  expression	  of	  the	  same	  markers	  (such	  as	  RC1)	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(Misson	  et	  al.,	  1991)	  and	  that	  appearance	  of	  an	  increasing	  population	  of	  astrocytes	  is	  coincident	  with	  disappearance	  of	  RG	  population.	  Also,	  RG	   fluorescent	   label	  with	  DiI	  and	   retroviral	   	   label	   are	   retained	   in	   the	   newborn	   astrocytes	   (Noctor	   et	   al.,	   2008;	  Voigt,	   1989).	   	   Astrocyte	   differentiation	   starts	   when	   RG	   cells	   lose	   their	   bipolar	  morphology	  to	  switch	  to	  an	  unipolar	  one,	  by	  retracting	  the	  pial	  process.	  Then,	  these	  cells	   gain	   multipolar	   morphology	   thanks	   to	   the	   appearance	   of	   radial	   processes,	  typical	  of	  astroglial	  cell	  types.	  Newly	  born,	  immature	  astrocytes	  migrate	  to	  their	  final	  locations,	  where	   they	  undergo	   local	   divisions	  before	   terminal	   differentiation	   (Ge	   et	  al.,	   2012).	   In	   fact,	   recent	   studies	   show	   that	   most	   of	   mouse	   cortical	   astrocytes	   are	  generated	  from	  clonal	  divisions	  of	  early	  differentiated	  astrocytes	  (Ge	  et	  al.,	  2012)	  and	  that	  such	  clones	  may	  arrange	  domains	  of	  distinct	  astrocyte	  classes	  (García-­‐Marqués	  and	  López-­‐Mascaraque,	  2013).	  Also,	  there	  is	  still	  room	  for	  the	  presence	  of	  a	  yet-­‐to-­‐be	  identified	   astrocyte	   restricted	   progenitor	   population.	   	   It	   has	   been	   reported	   the	  evidence	  of	  a	  bipotent	  subpopulation	  which	  expresses	  A2B5	  and	  is	  able	  to	  give	  rise	  to	  oligodendrocytes	  and	  astrocytes	  too.	  This	  subpopulation	  has	  been	  early	  described	  in	  the	   rhombo-­‐spinal	   domain	   and	   then	   also	   reported	   in	   telencephalon.	   Some	   studies	  suggest	   the	  possible	  coexistence	  of	  both	  restricted	  and	  bipotential	  glial	  progenitors	  neonatally	  (Levison	  and	  Goldman,	  1993;	  Luskin	  and	  McDermott,	  1994).	  The	  gliogenic	  switch	  happens	  around	  E16-­‐18	  in	  murine	  cerebral	  cortex,	  when	  there	  is	  the	  NSCs	  transition	  from	  neurogenesis	  to	  gliogenesis	  (Deneen	  et	  al.,	  2006;	  Ge	  et	   al.,	   2012;	   Molofsky	   and	   Deneen,	   2015).	   During	   neuronogenesis,	   Dnmt1	   is	  responsible	   for	   the	   methylation	   of	   glial	   genes,	   while	   Ngn1	   sequesters	   p300/CBP	  complex	   which	   cannot	   bind	   pStat3	   proteins.	   First,	   NSCs	   switch	   to	   gliogenic	   fate	  thanks	   to	   Nuclear	   factor	   I	   (NfIA)	   activation,	   which	   inhibits	   Dnmt1	   and	   leads	   to	  demethylation	  of	   glial	   genes	  promoters.	  Additionally,	   bone	  morphogenetic	   proteins	  (BMPs),	  Notch	  signaling	  and	  other	  extrinsic	  factors	  activate	  Stat3:p300/CBP	  complex	  that	  initiate	  glial	  gene	  transcription.	  	  These	   mechanisms	   will	   be	   explained	   more	   in	   detail	   in	   the	   following	  paragraphs.	   Once	   they	   have	   been	   specified,	   the	   intermediate	   astrocyte	   precursors	  express	   some	   specific	   markers,	   such	   as	   Glast,	   FABP7/BLBP	   and	   FGFR3.	   Then,	  astrocytes	   migrate	   to	   colonize	   their	   final	   destination.	   	   Although	   there	   are	   studies	  examining	   polarity	   and	   basic	   migratory	   mechanisms	   underlying	   such	   migration,	  these	  processes	  remain	  not	  well	  characterized	  in	  vivo.	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After	  migration,	  astrocyte	  start	   their	  terminal	  differentiation	  and	  acquire	  the	  expression	   of	   the	   canonical	  markers	   Gfap	   (mainly	   in	   fibrous	   astrocytes),	   s100β	   (in	  protoplasmic	  astrocytes),	  Aldh1L1,	  AldoC,	  AScgb1,	  Glt1	  and	  Acquaporin4.	  However,	  each	  of	  these	  markers	  show	  some	  limitations,	  as	  illustrated	  in	  Table	  I.1	  (adapted	  from	  (Molofsky	  et	  al.,	  2012)).	  	  	  	  	  
Table	   I.1.	   	   Markers	   of	   astrocytes	   and	   their	   progenitors	   (Adapted	  from	  (Molofsky	   et	   al.,	  2012))	  	  	   Interestingly,	   the	   same	   patterning	   factors	   that	   modulate	   neuronal	   type	  generation	   can	   play	   an	   instructive	   role	   also	   in	   generation	   of	   diverse	   astrocyte	  subtypes.	   For	   instance,	   canonical	   signaling	   factors	   like	   Sonic	   Hedgehog	   (SHH),	  Fibroblast	  growth	   factor	  (FGFs),	  WNTs	  and	  BMPs	  provide	  positional	   information	  to	  developing	  macroglial	   cells	   through	  morphogen	  gradients	   along	   the	  dorsal–ventral,	  anterior–posterior	  and	  medial–	  lateral	  axes.	  	  Moreover,	   in	   spinal	   cord,	   different	   subtypes	   of	   astrocytes	   with	   different	  positional	   identities	   can	   be	   identified	   on	   the	   basis	   of	   their	   expression	   of	   different	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transcription	  factors	  (Pax6,	  Nkx6.1)	  and	  cell	  surface	  markers	  (Reln	  and	  Slit1).	  In	  fact,	  it	   has	   been	   shown	   that	   astrocytes	   are	   allocated	   in	   mouse	   spinal	   cord	   and	   brain	  accordingly	   to	   their	   embryonic	   origin	   sites	   in	   the	   VZ.	   These	   specific	   domains	  implicates	   some	   limitations	   of	   the	   astroglial	   response	   to	   injury	   (Tsai	   et	   al.,	   2012).	  Finally,	  astrocytes	  take	  cortical	  positions	  that	  reflect	  the	  inside-­‐out	  pattern	  of	  cortical	  neurons:	  later-­‐born	  glia	  take	  superficial	  positions	  indeed	  (Ichikawa	  et	  al.,	  1983)	  (Fig.	  
I.3).	  Nevertheless,	   the	   in	  vivo	  validation	  of	   the	   structure	  of	  gliogenic	   compartments	  and	  lineages	  is	  still	  fully	  in	  progress.	  	  





1.1.3	   Molecular	  mechanisms	  Several	   molecular	   mechanisms	   control	   the	   perfect	   timing	   of	   astrogenesis.	  Exhaustive	  studies	  have	  been	  made	  on	  the	  modulators	  of	  astroglial	  gene	  promoters	  (Gfap,	  S100β).	  	  As	   already	   stated	   above,	   early	   neural	   stem	   cells	   (NSCs)	   are	   insensitive	   to	  cytokines	   triggering	   the	   main	   pro-­‐astrogenic	   pathway,	   the	   Jak/Stat	   pathway.	   In	  particular,	   during	   the	   neuronogenic	   phase,	   proneural	   genes	   cooperate	   in	   order	   to	  promote	   neuronal	   differentiation	   and	   inhibit	   glial	   fate	   choice.	   For	   instance,	  Neurogenin	   1	   (Ngn1)	   binds	   the	   p300/CBP	   complex,	   so	   sequestering	   it	   from	   its	  interaction	  with	  Stat3,	  a	  well-­‐known	   inducer	  of	  glial	  genes	   transcription.	  Moreover,	  prominent	   methylation	   of	   glial	   genes	   is	   reached	   thanks	   to	   the	   help	   of	   DNA	  methyltransferase	   I	   (DNMT1).	  These	  mechanisms	  both	   lead	   to	   the	   inhibition	  of	   the	  Jak/Stat	  axis.	  Even	  when	   precursors	   face	   a	   heavy	   chromatin	   remodeling,	  which	   results	   in	  the	   demethylation	   of	   Gfap	   and	   S100β	   promoters,	   other	   independent	   brakes	   of	  astrogenesis	  are	  at	  work,	  such	  as	  the	  ErbB4-­‐NCoR	  signaling.	  	  Conversely,	  at	   the	  end	  of	  neuronogenic	  window,	  precursors	  are	   finally	  ready	  to	  initiate	  astrogenesis,	  thanks	  to	  the	  release	  of	  astrogenic	  brakes	  and	  to	  the	  action	  of	  multiple	  pro-­‐active	  pathways.	  Among	  them,	  Notch	  signaling	  help	   the	  demethylation	  of	  Gfap	  promoter	  though	   its	  downstream	  effector	  NFIA,	  and	  act	  synergistically	  with	  Jak/Stat	  pathway	  to	  promote	  astrogenesis.	  Meanwhile,	  newborn	  neurons	  release	  the	  cytokines	  which	  trigger	  Jak/Stat	  activation	  too.	  	  Noticeably,	  Jak/Stat	  pathway	  itself	  is	  finely	   regulated	   by	   several	   plug-­‐ins.	   Other	   signaling	   mechanisms	   help	   promoting	  astrogenesis	  initiation:	  Tgfβ,	  BMPs,	  PACAP/Dream	  pathway	  (summarized	  in	  Fig.	  I.14	  and	   Fig.	   I.15).	   Finally,	   specific	   mechanisms	   control	   the	   maintanance	   of	   astrocytic	  identity.	  All	  these	  mechanisms	  will	  be	  explained	  in	  detail	  below.	  	  	  
Inhibition	  of	  astrogenesis	  The	  main	  brakes	  of	  astrogenesis	  are	  at	  work	  during	  neuronogenesis	  in	  order	  to	   prevent	   premature	   astrogenesis.	   They	   are	   mostly	   represented	   by	   a	   group	   of	  mechanisms	  that	  inhibit	  the	  main	  astrogenic	  pathway,	  the	  Jak/Stat	  pathway,	  and	  by	  an	  independent	  antiastrogenic	  system,	  the	  Nrg1/ErbB4/NCoR/RBPJk	  pathway.	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-­‐	  	   Inhibition	  of	  CT1/JAK/STAT3	  pathway	  	  During	   neuronogenesis,	   the	   proneural	   factor	   Neurogenin	   1(Ngn1)	   binds	  p300/CBP	   complex	   so	   sequestering	   it	   from	   a	   possible	   interaction	   with	   phospho-­‐Stat3.	   At	   the	   same	   time,	   together	   with	   Ngn2,	   NeuroD1	   and	   Mash1,	   it	   promotes	  neuronal	  differentiation	  (Cheng	  et	  al.,	  2011).	  SHP2-­‐Ras-­‐Mek-­‐Erk	   pathway	   is	   also	   implicated	   in	   the	   promotion	   of	  neurogenesis	   at	   the	   expenses	   of	   astrogenesis,	   by	   inhibiting	   the	   canonical	   Jak/Stat	  axis.	   In	   particular,	   Src	   homology	   phosphotyrosine	   phosphatase	   2	   (SHP2)	   is	   a	  phosphatase	  that	  dephosphorylates	  Stat3.	  It	  is	  also	  suggested	  that	  SHP2	  could	  inhibit	  Stat3	  transcription	  by	  methylation	  of	  astrocyte	  genes.	  To	  date,	  no	  specific	  activator	  of	  the	   SHP2-­‐Ras-­‐Mek-­‐Erk	   pathway	   is	   identified	   which	   induces	   the	   inhibition	   of	  astrogenesis,	   although	   BDNF	   is	   a	   potential	   candidate	   (Barnabé-­‐Heider	   and	   Miller,	  2003).	  Moreover	   Reelin,	   together	   with	   Disabled	   1	   (Dab1),	   suppress	   astroglial	  differentiation	  by	  affecting	   Jak/Stat	  pathway.	   In	   fact,	  when	  Dab1	   is	  deleted	   in	  NSCs,	  NeuroD	   expression	   is	   decreased,	   which	   in	   turn	   results	   in	   augmented	   Stat3	  phosphorylation	  (Kwon	  et	  al.,	  2009).	  Another	  important	  role	  in	  silencing	  Stat3	  activity	  is	  exerted	  by	  the	  suppressor	  of	  cytokine	  signaling	  3	  (Socs3),	  which	  also	  increases	  neurogenesis	  (Cao	  et	  al.,	  2006).	  Finally,	  a	  crucial	  role	  is	  played	  by	  epigenetic	  regulation	  of	  Stat3-­‐	  binding	  sites	  on	  glial	  gene	  promoters.	  This	  will	  be	  discussed	  more	  in	  detail	  in	  the	  dedicated	  section.	  	  	  
-­‐	   Nrg1/ErbB4/NCoR/RBPJk	  antiastrogenic	  pathway	  This	   pathway	   represents	   a	   crucial	   brake	   to	   prevent	   premature	   astrogenesis.	  The	   ligand	   Neuregulin	   1	   (Nrg1),	   expressed	   by	   neural	   precursors	   and	   neurons,	   is	  	  involved	   in	   the	   “canonical”	   activation	   of	   ErbB	   receptors,	   which	   consists	   in	   their	  homo-­‐	   or	   hetero-­‐	   dimerization	   and	   the	   induction	   of	   their	   intracellular	   tyrosine	  kinases,	  which	  in	  turns	  activate	  the	  Raf/Mek/Erk	  and	  the	  phosphoinositide-­‐3-­‐kinase	  (PI3K)	   machineries	   (Mei	   and	   Xiong,	   2008).	   Conversely,	   	   as	   for	   the	   inhibition	   of	  astrogenesis,	  Nrg1	  exerts	  its	  role	  by	  binding	  the	  juxta-­‐membrane	  α (jMα)	  isoform	  of	  ErbB4,	  so	  activating	  an	  alternative	  pathway,	  called	  the	  non-­‐canonical	  pathway.	  In	  this	  case,	  upon	  its	  activation,	  ErbB4	  undergoes	  two	  sequential	  cleavages,	  by	  TACE	  (TNF-­‐α-­‐converting	  enzyme)	  and	  presenilin-­‐dependent	  γ	  secretase,	  respectively.	  This	  leads	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Figure	  I.4.	  ErbB4	  intracellular	  pathway.	  (Adapted	  from	  (Sardi	  et	  al.,	  2006))	  
11 
 
Spatio-­‐temporal	  epigenetic	  regulation	  Accessibility	   of	   chromatin	   to	   transcription	   is	   finely	   regulated	   during	  development.	   It	   has	   been	   demonstrated	   that	   the	   proper	   progression	   of	   cortico-­‐cerebral	  neurogenesis,	  followed	  by	  astrogenesis,	  needs	  a	  precise	  temporal	  regulation	  of	  chromatin	  accessibility	   to	  transcription.	   	  During	  early	  neurogenesis,	  chromatin	   is	  condensed	  at	  the	  level	  of	  glial	  genes.	  Also,	  there	  are	  generalized	  changes	  in	  chromatin	  structure	  which	  guide	  NSCs	  choice	  towards	  neuronal	  or	  astrocytic	  fates.	  Afterwards,	  when	   astrogenesis	   is	   about	   to	   peak	   up,	   there	   are	   specific	   epigenetic	   changes	   at	  proneural	  genes	  in	  order	  to	  down-­‐regulate	  their	  expression,	  as	  well	  as	  a	  progressive	  opening	  of	  astrocytic	  chromatin.	  These	  events	  will	  be	  better	  explained	  below.	  	  	  
-­‐	   Chromatin	  closure	  at	  glial	  genes	  during	  early	  neuronogenesis	  Interestingly,	  endogenous	  S100β	  and	  GFAP	  levels	  are	  null	   in	  the	  early	  cortex	  even	   if	   some	   cytokine	   and	   pStat	   are	   available.	   Remarkably,	   this	   situation	   doesn’t	  change	   even	   if	   early	   neuroblasts	   are	   transfected	   with	   a	   constitutively-­‐active	   Stat.	  Upon	   exposure	   to	   Lif,	   pStat3	   is	   upregulated	   but	   its	   binding	  with	   Gfap	   promoter	   is	  prevented.	   It	   is	   reasonable	   to	   ascribe	   this	   phenomenon	   to	   the	   low	   accessibility	   of	  Stat3	  responsive	  elements	  (Stat3-­‐RE)	  on	  glial	  genes	  promoters.	  	  First,	  astrocytic	  chromatin	  closure	  depends	  on	  the	  augmented	  methylation	  of	  DNA	  at	  glial	  genes.	  DNA	  methyltransferase	  gene	  (Dnmt1)	  is	  a	  potential	  candidate	  for	  the	  methylation	  of	  CpG	  residues	  of	  DNA	  during	  neuronogenesis.	   	   	  In	  fact,	  deletion	  of	  such	  genes	   in	  NSCs	  promotes	   the	  switch	   from	  neurogenesis	   to	  astrogenesis	   (Fan	  et	  al.,	  2005).	  Such	  methylation	  recruits	  methyl	  CpG	  binding	  proteins	  such	  as	  methyl	  CpG	  binding	   protein	   2	   (MeCP2),	   which,	   together	   with	   Sin3	   transcription	   regulator	  homolog	  A	  (Sin3A),	   further	  condense	  chromatin	  and	  hence	  inhibits	  gene	  expression	  ((Fan	   et	   al.,	   2005;	   Icardi	   et	   al.,	   2012;	   Jones	   et	   al.,	   1998;	   Namihira	   et	   al.,	   2004)).	  Moreover,	   the	   SHP2-­‐Ras-­‐Mek-­‐Erk	   pathway	   may	   play	   an	   additional	   role	   in	   such	  promoter	   methylation,	   considering	   that	   it	   has	   been	   shown	   to	   induce	   DNA	  methylation	  by	  	  DNA	  methyltransferase	  3	  in	  non-­‐neural	  cells	  (Pruitt	  et	  al.,	  2005).	  In	   addition	   to	   DNA	   methylation,	   a	   second	   crucial	   mechanism	   controlling	  chromatin	   remodeling	   is	   represented	   by	   Histone	   3	   differential	   covalent	  modifications.	   The	   peculiar	   hallmarks	   of	   repressed	   chromatin	   state	   are	   di-­‐methylation	  at	  histone3-­‐lysine	  9	   (H3K9me2)	  and	   tri-­‐methylation	  of	  histone3-­‐lysine	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Figure	   I.5.	   Epigenetic	   regulation	   of	   the	   Gfap	   promoter	   by	   Nf1a	   and	   RA	   (OFF	   state)	  (Adapted	  from	  (Mallamaci,	  2013))	  	  	  
-­‐	   Large-­‐scale	  changes	  of	  chromatin	  structure	  It	   has	   been	   shown	   that	   the	   young	   NSCs,	   prone	   to	   self-­‐renewal	   or	   neuronal	  differentiation,	   preferentially	   show	   a	   chromatin	   open	   configuration	   in	   general.	  Subsequently,	   chromatin	   undergoes	   a	   progressive	   compaction	   which	   will	   channel	  neural	   precursors	   towards	   astrocytic	   fate	   (Kishi	   et	   al.,	   2012).	   The	   mechanism	   by	  which	  such	  generalyzed	  changes	  impact	  NSCs	  choice	  is	  still	  elusive.	  An	  hypothesis	  is	  that	   this	   could	   result	   in	   a	   reduction	   of	   proneural	   genes’	   transcription,	   which	  indirectly	  de-­‐repress	  astrogenesis.	  	  This	  epigenetic	  change	  is	  linked	  to	  two	  main	  groups	  of	  genes.	  The	  first	  one	  is	  High	   mobility	   group	   A	   (HmgA)	   proteins	   1	   and	   2,	   which	   bind	   to	   histone	   H1,	   so	  preventing	  its	  interaction	  with	  internucleosomal	  DNA	  linkers.	  In	  this	  way,	  chromatin	  remains	  accessible	  during	  the	  neurogenic	  window.	  HmgA	  levels	  decrease	  at	  the	  end	  of	  neuronal	  differentiation,	  and	  this	  could	  be	  helpful	  for	  astrogenesis	  onset	  (Kishi	  et	  al.,	  2012).	  Besides	  HmgA,	  N-­‐myc	  is	  also	  expressed	  at	  high	  level	  early	  in	  development,	  when	   it	   up	   regulates	   the	   histone	   acetyl-­‐transferase	   gene	   GCN5.	   It	   supports	   the	  acetylation	   of	   histone	   H3	   and	   H4,	   resulting	   in	   a	   more	   open	   state	   of	   chromatin	  (Knoepfler	  et	  al.,	  2006).	  N-­‐myc	  effect	  is	  counteracted	  by	  p19Arf,	  which	  is	  conversely	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highly	  expressed	  in	  late	  neural	  precursors	  and	  drive	  them	  to	  astroglial	  differentiation	  (Nagao	  et	  al.,	  2008).	  	  
	  
-­‐	   Epigenetic	  changes	  at	  pro	  neural	  genes	  A	  prominent	  change	  at	  proneural	  chromatin	  has	  been	  shown	  in	  the	  proximity	  of	   the	   Ngn1	   transcriptional	   start	   site.	   Infact,	   there	   is	   a	   progressive	   increase	   of	   the	  repressive	   hallmark	   trimethyl-­‐histone3-­‐lysine27	   (H3K27me3).	   This	   can	   explain	   the	  graduated	  downregulation	  of	  Ngn1	   in	  vivo	  at	   the	  end	  of	  neuronogenesis.	  Polycomb	  group	  (PcG)	  proteins	  are	  responsible	  of	  reducing	  histone	  acetylation	  and	  increasing	  H3K27	   methylation	   at	   Ngn1	   promoter	   region	   (Hirabayashi	   et	   al.,	   2009).	   This	  mechanism	   precedes	   the	   onset	   of	   astrogenesis	   and	   is	   crucial	   for	   	   the	   neurono-­‐to-­‐astrogenic	  switch.	  	  	  
-­‐	   Epigenetic	  remodeling	  of	  astroglial	  genes	  One	   of	   the	   main	   events	   involved	   in	   chromatin	   opening	   deals	   with	   Nf1A	  capability	  to	  mediate	  DNA	  demethylation,	  by	  inducing	  the	  dissociation	  of	  Dnmt1	  from	  the	   Gfap	   promoter.	   At	   least	   four	   Nf1a	   binding	   sites	   have	   been	   mapped	   on	   Gfap	  promoter	  ((Cebolla	  and	  Vallejo,	  2006;	  Piper	  et	  al.,	  2010)).	  It	  has	  been	  suggested	  that	  Dnmt1	  release	  results	  in	  the	  passive	  loss	  of	  methylation	  of	  Gfap	  promoter	  (Namihira	  et	   al.,	   2009).	   Nf1A	   is	   induced	   by	   Notch	   signalling,	   one	   of	   the	   main	   promoters	   of	  astrogenesis	  (Grandbarbe	  et	  al.,	  2003),	  which	  will	  be	  further	  explained.	  	  Although	  the	  vast	  majority	  of	  the	  studies	  have	  been	  done	  on	  Gfap	  gene,	  such	  demethylation	   have	   been	   described	   in	   many	   other	   cases	   (AldoC,	   ATP-­‐sensitive	  inward	  rectifier	  potassium	  channel	  10	  gene(Kcnj10),	  sorption	  peptidase	  inhibitor	  b8	  gene	  (Serpinb8)	  and	  SRY-­‐box	  containing	  gene	  8	  (Sox8)	  among	  them)	  (Hatada	  et	  al.,	  2008).	  Another	   key	   signal	   for	   opening	   the	   chromatin	   structure	   at	  Gfap	  promoter	   is	  fibroblast	  growth	  factor	  2	  (Fgf2).	  Ff2	  is	  able	  to	  suppress	  H3K9	  methylation	  in	  favor	  to	  H3K4	  hypermethylation	  at	  the	  Stat3	  binding	  site.	  This	  can	  induce	  Gfap	  expression	  in	  the	  presence	  of	  CNTF	  (Irmady	  2011).	  	  Fgf2	  signaling	  might	  stimulate	  H3K9→H3K4me	  switch	  thanks	  to	  methyltransferase	  SET7/9	  ((Nishioka	  et	  al.,	  2002;	  Song	  and	  Ghosh,	  2004)).	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Additionally,	   retinoid	   acid	   (RA)	   changes	   the	   conformational	   state	   of	   its	  receptor	   bound	   to	   RARE	   site	   at	   the	   Gfap	   promoter	   region.	   This	   leads	   to	   the	  replacement	   of	  NCoR-­‐HDAC	  by	  histone	   acetyl	   transferase	  p300/CBP,	  which	   in	   turn	  increase	  histone	   acetylation	   at	   surrounding	   sites	   ((Asano	   et	   al.,	   2009;	   Jepsen	   et	   al.,	  2007)).	  Remarkably,	  p300/CBP	  complex	  had	  been	  previously	  made	  available	  thanks	  to	  the	  downregulation	  of	  Ngn1,	  which	  no	  longer	  binds	  to	  it.	  Among	   further	   agents	   inducing	   astroglial	   chromatin	   opening,	   there	   are	   also	  Coup-­‐tf1	  and	  2.	  Since	  these	  agents	  are	  not	  sufficient	  to	  anticipate	  astrogenesis’	  onset,	  they	  might	  play	  only	  a	  permissive	  role.	  H3K9me2→H3K4me2	  switch,	  H3	  acetylation	  and	  DNA	  demethylation	  are	  evoked,	  even	  if	  indirectly,	  by	  Coup-­‐tf1	  and	  2	  (Naka	  et	  al.,	  2008).	  	  All	  these	  mechanisms	  are	  summarized	  in	  Fig.	  I.6	  and	  Fig	  I.7.	  	  
Figure	  I.6.	  Epigenetic	  regulation	  of	  the	  Gfap	  promoter	  by	  Nf1a	  and	  RA	  (ON	  state)	  




Figure	  I.7.	  	  Summary	  of	  epigenetic	  remodeling	  of	  the	  Gfap	  promoter.	  (Adapted	  from	  (Kanski	  et	  al.,	  2014))	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Stimulation	  of	  astrogenesis	  
-­‐	   Ct1/Jak/Stat3	  pathway	  Within	  cerebral	  cortex,	  as	  well	  as	  many	  other	  regions	  in	  the	  CNS,	  a	  key	  role	  in	  the	   trigger	   of	   astrocytogenesis	   is	   exerted	   by	   the	   Interleukin-­‐6	   (IL-­‐6)	   family	   of	  gliogenic	  cytokines,	  including	  ciliary	  neurotrophic	  factor	  (CNTF),	  leukemia	  inhibiting	  factor	  (LIF),	  cardiotrophin-­‐1	  (CT-­‐1),	  neuropoietin	  and	  CT-­‐like	   factor.	  Neurons	  could	  be	  the	  main	  promoter	  of	  gliogenesis.	  Indeed,	  several	  studies	  report	  that	  these	  factors	  are	   secreted	   by	   newborn	   neurons,	   once	   they	   have	   been	   generated.	   These	   secreted	  factors	   bind	   to	   their	   α-­‐coreceptors,	   such	   as	   Ciliary	   neurotrophic	   factor	   receptor	   α,	  CntfRα,	  and	  elicit	  the	  heterodimerization	  of	   	  the	  two	  β-­‐subunits	  of	  glycoprotein	  130	  (gp130)	   and	   Lif-­‐receptor	   β	   (LifRβ).	   This	   heterodimerization	   activates	   the	  gp130/Jak/Stat	  pathway	  in	  neural	  cortical	  precursors,	  therefore	  specifying	  the	  onset	  of	   astrogliogenesis	   (Rowitch	   and	   Kriegstein,	   2010).	   Specifically,	   such	  heterodimerization	  is	  followed	  by	  the	  phosphorylation	  of	  Janus	  tyrosine	  kinase	  1	  and	  2	   (Jak1,2),	   constitutively	   bound	   to	   gp130/LifRβ.	   Jak1,2	   in	   turn	   phosphorylate	   	   two	  key	   proteins:	   the	   suppressor	   of	   high-­‐copy	   PP	   1	   protein	   2	   (Shp2)	   and	   Signal	  transducer	   and	   activator	   of	   transcription	   1	   and	   3	   (Stat1/3),	   both	   associated	   to	  specific	  binding	   sites	  on	   internal	   sites	  of	   the	   same	   receptors.	  Once	  phosphorylated,	  Stat1/3,	  they	  bind	  to	  the	  p300/CBP	  complex	  and	  translocate	  into	  the	  nucleus,	  where	  they	  bind	  specific	  pStat-­‐responsive	  elements	  located	  on	  Gfap-­‐,	  S100β-­‐	  and	  Aquaporin-­‐	  promoters	   and	   activate	   the	   transcription	   of	   the	   respective	   genes	   (He	   et	   al.,	   2005).	  	  Shp2,	   instead,	   triggers	   the	  mitogen-­‐activated	  Erk	  kinase	   (Mek)/extracellular	   signal-­‐regulated	   kinase	   (Erk)	   and	   the	   Akt	   cascades	   (Ernst	   and	   Jenkins,	   2004).	   It	   doesn’t	  directly	   transactivate	   astroglial	   genes,	   but	   it	   is	   crucial	   to	   the	   self-­‐inhibition	   of	   this	  main	  astrogenic	  axis.	  	  	  Interestingly,	   production	   of	   Gfap+	   astrocytes	   is	   completely	   abolished	   in	  	  LIFRβ-­‐/-­‐	   and	   gp130-­‐/-­‐,	   strongly	   affected	   in	   Ct-­‐1-­‐/-­‐	   and	   only	   slightly	   reduced	   in	   CNTF	  and	  LIF	  mutants	  (Barnabé-­‐Heider	  et	  al.,	  2005;	  Bonni	  et	  al.,	  1997;	  Koblar	  et	  al.,	  1998;	  Ochiai	  et	  al.,	  2001).	  These	  data	  not	  only	  point	  to	  Jak/Stat	  axis	  as	  the	  main	  inducer	  of	  astrogenesis,	  but	  also	  suggest	  that	  the	  real	  ligands	  involved	  in	  the	  initiation	  of	  the	  in	  vivo	   cascade	   probably	   is	   Ct1,	   specifically	   expressed	   by	   cortical	   neurons	   (Barnabé-­‐Heider	   et	   al.,	   2005),	   possibly	   with	   the	   early	   help	   of	   Lif	   in	   some	   regions	   and	   the	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subsequent	  support	  by	  	  Cntf,	  released	  by	  astrocytes,	  later	  in	  development	  (Derouet	  et	  al.,	  2004;	  Lillien	  et	  al.,	  1988).	  Numerous	  modulatoy	   plugins	   act	   on	   this	   axis.	   First	   of	   all,	   two	   autocatalytic	  loops	   upregulate	   the	   process.	   pStat1	   and	   3	   themselves	   upregulate	   directly	   the	  transcription	  of	  gp130,	  Jak1,	  Stat1	  and	  Stat3,	  therefore	  enhancing	  the	  responsiveness	  of	  the	  system	  (He	  et	  al.,	  2005)	  (Fig.	  I.8).	  Also,	  as	  stated	  before,	  Cntf	  is	  produced	  from	  newborn	  astrocytes	  and	  mimics	  the	  effect	  of	  Ct1,	  by	  synergyzing	  with	  it.	  	  Moreover,	   as	   the	   proper	   balance	   between	   astrogenesis	   and	   neuronogenesis	  needs	   to	   be	   mantained,	   negative	   modulators	   act	   on	   Jak/Stat	   axis.	   In	   details,	   Jak2	  phosphorylation	  is	  limited	  thanks	  to	  the	  negative	  feedback	  provided	  by	  Suppressor	  of	  
cytokine	  signaling	  gene	  3	  (Socs3)	  and	  Shp2.	  Socs3	  binds	  to	  the	  receptors	  and	  triggers	  the	   degradation	   of	   the	   ligand-­‐receptor	   complex	   as	   well	   as	   the	   inhibition	   of	   Jak2	  phosphorylation	   (Krebs	   and	  Hilton,	   2001).	   	   Shp2	   also	   binds	   to	   the	   same	   receptors	  phospho-­‐tyrosine	   residues	   which	   interacts	   with	   Socs3	   (Schmitz	   et	   al.,	   2000)	   and	  dephosphorylates	   Jak2,	   so	   dampening	   the	   firing	   of	   	   the	   pathway	   (Lehmann	   et	   al.,	  2003)	  	  (Fig	  I.8).	  Furthermore,	   a	   prominent	   heteroregulation	   is	   crucial	   to	   finely	   tune	   Jak/Stat	  axis.	   Apart	   from	   competing	   with	   pStat1/pStat3	   for	   the	   binding	   to	   the	   CBP/p300-­‐pSmad1/pSmad4	  complex,	  pro	  neural	  genes	  Neurog1	  and	  2	  are	  able	  to	  downregulate	  the	   transcription	   levels	   of	   gp130,	   Jak1	   and	   Stat1/3	   (He	   et	   al.,	   2005).	   	   On	   the	   other	  hand,	   Neurofibrin	   1	   (Nf1)	   is	   able	   to	   convert	   RasGTP	   in	   its	   inactive	   form	   RasGDP	  (Scheffzek	  et	   al.,	   1997),	   so	   inhibiting	  Raf/Mek/Erk	  pathway	  during	  neuronogenesis	  (Wang	   et	   al.,	   2012).	   In	   the	   absence	   of	   Nf1,	   RasGTP	   can	   activate	   the	   cascade	   of	  Raf/Mek/Erk,	   which	   results	   in	   the	   stimulation	   of	   gp130	   transcription	   through	   the	  final	  effectors	  Etv5/Erm	  proteins	  (Fig.	  I.9).	  	  Among	   the	  various	  pathways	   interfering	  with	   the	   IL-­‐6/Jak/Stat	   transduction	  machinery,	   the	   EGFR	   one	   plays	   a	   master	   role	   as	   a	   positive	   regulator.	   Lillien	   et	   al.	  performed	  an	  elegant	  experiment	  in	  which	  they	  demonstrate	  that	  EGFR	  (induced	  by	  Fgf2)	   is	   necessary	   and	   sufficient	   to	   promote	   cortical	   progenitors’	   differentiation	   to	  astrocytes,	   under	   high	   Lif	   (Viti	   et	   al.,	   2003).	   This	   EGF	   receptor	   has	   been	   shown	   to	  increase	   Stat3	   levels	   and,	   remarkably,	   to	   render	   Stat3	  more	   easily	   phosphorylable	  under	  high	  Lif,	  probably	  by	  scaffolding	  Jak2	  and	  Stat3	  together.	  The	  transfection	  of	  a	  constitutively-­‐activated,	   phospho-­‐mimetic	   variant	   of	   Stat3	   into	   EgfR-­‐/-­‐	   progenitors	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was	   however	   not	   able	   to	   rescue	   GFAP	   expression.	   This	   suggests	   that	   the	   full	  astrocytogenic	  activity	  of	  EgfR	  requires	  a	  wider	  range	  of	  still	  unknown	  effect	  which	  are	  independent	  of	  Stat3	  activation	  (Fig.	  I.9).	  EgfR	  regulation	  of	  astrogenesis	  will	  be	  the	  subject	  of	  a	  dedicated	  paragraph.	  	  Finally,	  different	  pathways	  modulate	  Stat3	  phosphorylation.	  Delta/Notch/Hes	  axis	  is	  one	  of	  the	  major	  pathway	  involved.	  Hes1	  and	  Hes5	  act	  as	  bridges	  between	  jak2	  and	  pStat3.	  In	  this	  way,	  they	  facilitate	  the	  phosphorylation	  of	  the	  former	  to	  the	  latter	  (Kamakura	  et	  al.,	  2004).	  	  	  
Neural	  myelocymatosis	  prooncogene	   (N-­‐myc)	  and	   INK4ap19	  protein/alternate	  
reading	  frame	  of	  the	  INK4a/ARF	  locus	   (p19Arf)	   	   inhibit	   reciprocally.	  The	   first	  one	   is	  involved	   in	   the	   promotion	   of	   neurogenesis,	   by	   promoting	   NSCs	   self-­‐renewal.	   The	  second	   one	   sustain	   astrogenesis;	   it	   is	   stimulated	   by	   pStat3	   and	   facilitates	   with	   a	  positive	  feedback	  mechanism	  Stat3	  phosphorylation	  via	  p53	  (Nagao	  et	  al.,	  2008)	  .	  	  	  
	  












-­‐	   Notch	  signaling	  	  Notch	  signaling	  is	  a	  notoriously	  highly	  conserved	  cell	  signaling	  system	  present	  in	   most	   multicellular	   organisms.	   This	   pathway	   performs	   different	   roles	   during	  development.	  It	   is	  essential	  for	  the	  maintainance	  of	  NSCs	  and	  it	   is	  endowed	  with	  an	  instructive	   role	   to	  directly	  promote	   the	  differentiation	  of	   several	   glial	   cell	   subtypes	  (Louvi	  and	  Artavanis-­‐Tsakonas,	  2006)	  (Fig.	  I.10).	  	  
	  
Figure	   I.10.	   Notch	   signaling	   throughout	   glial	   differentiation.	   (Adapted	  from	  (Louvi	  and	  Artavanis-­‐Tsakonas,	  2006))	  	  	   The	  well-­‐known	  canonical	  signaling	  pathway	  is	  activated	  by	  the	  Notch	  ligands:	  Jagged	   and	   Delta-­‐like	   proteins.	   When	   ligands	   are	   bound,	   Notch	   is	   cleaved	   by	   γ-­‐secretase	  complex,	  containing	  presenilin1,	  Notch	  intracellular	  domain	  (NICD)	  is	  then	  released.	   It	   follows	   that	  NICD	   translocates	   into	   the	   nucleus	  where	   it	   interacts	  with	  DNA	   binding	   protein	   (such	   as	   c-­‐promoter	   binding	   factor	   1,	   CSL,	   aka	   Rbpjk)	   and	  stimulates	  transcription	  of	  	  Notch	  target	  genes,	  such	  as	  hairy	  enhancer	  of	  split	  (Hes),	  Hes1	  and	  Hes5	  (Guruharsha	  et	  al.,	  2012).	  During	  the	  neurogenic	  window,	  Hes1	  and	  Hes5	   inhibit	   neural	   genes	   transcription	   (Kageyama	   et	   al.,	   2005),	   while	   stimulating	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NSCs	  self-­‐renewal	  (Kopan	  and	  Ilagan,	  2009).	  When	  development	  proceeds,	  newborn	  neurons	   keep	   stimulating	   Notch,	   by	   expressing	   its	   ligands.	   Thus,	   at	   late	  developmental	   stages,	   Notch	   signaling	   promotes	   the	   epigenetic	   remodeling	   of	  Gfap	  promoter	   through	   its	   target	   Nf1A,	   which	   promotes	   Dnmt1	   released,	   as	   discussed	  above.	   	  The	  mechanisms	   that	   regulate	   this	   switch	   in	   the	  Notch	   response,	   from	  self-­‐renewing	  to	  astrogenic,	  still	  remain	  unclear.	  	  	  Noticeably,	   Notch	   signalling	   acts	   synergistically	   with	   Jak/Stat	   axis	   to	   promote	  astrogenesis	   (Fig.	   I.11).	   Stat3	   itself	   induces	   the	  Notch	   ligand	  DLL1,	  which	   activates	  Notch	   signaling.	   Moreover,	   Socs3,	   the	   Stat3	   inhibitor,	   also	   suppresses	   Hes5	  expression	  (Cao	  et	  al.,	  2006).	  On	  the	  other	  hand,	  Hes1	  induces	  Stat3	  phosphorylation	  physically	  connecting	   Jak2	  to	   it.	  Notch	  and	   Jak/Stat	  cross	   talk	  establishes	  a	  positive	  feedback	   loop	   that	   promotes	   the	   astrogenesis	   initiation	   (Kamakura	   et	   al.,	   2004).	  	  However,	  the	  astrogenic	  activity	  of	  Notch	  signalling	  requires	  Jak/Stat	  signalling,	  but	  not	  viceversa	  (Ge	  et	  al.,	  2012).	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  I.11.	  Sinergic	  effect	  of	  Jak/Stat	  and	  Notch	  signaling	  at	  the	  onset	  of	  astrogenesis.	  
(Adapted	  from	  (Kanski	  et	  al.,	  2014))	  	   Furthermore,	   Notch	   effector	   RBPJk,	   CSL-­‐family	   factor,	   directly	   binds	   to	   an	  element	   within	   the	   GFAP	   promoter,	   at	   about	   180bp	   with	   respect	   to	   the	   TSS,	  stimulating	  directly	  transcription	  (Ge	  et	  al.,	  2012).	  	  Intriguingly,	  RBPJk	  is	  able	  to	  bind	  NCoR	   (Kao	   et	   al.,	   1998).	   This	   complex	   could	   potentially	   silence	   astroglial	   genes	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during	  neuronogenesis.	  Starting	  from	  E15.5,	  when	  Jak/Stat	  axis	  leads	  to	  progressive	  translocation	  of	  NCoR	   to	   the	  cytoplasm	  (Sardi	  et	  al.,	  2006),	  RBPJk	  would	  be	   free	   to	  bind	  NICD	  and	  stimulate	  gliogenesis	  (Miller	  and	  Gauthier,	  2007).	  	  
	  


















Figure	  I.12.	  BMP	  signaling	  in	  neuronogenesis	  and	  gliogenesis.	  	  
	  
	  
-­‐	   Tgf-­‐β	  signaling	  Transforming	  factors	  beta	  (TGF-­‐βs)	  are	  multifunctional	  growth	  factors	  which	  act	   in	   key	   events	   of	   development	   and	   cell	   repair	   (Shi	   and	  Massagué,	   2003).	   Tgf-­‐β1	  involves	  mainly	   2	   threonine	   kinase	   receptor,	   TgfRI	   and	   TgfRII,	   highly	   expressed	   in	  early	  development,	  	  which	  in	  turn	  activate	  Smad2/3	  and	  Smad4	  transcription	  factors.	  These	   proteins	   are	   phosphorylated	   and	   then	   complexed	   in	   Smad2/3-­‐4	   complexes,	  which	   translocate	   to	   the	   nucleus	   and	   regulate	   transcription	   	   (Shi	   and	   Massagué,	  2003).	  	  Tgf-­‐β	   is	  not	  only	   implicated	   in	   late	  advancement	  of	  astrocyte	  differentiation,	  but	   it	   also	  has	  got	   a	   role	   in	   the	   commitment	  of	  pluripotent	  precursors	   to	   astroglial	  fates.	  In	  fact,	  cortical	  neurons	  may	  modulate	  the	  differentiation	  from	  radial	  glia	  cells	  to	   astrocytes,	   by	   secreting	   Tgf-­‐β1	   (de	   Sampaio	   e	   Spohr	   et	   al.,	   2002;	   Stipursky	   and	  Gomes,	   2007).	   If	   conditioned	   medium	   derived	   from	   pure	   neuronal	   culture	   or	  astrocyte-­‐neuronal	  co-­‐culture	  is	  added	  to	  E14	  cortical	  cultures	  in	  mouse,	  it	  is	  able	  to	  activate	  Gfap	   transcription	  and	  down	  regulate	  RG	  markers,	  such	  as	  Nestin	  and	  Blbp	  	  (Stipursky	  and	  Gomes,	  2007).	  Tgf-­‐β	  can	  exert	  its	  pro-­‐astrogenic	  function	  through	  diverse	  mechanisms.	  First,	  Smad2/3	   proteins	   cooperate	   with	   Stat3	   in	   order	   to	   increase	   Jak/Stat	   pathway-­‐
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mediated	   astrogenesis.	   Second,	   Tgf-­‐β	   may	   induce	   a	   non-­‐canonical	   MAPK/PI3K	  signaling	  in	  order	  to	  stimulate	  astrocytic	  differentiation	  (Stipursky	  et	  al.,	  2012).	  	  	  Intriguingly,	  a	  key	  mediator	  of	  Tgf-­‐β	  could	  be	  TAB2	  (Yamaguchi	  et	  al.,	  1995).	  A	  model	   in	  which	   Tgf-­‐β	   activation	  might	   sequester	   Tab2	   from	   the	   inhibitor	   complex	  with	   ErbB4-­‐NCoR,	   via	   Tak2	   has	   been	   proposed.	   This	   could	   indirectly	   induce	   glial	  genes	   transcription	   (Stipursky	   and	   Gomes,	   2007).	   The	   cross-­‐	   talk	   between	   ErbB4-­‐NCoR	   and	   Tgf-­‐β1	   signaling	   may	   be	   crucial	   to	   finely	   tune	   the	   neuronogenic-­‐to-­‐gliogenic	  switch.	  	  
-­‐	  	  	  	  	  	  	  Pacap/Pac/Dream	  pathway	  Vallejo’s	   team	  has	  discovered	  and	  characterized	   this	  pathway	   (Cebolla	  et	   al.,	  2008)	  and	  represents	  a	  fundamental	  biphasic	  regulation	  of	  astrocytic	  promoters	  (Fig.	  
I.13).	  In	  the	  absence	  of	  the	  secreted	  factor	  called	  PACAP,	  Dream	  transcription	  factor	  sits	   on	   the	  Gfap	   promoter	   and	  acts	   as	   a	   trans-­‐repressor.	  When	  PACAP	  binds	   to	   the	  PAC1	  receptor,	  cytoplasmic	  cAMP	  is	  upregulated	  and	  calcium	  massively	  dashes	  into	  the	   cell.	   Dream	   is	   sensitive	   to	   the	   Ca2+	   and	   is	   converted	   into	   a	   trans-­‐activator. The	  PACAP/PAC1/cAMP/Dream	   pathway	   works	   in	   parallel	   to	   theCT1/IL6R/Jak/Stat	  pathway	  illustrated	  above.	  That	  is	  the	  reason	  why,	  if	  Jak/Stat	  axis	  is	  efficient,	  Dream-­‐KO	   only	   determines	   a	   transient	   shrinkage	   of	   the	   astrocytic	   compartment	   between	  E17	  and	  P7,	  associated	  to	  an	  enlargement	  of	  the	  neuronal	  one	  (Cebolla	  et	  al.,	  2008).	  	  	  	  	  	  	  	  	  	  	  




























Figure	   I.15.	   Summary	   of	   the	   integrated	   network	   of	   stimuli	   converging	   to	   initiate	  
astrogenesis.	  (Adapted	  from	  (Kanski	  et	  al.,	  2014))	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Modulation	  of	  astroblasts	  population	  kinetics	  This	  regulation	  is	  still	  poorly	  understood	  and	  few	  genes	  have	  been	  found	  to	  be	  implicated	  in	  it.	  Two	  of	  them	  are	  here	  explained,	  the	  same	  genes	  were	  also	  studied	  in	  my	  work.	  	  -­‐	   Epidermal	  growth	  factor	  receptor	  (EgfR)	  signaling	  	  	   EgfR	   is	   a	   cell-­‐surface	   receptor,	  member	  of	   the	  ErbB	   family	  of	   receptors.	   It	   is	  expressed	   at	   low	   level	   in	   the	   ventricular	   zone	   of	   the	   neuronogenic	   pallium	   and,	   at	  progressively	   higher	   levels	   in	   basal	   proliferative	   layers	   during	   development	   in	  cerebral	  cortex	  (Caric	  et	  al.,	  2001).	  	  	   EgfR	   is	   an	   important	   regulator	   of	   astrogenesis.	   	   First,	   it	   is	   involved	   in	   the	  commitment	  of	  precursors	  to	  astroglial	  fates.	  For	  instance,	  mice	  lacking	  EgfR	  show	  a	  delayed	   astrocyte	   development	   (Kornblum	   et	   al.,	   1998;	   Sibilia	   et	   al.,	   1998).	   Also,	  overexpression	   of	   EgfR	   in	   rat	   cortex	   during	   neuronogenesis	   upregulates	   astrocytic	  output.	  Administration	  of	  the	  two	  main	  EgfR	  ligands	  EgF	  and	  Tgfa	  does	  not	  elicit	  the	  same	  results,	  thus	  suggesting	  that	  EgfR	  levels,	  rather	  than	  ligand	  levels,	  are	  crucial	  for	  the	   firing	   of	   EgfR	   pathway	   and	   in	   turn	   for	   astrogenesis.	  When	   EgfR	   levels	   become	  sufficiently	   high	   at	   the	   end	   of	   neuronogenesis,	   astrogenesis	   can	   be	   induced.	   The	  molecular	   mechanism	   could	   possibly	   be	   explained	   by	   the	   fact	   that	   EgfR	   facilitate	  transmission	   of	   Ct1	   signal	   through	   Jak/Stat	   axis,	   via	   Stat3	   upregulation,	   as	   already	  mentioned	   above	   (Burrows	   et	   al.,	   1997;	   Viti	   et	   al.,	   2003).	   Remarkably,	   the	  upregulation	  of	  Stat3	  induced	  by	  EgfR	  sensitizes	  embryonic	  neural	  precursors	  to	  the	  astrogenic	  cytokines,	  such	  as	  Lif,	  sufficiently	  to	  promote	  astrogenesis,	  even	  in	  front	  of	  low	  levels	  of	  these	  ligands	  (Viti	  et	  al.,	  2003).	  	   A	   further	   role	   of	   Egf/EgfR	   signaling	   is	   the	   promotion	   of	   proliferation	   of	  astrocyte-­‐commuted	   precursors.	   To	   appreciate	   this	   effect	   on	   proliferation,	   simple	  delivery	   of	   exogenous	   ligand	   (Egf)	   is	   sufficient,	   when	   EgfR	   levels	   are	   already	  increased	   (Viti	   et	   al.,	   2003).	   Interestingly,	   experimental	   overexpression	   of	   EgfR	   in	  early	  cortical	  precursors	  (E11-­‐E13	   in	  mice)	  upregulates	   frequencies	  of	  both	  S100β+	  and	   Gfap+	   astrocytes,	   whereas	   Stat3	   overexpression	   in	   the	   same	   cells	   increases	  S100β+	  cells	  only.	  	  On	  the	  one	  hand,	  this	  suggests	  that	  there	  must	  be	  a	  Egf-­‐dependent	  mechanism	   different	   from	   Stat3	   upregulation,	   in	   order	   to	   selectively	   induce	   Gfap	  expression.	  On	  the	  other	  hand,	  such	  expansion	  of	  Gfap+	  compartment	  couldd	  be	  due	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to	  the	  increased	  proliferation	  rate	  of	  astroglial-­‐committed	  progenitors	  (Garrett	  et	  al.,	  2002).	  
	  
-­‐	  	   Fibroblast	  growth	  factor	  9	  (Fgf9)	  signaling	  This	  protein	  is	  a	  member	  of	  the	  huge	  fibroblast	  growth	  factors	  (FGF)	  family.	  In	  general,	  members	  of	  this	  family	  hold	  plenty	  of	  mitogenic	  and	  cell	  survival	  properties	  and	  are	   involved	   in	  various	  biological	  processes,	   including	  embryonic	  development,	  cell	  growth,	  morphogenesis,	  tissue	  repair,	  tumor	  growth	  and	  invasion.	  	  In	  particular,	  Fgf9	  is	  a	  secreted	  factor	  that	  shows	  its	  main	  effect	  as	  a	  growth-­‐stimulating	  effect	  on	  cultured	  glial	  cells.	  	  In	  the	  nervous	  system	  it	  has	  been	  shown	  to	  be	  produced	  mainly	  by	  neurons	  and	  may	  be	  fundamental	  for	  glial	  cell	  induction	  and	  development	   (Santos-­‐Ocampo	   et	   al.,	   1996).	   In	   particular,	   it	   promotes	   a	   huge	  expansion	  of	   the	  perinatal	  astrogenic	  proliferating	  pool	   (Seuntjens	  et	  al.,	  2009)	  and	  also	   delays	   terminal	   differentiation	   of	  mature	   astrocytes	   (Lum	  et	   al.,	   2009).	   	   It	   has	  been	   thought	   to	   be	   produced	   by	   neurons,	   as	   neurogenesis	   is	   termined,	   in	   order	   to	  induce	   the	   onset	   of	   production	   of	   glial	   cells.	   Mad	   interacting	   protein	   1	   (Sip1)	  transcription	   factor	   slows	   down	   astroblasts	   proliferation,	   probably	   via	   Fgf9	  inhibition	  (Seuntjens	  et	  al.,	  2009).	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1.2	   Glioblastoma	  Multiforme	  
	  
1.2.1	   Generalities	  Glioblastoma	  multiforme	  (GBM)	  is	  the	  one	  of	  the	  deadliest	  human	  cancers	  and	  the	  most	  common	  primary	  brain	  tumors’	  subtype.	  Glioma	  tumors	  are	  aggressive	  and	  highly	   invasive	   central	   nervous	   system	   tumors.	   GBM	   is	   characterized	   as	   a	   glioma	  subtype,	  among	  other	  different	  gliomas,	  with	  diverse	  origin	  and	  features	  typified	  up	  to	   now.	   Gliomas	   are	   pathologically	   defined	   as	   tumors	   displaying	   histological	   and	  immunohistochemical	  evidence	  of	  glial	  differentiation.	  According	  to	  the	  World	  Health	  Organization	  (WHO)	  classification	  gliomas	  are	  characterised	  and	  graded.	  Firstly,	  they	  are	   distinguished	   on	   their	   hypothesized	   line	   of	   differentiation,	   which	   can	   be	  astrocytic,	   oligodendroglial	   or	   ependymal	   one.	   	   Then,	   they	   are	   graded	   on	   a	  malignancy	  scale	  of	  I	  to	  IV.	  Grade	  I	  tumors	  are	  benign	  and	  can	  be	  surgically	  removed	  if	  accessible	   for	  the	  resection.	  Grade	  II	   tumors	  are	   low-­‐grade	  malignant	  and	  are	  not	  surgically	  curable.	  Grade	  III	  tumors	  are	  malignant,	  leading	  to	  death	  within	  few	  years;	  grade	   IV	   tumors	   are	   highly	   malignant	   and	   lethal	   within	   9-­‐12	   months	   on	   average.	  Gliomas	  do	  not	  often	  metastasize	  outside	  the	  CNS,	  thus,	  tumor	  grade	  characterization	  is	  the	  main	  determinant	  of	  the	  patient’s	  clinical	  outcome.	  The	   common	   gliomas	  which	   affect	   the	   cerebral	   hemispheres	   of	   adult	   brains	  are	  also	  called	  diffuse	  gliomas	  because	  of	  their	  highly	  infiltrative	  nature.	  Infiltration	  is	  the	  main	  feature	  of	  malignancy.	  A	  highly	  infiltrative	  tumor	  renders	  surgical	  resection	  technically	  demanding	  and	  mostly	   ineffective.	  As	  anticipated	  above,	  diffuse	  gliomas	  are	   classified	   histologically	   as	   astrocytomas,	   oligodendrogliomas,	   or	   tumors	   with	  miscellaneous	  morphological	   features,	   such	   as	   oligoastrocytomas.	   To	   go	   further	   in	  detail,	  WHO	   classification	   distinguishes	   astrocytic	   tumors	   as	   pilocytic	   astrocytoma,	  grade	  I;	  astrocytoma,	  grade	  II;	  anaplaestic	  astrocytoma,	  grade	  III;	  finally	  glioblastoma	  multiforme	   (GBM),	   grade	   IV.	   GBM	   is	   the	   most	   malignant,	   it	   accounts	   for	  approximately	   12-­‐15%	   of	   all	   brain	   tumors,	   and	   in	   particular	   60-­‐70%	   of	   astrocytic	  tumors.	  GBM	  patients	  mean	  survival	  may	  go	  up	  to	  18	  months	  if	  tumor	  is	  treated	  by	  surgical	  resection,	  combined	  with	  radiotherapy	  and	  chemotherapy,	  unfortunately	  the	  mean	  survival	  time	  is	  less	  in	  the	  vast	  majority	  of	  cases.	  	  	  GBM	  presents	  histological	  features	  of	  high	  malignancy,	  such	  as	  high	  cellularity,	  cellular	   pleiomorphism,	   rapid	   proliferation,	   microvascular	   proliferation,	   diffused	  
28 
 
invasion	  and	  necrosis.	  These	  characteristics	  are	  the	  main	  criterion	  for	  the	  diagnosis	  of	  GBM	  (Steck	  et	  al.,	  1997).	  	  	  GBM	   incidence	   increases	   with	   age.	   In	   fact,	   primary	   GBM	   tumors	   affect	   62-­‐years	  people	  on	  average	  while	  they	  are	  very	  rare	  in	  children.	  GBM	  occurs	  both	  in	  men	  and	  women,	  although	  primary	  GBM	  occurs	  more	  in	  men	  and	  secondary	  GBM	  more	  in	  women	  (Schwartzbaum	  et	  al.,	  2006).	  	  
1.2.2	   Clonal	  origin	  There	   are	   two	   GBM	   subtypes:	   primary	   and	   secondary	   GBM.	   Primary	   GBM	  occurs	   de	   novo,	   mainly	   in	   older	   patients,	   usually	   with	   no	   prior	   clinical	   evidence.	  Secondary	   GBM	   affect	   younger	   patients	   and	   has	   got	   a	   distinct	   clinical	   history.	   It	   is	  initially	   present	   as	   a	   low-­‐grade	   astrocytoma,	   which	   subsequently	   transforms	   into	  GBM	  within	   5-­‐10	   year	   as	   a	   recurrency,	   regardless	   of	   treatments	   received.	   Primary	  and	  secondary	  GBM	  subtypes	  show	  different	  frequency	  of	  specific	  genetic	  mutations	  associated	  with	  GBM.	  On	  the	  basis	  of	  the	  diverse	  frequencies	  of	  the	  associated	  genetic	  mutation,	   they	   have	   been	   proposed	   to	   represent	   two	   different	   clinical	   entities,	  developing	   along	   diverse	   pathways	   of	   origin.	   However,	   they	   behave	   in	   a	   clinical	  indistinguishable	  fashion	  and	  the	  median	  survival	  upon	  their	  establishment	  is	  mostly	  the	  same,	  as	  well	  as	  resistance	  to	  all	  the	  therapies.	  	  	  In	   general,	   the	   origin	   of	   GBM	   is	   still	   not	   well	   understood.	   The	   presence	   of	  different	   glioma	   variants	   depending	   on	   diverse	   histological	   hallmarks,	   such	   as	  astrocytic,	   oligodendrocytic	   or	   mesenchymal,	   suggest	   that	   independent	  transformation	   events	   may	   occur	   in	   various	   terminally	   differentiated	   cells.	   More	  likely,	   the	  malignant	   transformation	  may	   occur	   in	   a	   progenitor	   cell,	   that	   is	   able	   to	  differentiate	  in	  different	  cell	  types.	  	  Additionally,	   adult	   neural	   stem	   cells	   or	   early	   glial	   progenitors	   could	   initiate	  gliomagenesis.	  Although	  such	  cells	  are	   localized	  in	  precise	  areas	  of	  the	  brain,	  which	  are	   not	   often	   affected	   by	   GBM,	   they	   display	   both	   proliferative	   and	   migratory	  potentials,	   so	   that	   they	   could	   transform	   into	   tumor	   anywhere	   in	   the	   brain.	   Also,	   a	  tumor-­‐associated	  mutation	  may	  activate	   the	  migratory	  property	  of	   these	   cells,	   as	   it	  has	  been	  shown	  in	  embryogenesis	  or	  in	  response	  to	  exogenous	  EGF	  stimulus	  in	  adult	  mice	  (Craig	  et	  al.,	  1996;	  Fricker-­‐Gates	  et	  al.,	  2000).	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Another	   possible	   source	   of	   GBM	   could	   be	   the	   mature	   astrocytes	   which	  dedifferentiate	  in	  response	  to	  a	  genetic	  mutation.	  	  There	  are	  already	  cells	  in	  the	  adult	  brain	   that	   are	   able	   to	   dedifferentiate	   in	   response	   to	   specific	   stimuli.	   Mature	  astrocytes	   are	   able	   to	   dedifferentiate	   into	   an	   earlier	   radial	   glia-­‐like	   phenotype	   and	  acquire	  proliferative	  and	  migratory	  abilities.	  This	  could	  be	  the	  basis	  of	  gliomagenesis.	  	  	  
1.2.3	   Standard	  therapy	  The	  current	  standard	  of	  care	  for	  GBM	  tumor	  is	  based	  on	  a	  combined	  approach.	  A	   surgical	   resection	  of	   the	  mass,	   if	   feasible,	   is	  performed	   first.	  This	  might	   lead	   to	  a	  rapid	  improvement	  of	  the	  neurological	  symptoms	  and,	  in	  turn,	  dictate	  the	  possibility	  to	   intervene	   with	   the	   subsequent	   therapy	   options.	   These	   are	   needed	   in	   order	   to	  improve	   survival.	   A	   combination	   of	   radiotherapy	   and	   chemotherapy	   follows.	   In	  particular,	  chemotherapy	  for	  GBM	  involves	  alkylating	  agents,	  such	  as	  Temozolomide	  (TMZ).	   Its	   therapeutic	  benefit	  depends	  on	   its	   capability	   to	   alkylate/methylate	  DNA,	  mostly	  at	  the	  N-­‐7	  or	  O-­‐6	  position	  of	  guanine	  residues.	  In	  this	  way,	  TMZ	  damages	  DNA	  and	   triggers	   tumor	   cell	   death.	  However,	   some	  GBMs	   are	   able	   to	   repair	   this	   kind	  of	  DNA	  damage,	  thanks	  to	  the	  expression	  of	  O-­‐6-­‐methylguanine-­‐DNA	  methyltransferase	  (MGMT)	   gene	   	   (Jacinto	   and	   Esteller,	   2007).	   These	   cells	   become	   resistant	   to	   TMZ	  therapy.	  Conversely,	  in	  some	  tumors	  epigenetic	  silencing	  of	  the	  MGMT	  gene	  inhibits	  the	   synthesis	   of	   this	   enzyme	   and	   facilitate	   the	   sensitiveness	   to	   the	   therapy.	   This	   is	  why	  TMZ	  is	  effective	  for	  treating	  patients	  positive	  to	  methylated	  promoter	  of	  MGMT.	  The	   presence	   of	  MGMT	   protein	   in	   brain	   tumors,	   instead,	   predict	   poor	   response	   to	  TMZ	  (Hegi	  et	  al.,	  2009).	  Although	   the	   standard	   of	   therapy	   for	   GBM	   has	   evolved	   into	   multimodal	  approaches,	   several	   patients	   still	   suffer	   the	   tumor	   progression	   due	   to	   the	   high	  infiltration	   of	   malignant	   cells	   into	   the	   brain	   tissues.	   Moreover,	   given	   the	   high	  heterogeneity	   of	   GBM,	   new	   therapies	   are	   aimed	   at	   finding	   specific	   personalized	  treatments.	  	  
	  
1.2.4	   Heterogeneity	  of	  molecular	  mechanisms	  undelying	  GBM	  Glioblastoma	   multiforme	   is	   a	   highly	   heterogeneous	   tumor.	   	   It	   was	   the	   first	  cancer	   to	  be	   systematically	   studied	  by	   the	  Cancer	  Genome	  Atlas	  Research	  Network	  (TCGA).	  From	  the	   first	  genomic	  and	   transcriptomic	  analysis	  of	   two	  hundreds	  GBMs	  
30 
 
already	   showed	   that	   a	   systematic	   analysis	   in	   a	   huge	   cohort	   of	   samples	   can	   help	   to	  distinguish	  the	  core	  biological	  pathways,	  relevant	  to	  tumor	  malignancy.	  	  The	   first	   three	   core	   pathways	   reported	   in	   the	   initial	   TCGA	  publication	  were	  p53,	  Rb	   and	   receptor	   tyrosine	   kinase	   (RTK)/Ras/Phosphoinositide	   3-­‐kinase	   (PI3K)	  signaling	   (TCGA	   2008).	   It	   was	   then	   showed	   that	   different	   combination	   of	   such	  alterations	  were	   found	   in	  different	  molecular	   subtypes	  of	  glioblastoma,	   resulting	   in	  high	   interpersonal	   variability.	   This	   may	   influence	   clinical	   outcome	   and	   specific	  individual	  response	  to	  therapy	  (Noushmehr	  2010,	  Verhaak	  2010).	  It	  is	  now	  clear	  that	  GBM	   growth	   and	   adaptation	   to	   targeted	   molecular	   treatments	   are	   driven	   by	   a	  signaling	  network	  with	   functional	  redundancy.	  Therefore,	  a	  deep	  comprehension	  of	  molecular	   alterations	   becomes	   more	   and	   more	   important	   to	   understand	   GBM	  pathogenesis,	   to	   infer	   tumor	   biology	   and	   finally	   to	   develop	   effective	   therapies.	   A	  wider	  variety	  of	  somatic	  genomic	  alterations	  have	  been	  described	  in	  recent	  years	  and	  a	  complex	  landscape	  was	  provided	  (Brennan	  et	  al.,	  2013)	  	  (Fig.	  I.17).	  Among	  molecular	  mechanisms	  underlying	   it,	   there	  are	  pathways	   involved	   in	  the	   regulation	   of	   cell	   cycle,	   apoptosis,	   cell	   growth	   and	   survival,	   migration.	  Understanding	  the	  function	  of	  such	  mechanisms	  in	  normal	  brain	  development	  helps	  the	   investigation	   of	   how	   dysregulation	   may	   drive	   gliomagenesis.	   Here,	   the	   major	  genetic	   alterations	   associated	   with	   GBM	   and	   their	   relative	   pathways	   will	   be	  explained.	  	  
-­‐	   Growth	  factors	  pathways	  PDGF	  ligand	  and	  EGF	  receptor	  have	  been	  found	  prominently	  overexpressed	  in	  low-­‐grade	   gliomas	   and	   in	   GBMs,	   respectively.	   This	   suggests	   they	   could	   have	   a	  possible	  role	  in	  gliomagenesis.	  	  Receptor	  tyrosine	  kinases	  act	  through	  several	  effector	  arms,	   such	   as	   Ras/MAP	   K	   (MAP	   kinase),	   PI3-­‐K	   (phosphoinositide	   3-­‐kinase),	   PLC-­‐γ	  (Phospholipase	  C),	  and	   JAK-­‐STAT,	   in	  order	   to	  regulate	  cell	  proliferation,	  cell	   scatter	  and	  migration	  and	  cytokine	  stimulation.	  PDGF	   is	   one	  of	   the	  main	   regulators	   of	   oligodendrocyte	  development.	  During	  embryogenesis,	   it	   is	   expressed	   by	   neurons	   and	   astrocytes,	   whereas	   its	   receptor	  (PDGFR-­‐α)	   is	   restricted	   to	   glial	   progenitors	   and	   neurons	   (Yeh	   et	   al.,	   1993).	   After	  birth,	   PDGFR-­‐α	   is	   down-­‐regulated	   as	   glial	   progenitors	   differentiate	   into	  oligodendrocytes.	  Consistently,	  in	  the	  adult	  brain,	  PDGFR-­‐α	  expression	  is	  high	  in	  the	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ventricular	   and	   sub	   ventricular	   zone	   of	   the	   lateral	   ventricles,	   mainly	   restricted	   to	  neural	   stem	   cells,	   while	   PDGF	   is	   largely	   expressed	   by	   neurons	   and	   astrocytes	  (Oumesmar	  et	  al.,	  1997).	  Intriguingly,	  PDGFR-­‐α	  positive	  cells	  show	  a	  morphology	  and	  immunohistochemistry	  typical	  of	  glial	  progenitors.	  A	  subpopulation	  of	  these	  cells	  also	  express	   NG2	   (An	   integral	   membrane	   chondroitin	   sulfate	   proteoglycan)	   and	   are	  partiularly	  dynamic	   cells,	   able	   to	   respond	   to	   changes	   in	   environment.	   For	   instance,	  they	  can	  proliferate	  in	  response	  to	  stimuli	  such	  as	  demyelination	  and	  inflammation.	  	  Tumors	  often	  overexpress	  both	  PDGF	  ligands	  and	  receptors,	  so	  establishing	  a	  stimulatory	   loop.	   Interestingly,	   robust	   expression	   of	   PDGF	   and	   PDGFR-­‐α	   is	   often	  associated	  with	  p53	  mutations	  in	  low	  grade	  gliomas	  (Hermanson	  et	  al.,	  1996).	  Given	  this	   link,	   it	   was	   suggested	   that	   the	   proliferative	   stimulus	   by	   PDGF	   signaling	   could	  promote	   the	   reentry	   into	   cell	   cycle,	   which	   cannot	   be	   antagonized	   by	   p53,	   as	   it	   is	  mutated.	  However,	  even	  if	  in	  combination	  with	  bFGF	  PDGF	  promote	  proliferation	  of	  glial	   progenitors	   in	   vitro	   	   (McKinnon	   et	   al.,	   1990),	   overexpression	   of	   PDGF	   is	  associated	  with	  low	  proliferative	  rate	  in	  low	  grade	  gliomas	  in	  vivo.	  Therefore,	  it	  was	  suggested	   that	   PDGF	   signaling	   may	   exert	   its	   role	   through	   pathway	   different	   from	  Ras/MAPK.	   For	   instance,	   it	   is	   possible	   for	   PDGF	   to	   induce	   in	   tumor	   cell	  migration	  through	  activation	  of	  PI3-­‐K	  and	  PLC-­‐γ.	  	  EGFR	   gene	   amplification	   has	   been	   found	   in	   the	   majority	   of	   high	   grade	  astrocytomas	  (in	  57.4%	  of	  GBM	  studied	  in	  (Brennan	  et	  al.,	  2013)).	  This	  is	  why	  EGFR	  activation	  is	  thought	  to	  be	  one	  of	  the	  main	  responsible	  of	  malignant	  transformation	  process	   towards	   GBM.	   EGFR	   is	   critical	   to	   regulate	   astrocyte	   and	   oligodendrocyte	  development	   too.	   	  As	   explained	  before,	   EGFR	   is	   crucial	   to	   sustain	  proliferation	   and	  survival	   of	   the	   neural	   stem	   cell	   compartment.	   This	   role	   in	   normal	   development	  provides	  a	  clue	  of	  its	  role	  in	  GBM.	  High	  levels	  of	  Ras-­‐GTP	  effector	  have	  been	  found	  in	  high	  grade	  astrocytoma	  (Guha	  et	  al.,	  1997),	  thus	  suggesting	  that	  it	  can	  be	  activated	  by	  RTK	   activation	   driven	   by	   EGFR	   signaling.	   Approximately	   40%	   of	   GBM	   with	   EGFR	  amplification	  also	  commonly	  express	  a	  variant	   form	  called	  EGFRvIII	  or	  del2-­‐7EGFR,	  where	   genomic	   deletions	   eliminate	   exons	   2-­‐7	   in	   the	   EGFR	   mRNA.	   This	   mutation	  results	   in	   a	   truncated	   EGFR,	   which	   does	   not	   have	   the	   extracellular	   ligand-­‐binding	  domain	   and	   is	   constitutively	   activated,	   never	   down-­‐regulated.	   This	   of	   course	  enhances	   tumorigenic	   properties	   of	   cells,	   by	   increasing	   proliferation	   and	   reducing	  apoptosis	  (Nagane	  et	  al.,	  1996;	  Nishikawa	  et	  al.,	  1994).	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-­‐	   The	  p53	  pathway	  The	  p53	  pathway	  is	  the	  most	  commonly	  mutated	  pathway	  in	  tumorigenesis	  in	  general.	   The	   well-­‐known	   tumor	   suppressor	   p53	   is	   in	   charge	   to	   respond	   to	   DNA	  damage	   and	  numerous	   genotoxic	   and	   cytotoxic	   events	  by	   inducing	   cell	   cycle	   arrest	  and	   apoptosis.	   Also,	   it	   is	   an	   important	   transcription	   factor	   regulating	   thousands	   of	  genes,	  most	  of	  which	  involved	  in	  tumorigenesis	  and	  tumor	  invasion.	  	  Allelic	  loss	  of	  chromosome	  17p	  and	  p53	  mutations	  are	  equally	  frequent	  in	  	  low-­‐grade	  gliomas,	   anaplastic	   astrocytomas	   and	   secondary	   glioblastomas	   (Louis,	   1994).	   This	  suggests	  that	  p53	  inefficacy	  might	  be	  an	  early	  event	  in	  gliomagenesis.	  It	  seems	  it	  has	  got	   a	   prominent	   role	   in	   the	   development	   of	   secondary	   GBMs.	   Nevertheless,	   less	  frequent	  mutations	   are	   also	   found	   in	  primary	  GBMs,	  possibly	   as	   a	   secondary	   event	  due	  to	  genomic	  instability	  (Ohgaki	  and	  Kleihues,	  2007;	  Ohgaki	  et	  al.,	  2004;	  St	  Louis	  et	  al.,	  1999).	  The	  fact	  that	  brain	  radiation	  during	  childhood	  is	  a	  risk	  factor	  for	  the	  onset	  of	   gliomas	   (Neglia	   et	   al.,	   1991)	   is	   possibly	   provoked	   by	   the	   deactivation	   of	   p53-­‐dependent	  DNA	  damage	  checkpoint	  response,	  in	  order	  to	  allow	  cell	  survival	  following	  irradiation.	   	   In	   addition	   to	   increase	   proliferation,	   the	   p53	   loss	   can	   induce	   the	  accumulation	  of	  other	  genetic	  mutations	  that	  then	  result	  in	  the	  secondary	  GBMs.	  One	  of	  the	  most	  important	  modulators	  of	  p53	  is	  the	  downstream	  gene	  target,	  
MDM2,	  which	  has	  been	  found	  amplified	  in	  about	  10	  %	  of	  GBMs.	  MDM2	  binds	  to	  p53	  N-­‐terminal	   transactivation	   domain	   and	   inhibits	   p53	   transcriptional	   activity.	  Moreover,	   it	   serves	   as	   E3	   ubiquitin	   ligase,	   thus	   orchestrating	   ubiquitination	   and	  proteosomal	  degradation	  of	  p53	  (Huang	  et	  al.,	  1999;	  Kubbutat	  et	  al.,	  1997;	  Momand	  et	  al.,	  1992).	  MDM2	  transcription	  is	  induced	  by	  p53	  itself,	  so	  establishing	  a	  negative	  feedback	   loop.	   Interestingly	   MDM2	   amplification	   has	   been	   exclusively	   found	   in	  tumors	  that	  did	  not	  display	  p53	  mutations,	  suggesting	  that	  MDM2	  overexertion	  could	  represent	  an	  alternative	  way	  to	  knock-­‐down	  p53	  pathway	  (Reifenberger	  et	  al.,	  1996).	  	  ARF	   (p14ARF)	   is	   an	   upstream	   regulator	   of	   the	   p53	   pathway.	   It	   directly	   inhibits	  MDM2	   E3	   ubiquitin	   ligase	   activity	   (Kamijo	   et	   al.,	   1998;	   Zhang	   et	   al.,	   2008).	  Inactivation	  or	  mutation	  of	  ARF	  have	  been	   found	   in	  both	   low	  grade	  and	  high	  grade	  gliomas.	  Together	  with	   INK4a	  (p16INK4a),	  an	   important	  regulator	  of	  pRB	  pathway,	  ARF	   is	   encoded	   by	   CDK2A	   locus.	   Deletion	   of	   such	   locus	   are	   frequent	   in	   GBMs.	  Moreover,	   co-­‐deletion	   of	   ARF	   and	   INK4a	   promote	   the	   transformation	   from	   low-­‐	   to	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high-­‐grade	  gliomas	  (Labuhn	  et	  al.,	  2001).	  This	  suggest	  this	  deletion	  could	  represent	  a	  key	  event	  in	  gliomagenesis.	  	  	  












Figure	  I.16.	  	  Integration	  between	  RTK	  pathways	  and	  the	  cell	  cycle.	  	  (Adapted	  from	  (Maher	  et	  al.,	  2001))	  
	  
	  
-­‐	   Chromosome	  10q	  tumor	  suppressors	  (PTEN,	  Mxi1,	  DMBT1)	  Loss	  of	  heterozygosity	  on	   chromosome	  10	   is	   commonly	   found	   in	  high-­‐grade	  gliomas.	   PTEN	   (phosphatase	   and	   tensin	   homology)	   is	   a	   tumor	   suppressor	   gene	  located	  on	  such	  chromosome.	  Mutations	  in	  PTEN	  gene	  locus	  have	  been	  identified	  in	  a	  wide	   variety	   of	   tumors,	   including	   both	   primary	   and	   secondary	   GBMs.	   PTEN	  negatively	   regulates	   PI3K/AKT/PKB	   pathway	   by	   inhibiting	   Akt	   signaling	   via	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reduction	   of	   intracellular	   levels	   of	   phosphatidylinositol-­‐3,4,5-­‐triphosphate	  (Stambolic	   et	   al.,	   1998).	   Normally	   Akt	   activates	   the	   downstream	   effector	   mTOR,	  composed	  by	  mTORC1	  and	  mTORC2,	  which	  integrates	  several	  upstream	  signals	  and	  regulate	   cell	   growth	   and	   division.	   	   Conversely,	   PI3K/AKT/mTOR	   pathway	   is	  stimulated	  by	  growth	  factors	  and	  their	  receptors,	  such	  as	  EGFR	  and	  PDGFR.	  	  Thus,	  mutation	  or	  deletions	  of	  PTEN	  	  and	  amplification	  of	  EGFR/PDGFR	  result	  in	  over	  activation	   of	   PI3K	   signaling	   in	   GBM,	   which	   may	   clearly	   play	   an	   important	   role	   in	  glioma	  development	  and	  malignancy.	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Figure	  I.18.	  Summary	  of	  overall	  alteration	  rate	  for	  canonical	  PI3K/MAPK,	  p53	  and	  Rb	  
regulatory	  pathways.	  (Adapted	  from	  (Brennan	  et	  al.,	  2013))	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1.3	   Emx2	  gene	  
	  
1.3.1	   Emx2	  phylogenesis	  and	  structure	  
Emx2	   is	   an	  homeobox	   regulatory	   gene	  encoding	   for	   a	   transcription	   factor.	   It	  shares	   an	   evolutionary	   common	   origin	   with	   the	   Drosophila	   melanogaster	   empty	  
spiracles	  (ems),	  showing	  82%	  of	  homology	  in	  its	  homeobox	  domain.	  Ems	  regulates	  the	  formation	  of	  pre-­‐antennal,	  antennal	  and	  intercalary	  segments	  of	  the	  embryo	  (Cohen	  and	  Jürgens,	  1990;	  Dalton	  et	  al.,	  1989).	  
Emx2	   is	   expressed	   early	   in	   the	   cerebral	   cortex.	   Indeed,	   it	   is	   activated	   in	   the	  mouse	  embryonic	  central	  nervous	  system	  at	  around	  E8.0-­‐E8.5	  (Gulisano	  et	  al.,	  1996).	  From	   this	   stage,	   it	   becomes	   more	   and	   more	   expressed	   in	   anterior	   dorsal	  neuroectodermal	  regions	  of	  the	  embryo.	  At	  E9.5,	  its	  expression	  domain	  includes	  the	  overlapping	   region	   of	   expression	   of	   Emx1	   (anterior	   boundary)	   and	   part	   of	  presumptive	  diencephalon.	  At	   this	   stage,	  Emx2	  mRNA	   is	   found	  also	   in	   the	  olfactory	  placodes	  and	  the	  coelomic	  epithelium	  which	  will	  generate	  the	  urogenital	  system..	  From	   E10	   Emx2	   expression	   is	   confined	   to	   the	   neuroepithelium	   while	   is	   absent	   in	  most	  postmitotic	  neurons	  of	   the	  transitional	   field	  and	  cortical	  plate	  (Gulisano	  et	  al.,	  1996).	   At	   E12.5	   Emx2	   mRNA	   becomes	   restricted	   to	   the	   ventricular	   zone	   (vz),	  following	   a	   posterior/medialhigh-­‐anterior/laterallow	   gradient.	   This	   pattern	   of	  expression	  becomes	  more	  pronounced	   from	  E14.5	  onwards	   ((Gulisano	  et	   al.,	   1996;	  Simeone	  et	  al.,	  1992)).	  Furthermore,	  the	  distribution	  of	  the	  Emx2	  protein	  displays	  the	  same	   anterior-­‐posterior	   and	   medio-­‐lateral	   gradient.	   Until	   E17.0,	   Emx2	   domain	   of	  expression	  remains	  confined	  to	  the	  proliferative	  layers	  of	  the	  cortex	  plus	  the	  pioneer	  neurons	  of	  Cajal-­‐Retzius	  	  (Mallamaci	  et	  al.,	  1998).	  The	   peculiar	   pattern	   of	   expression	   of	   Emx2	   mRNA	   and	   protein	   strongly	  suggested	  a	  role	  in	  cortical	  polarity,	  cell	  identity	  and	  patterning	  in	  the	  initial	  phases	  of	   arealization	   of	   cerebral	   cortex.	   Also,	   the	   presence	   of	   Emx2	   in	   the	   proliferative	  layers	  pointed	  out	  a	  suitable	  role	   in	  the	  regulation	  of	  proliferation,	  as	  well	  as	   in	  the	  migration	   of	   cortical	   neuroblasts	   to	   their	   final	   destination	   in	   the	   mature	   cortex	  (McConnell,	  1995).	  Finally,	  as	  Emx2	  mRNA	  is	  prevalently	  present	  in	  neuroepithelium,	  where	  neuroblasts	  divide	  giving	  rise	  to	  all	  the	  populations	  of	  the	  later	  mature	  cortex,	  
Emx2	  was	  hypothesized	  to	  play	  an	  important	  role	  in	  fate	  decision.	  Consistently	  with	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these	   predictions,	   Emx2-­‐/-­‐	  mutant	   mice	   display	   deep	   damages	   in	   central	   nervous	  system.	   The	   cerebral	   hemispheres,	   olfactory	   bulbs	   and	   hippocampus	   are	   roughly	  shrunken	  and	  the	  dentate	  gyrus	  is	  absent	  (Pellegrini	  et	  al.,	  1996;	  Yoshida	  et	  al.,	  1997).	  These	   brains	   also	   show	   disruption	   of	   migration,	   differentiation	   and	   innervation	   in	  specific	  neuronal	  populations	  (Mallamaci	  et	  al.,	  2000a,	  2000b;	  Muzio	  and	  Mallamaci,	  2005).	  The	  importance	  of	  Emx2	  is	  confirmed	  by	  the	  fact	  that	  Emx2	  -­‐/-­‐	  mutant	  die	  soon	  after	   birth	   because	   of	   the	   absence	   of	   urogenital	   system.	   Apart	   from	   CNS	   damages,	  they	   suffer	   specific	   skeletal	   defects,	   including	   the	   absence	   of	   scapulae	   and	   ilia	  (Pellegrini	  et	  al.,	  2001).	  	   	  In	   the	  mouse,	  Emx2	   is	   located	   on	   chromosome	   19.	   Its	  mRNA	   includes	   three	  exons,	   is	  2598	  bp	   long	  and	  encodes	   for	  a	  homeodomain	   transcription	   factor	  of	  253	  aminoacids.	   Interestingly,	   a	   transcript	  encoded	  by	  Emx2	  opposite	   strand	  was	   found	  both	  in	  human	  and	  in	  mouse.	  This	  antisense	  transcript	  overlaps	  with	  the	  Emx2	  mRNA	  gene	  head-­‐to-­‐head	   and	  has	  been	   called	  Emx2OS	   (Noonan	   et	   al.,	   2003).	   	   It	   has	  been	  demonstrated	   (Spigoni	   et	   al.,	   2010)	   that	   this	   non-­‐coding	   RNA	   is	   involved	   in	   the	  regulation	   of	   Emx2	   pattern	   of	   expression.	   In	   fact,	   the	   two	   transcripts	   are	   both	  expressed	  in	  periventricular	  neural	  precurors	  of	  the	  cortical	  primordium,	  but	  show	  a	  mutually	  exclusive	  pattern	  in	  post-­‐mitotic	  progenies	  of	  these	  precursors	  (Mallamaci	  et	   al.,	   1998;	   Simeone	   et	   al.,	   1992).	   	  While	  Emx2OS-­‐ncRNA	   is	   expressed	   in	  newborn	  neurons	   belonging	   to	   the	   cortical	   plate,	   Emx2	   is	   highly	   expressed	   in	   Cajal-­‐Retzius	  neurons	   residing	   within	   the	   marginal	   zone	   (Mallamaci	   et	   al.,	   1998).	   	   This	   mutual	  distribution	   proposes	   a	   possible	   negative	   cross-­‐regulation	   between	   the	   two.	  Remarkably,	  Emx2	  antisense	  transcript	  seems	  to	  have	  a	  role	  in	  the	  shutting	  down	  of	  the	   expression	  of	  Emx2	   in	   the	  post-­‐mitotic	   cells	   of	   the	   cortical	   plate	   (Spigoni	   et	   al.,	  2010).	  	  	  
1.3.2	   Emx2	  role	  in	  R/C	  and	  D/V	  neural	  specification	    
	  	  	  	  	  	  	  	  	  	  	  	  	  Emx2	  is	  primarily	   involved	   in	   large	  scale	  patterning	  of	   the	  rostral	  CNS,	  along	  the	   rostro-­‐caudal	   and	   the	   dorso-­‐ventral	   axis.	   Furthermore,	   it	   contributes	   to	  regulation	  of	  different	  aspects	  of	  cortico-­‐cerebral	  development.	  	  As	   for	   rostrocaudal	   specification	   of	   CNS,	   Emx2	   is	   firstly	   expressed	   in	   the	   territory	  rostral	  to	  the	  zona	  limitans	  intratalamica	  (ZLI)	  and	  contributes	  to	  its	  specification	  as	  telencephalic	  prethalamic	  field,	  in	  combination	  with	  Otx2	  and	  Pax6.  
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Relevant	   rostrocaudal	   patterning	   errors	   occurs	   indeed	   in	   Emx2-­‐/-­‐,	   Otx2-­‐/+	  mutants,	   where	   there	   is	   a	   shrinkage	   of	   the	   anterior	   prosencephalon	   and	   an	  enlargement	   of	   the	   tectum	   and	   the	   rombencephalon	   (Kimura	   et	   al.,	   2005).	   Emx2-­‐/-­‐	  Pax6-­‐/-­‐	  mouse	  embryos	  conversely	  show	  a	  duplication	  of	  the	  tectum	  and	  the	  collapse	  of	  prosomers	  anterior	  to	  the	  zona	  limitans	  intra-­‐thalamica	  (ZLI)	  	  after	  E10.5	  (Kimura	  et	  al.,	  2005).	  As	  for	  dorso-­‐ventral	  patterning,	  Emx2	  cooperates	  with	  Pax6	  in	  specifying	  the	  dorsal	  telencephalon	  as	  pallium.	  When	  both	  Emx2	  or	  Pax6	  are	  not	  present,	  the	  whole	  cortical	  development	  is	  disrupted	  and	  the	  cortex	  evolves	  to	  a	  striatum-­‐like	  structure	  (Muzio	   et	   al.,	   2002).	   Later,	   at	  E14.5,	   the	   striatum	   itself	   of	   these	  Emx2/Pax6	  double	  mutants	  further	  acquires	  features	  peculiar	  to	  the	  globus	  pallidus	  (Muzio	  et	  al.,	  2002).	  	  
1.3.3	   Emx2	  roles	  in	  neural	  precursors	  kinetics:	  early	  and	  late	  activity	  
Emx2	   controls	   proliferation	   and	   migration	   of	   cortical	   neuroblasts,	   it	  establishes	   cell	   role	   and	   identity	   within	   the	   proliferative	   layers	   and	   it	  maintains	   a	  position-­‐dependent	   signal	   within	   the	   developing	   cortex.	   However,	   the	   influence	   of	  this	  transcription	  factor	  on	  cortical	  precursor	  kinetics	  and	  histogenesis	  is	  amazingly	  complex.	  In	  early,	  neural	  precursors,	   it	  promotes	  cell	   cycle	  progression	  and	   it	   inhibits	  premature	   neuronal	   differentiation	   (Muzio	   et	   al.,	   2005).	   In	   this	   respect,	   Emx2-­‐/-­‐	  mutants	  show	  an	  elongation	   in	  neuroblasts	  cycling	   time	  due	   to	   lengthening	  of	  DNA	  synthesis	   phase.	   In	   addition,	   cortical	   progenitors	   leave	   cell	   cycle	   more	   frequently.	  These	   phenomena	   are	   associated	   with	   an	   increase	   in	   pro-­‐neural/anti-­‐neural	   gene	  expression	   ratio,	   a	   downregulation	   of	   the	   lateral	   inhibition	   machinery	   and	   a	  depression	  of	  the	  canonical	  Wnt	  signalling	  (Muzio	  et	  al.,	  2005).	  All	  these	  phenomena	  are	  more	  pronounced	  in	  the	  caudomedial	  than	  in	  rostral	  pallium.	  On	  the	  contrary,	  in	  more	  advanced	  neural	  stem	  cells,	  Emx2	  expression	  leads	  to	  the	  stop	  of	  proliferation	  and	  the	  decision	  to	  undergo	  neuronal	  differentiation	  (Galli	  et	  al.,	  2002;	  Gangemi	  et	  al.,	  2006).	  Brancaccio	   et	   al	   (Brancaccio	   et	   al.,	   2010)	   confirmed	   the	   bimodal	   impact	   of	  Emx2	   on	   NSC	   proliferation/differentiation	   kinetics.	   Moreover,	   they	   reported	   some	  new	  roles	   for	   this	   transcription	   factor.	  As	   shown	  by	   these	  authors,	  Emx2	  promotes	  the	   transition	   from	   NSCs	   to	   early	   bipotent	   glial	   progenitors,	   inhibits	   further	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expansion	  of	   these	  progenitors	  and	  ultimately	  decrease	  their	   final	  astroglial	  output.	  Moreover,	   it	   protects	   NPs	   from	   cell	   death	   and	   accelerates	   their	   neuronal	  differentiation	  (Brancaccio	  et	  al.,	  2010).	  	  
1.3.4	   Emx2	   role	   in	   cortical	   regionalization,	   arealization	   and	  
neocortical	  lamination	  
Emx2	  is	  expressed	  early	  in	  the	  cortical	  primary	  proliferative	  layers,	  following	  a	  caudomedialhigh-­‐rostrolaterallow	   gradient.	   Thus	   it	   is	  more	   expressed	   in	   presumptive	  V1	  area	  and	  less	  in	  presumptive	  frontal/motor	  areas.	  As	  such,	  it	  has	  a	  prominent	  role	  in	   cortical	   regionalization	   and	   arealization,	   as	   an	   inducer	   of	   caudomedial	   fates	  (Bishop	   et	   al.,	   2000;	   Gulisano	   et	   al.,	   1996;	   Mallamaci	   et	   al.,	   2000a;	   O’Leary,	   1989;	  Simeone	  et	  al.,	  1992).	  In	  absence	  of	  Emx2,	  the	  neo/paleocortex	  is	  enlarged	  whereas	  the	   archicortical	   areas	   are	   strongly	   reduced:	   the	   dentate	   gyrus	   disappears	   and	   the	  hippocampus	   is	   shrunken.	   Along	   the	   antero-­‐posterior	   axis	   the	   caudomedial	   areas	  (such	   as	   V1)	   are	   almost	   completely	   shrunken	   in	   favour	   of	   the	   rostrolateral	   ones,	  which	  are	  enlarged	  (Mallamaci	  et	  al.,	  2000a)	  .	  Opposite	  distorsions	  of	  the	  areal	  profile	  are	  displayed	  by	  gain-­‐of-­‐function	  mutants	  (Hamasaki	  et	  al.,	  2004).	  Furthermore,	   Emx2-­‐/-­‐	   mutants	   display	   an	   an	   abnormal	   radial	   migration	   of	  cortical	   plate	   neurons	   which	   is	   quite	   similar	   to	   that	   of	   Reeler	   mutant	   mice.	   Early	  cortical	   plate	   neurons	   do	   not	   infiltrate	   the	   preplate,	   which	   is	   not	   split	   in	  marginal	  zone	   and	   subplate	   and	   forms	   a	   structure	   called	   super-­‐plate.	  On	   the	   other	   side,	   late	  born	  neurons	  do	  not	  follow	  the	  classical	  inside-­‐out	  rules.	  All	  that	  likely	  emerges	  as	  a	  consequence	   of	   impaired	   generation/differentiation	   of	   pioneer	   layer	   I	   neurons	   in	  charge	  of	  orchestrating	  neocortical	   lamination	  In	  fact,	  these	  mutants,	  from	  E13.5	  on	  
Reln-­‐mRNA	  expression	  is	  reduced	  until	  it	  completely	  disappears	  at	  E15.5	  (Mallamaci	  et	  al.,	  2000a).	  This	  reflects	  the	  fact	  that	  Cajal-­‐Retzius	  cells,	  normally	  originating	  from	  the	   cortical	   hem	   and	   populating	   cortex	   along	   a	   caudomedialhigh-­‐rostrolaterallow	  gradient,	   are	   almost	   absent	   in	  Emx2-­‐/-­‐	   in	   the	   caudomedial	   region,	   possibly	  due	   to	   a	  reduction	  of	  the	  corresponding	  neuronogenic	  pool.	  
	  
1.3.5	   Emx2	  extraneural	  expression	  Apart	   from	   being	   expressed	   in	   CNS,	   Emx2	   shows	   various	   patterns	   of	  expression	  which	  underlie	  its	  importance	  in	  multiple	  tissues.	  At	  E12.5	  for	  instance	  it	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is	   expressed	   in	   the	   developing	   olfactory	   epithelium,	   the	   kidneys	   and	   the	   gonads.	  Indeed,	   knocked-­‐down	   mutants	   die	   soon	   after	   birth	   because	   they	   defects	   of	  development	  of	  the	  urogenital	  system.	  Interestingly,	   in	   Emx2-­‐/-­‐	   mice	   the	   early	   stages	   of	   gonad	   development	   are	  disrupted,	  with	  a	  dramatic	  enlargement	  of	  the	  surface	  of	  epithelial	  cells	  hosting	  tight	  junctions	   and	   migration	   of	   the	   epithelial	   cells	   significantly	   affected	   (Kusaka	   et	   al.,	  2010).	  Microarray	  analysis	  of	  the	  epithelial	  cells	  of	  the	  embryonic	  gonad	  displays	  a	  dramatic	  upregulation	  of	  EGFR	  in	  Emx2	  KO	  mice.	  Based	  on	  previous	  demonstration	  of	  an	  Egfr	  involvement	   in	   regulation	   of	   tight	   junctions	   assembly,	   such	   ectopic	   expression	   of	  EGFR	  was	  strongly	  suggested	  to	  act	  as	  a	   link	  between	  Emx2	  ablation	  and	  junctional	  anomalies	  of	  Emx2-­‐LOF	  mutants.	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1.4	   Foxg1	  gene	  
	  
1.4.1	   Foxg1	  phylogenesis	  and	  structure	  Forkhead	   box	   G1	   (Foxg1),	   formerly	   known	   as	   brain	   factor-­‐1	   (Bf-­‐1)	   is	   a	  regulatory	   	   gene	   of	   the	   forkhead	   family	   encoding	   for	   a	   winged-­‐helix	   transcription	  factor	  (TF).	  The	   Forkhead	   family	   is	   characterized	   by	   a	   conserved	   DNA-­‐binding	   domain	  called	  the	  ‘Forkhead	  box’,	  or	  FOX.	  The	  name	  ‘Forkhead’	  takes	  its	  origin	  from	  a	  study	  in	  Drosophila	  where	  a	  mutation	  in	  a	  paralog	  of	  this	  gene	  caused	  the	  formation	  of	  an	  ectopic	  head	  structure	  that	  resembles	  a	  fork.	  Sometimes	  the	  forkhead	  proteins	  can	  be	  referred	   to	  as	   ‘winged	  helix’	  proteins	  because	  of	   the	   three	  α-­‐helices	   flanked	  by	   two	  loops	   resembling	   butterfly	   wings,	   which	   have	   been	   revealed	   thanks	   to	   X-­‐ray	  crystallography.	   Such	   family	   is	   composed	   by	  more	   than	   100	  different	   transcription	  factors,	  displaying	  the	  most	  disparate	  functions. The	  human	  FOXG1	   gene	   is	   located	  on	   chromosome	  14	   in	  position	  13	  on	   the	  long	   (q)	   arm.	   Foxg1	   protein	   usually	   acts	   as	   a	   transcriptional	   repressor	   either	   in	   a	  direct	   or	   indirect	   manner.	   It	   plays	   a	   central	   role	   in	   the	   developing	   telencephalon.	  Indeed,	  Foxg1,	   among	  many	  other	   cortico-­‐cerebral	  patterning	  genes,	   is	   a	   crucial	  TF	  for	  many	   aspects	   of	   cerebral	   cortex	   development.	   It	   is	   involved	   in	   cerebral	   cortex	  morphogenesis,	   including	   early	   distinction	   between	   pallial	   and	   subpallial	   fields,	   in	  dorsoventral	   patterning	   of	   the	   pallium,	   cell	   cycle	   control,	   lineage	   fate	   choices	  induction,	   regulation	   of	   neocortical	   cell	   differentiation	   and	   migration,	   tuning	   of	  astrogenesis	  rates.	  	  Most	  of	  these	  roles	  are	  elucidated	  below.	  	  Remarkably,	   a	   proper	   dosage	   allele	   of	   this	   gene	   seems	   to	   be	   crucial.	   Even	  subtle	   alterations	   in	   its	   expression	   can	   lead	   to	  defects	   in	   the	  brain	  development	  or	  pathological	  conditions	  such	  as	  Rett	  Syndrome	  or	  West	  Syndrome.	  
	  
1.4.2	   Foxg1	  in	  telencephalic	  patterning	  and	  cortical	  arealization	  Starting	   from	   E7	   in	   mice,	   the	   primitive	   node	   or	   organizer	   and	   the	   anterior	  visceral	  endoderm	  (AVE)	  send	  signals	  for	  neural	  induction	  and	  maintenance	  in	  order	  to	   organize	   the	   early	   rostro-­‐caudal	   patterning	   (Thomas	   and	   Beddington,	   1996).	   In	  particular,	   the	   AVE	   secretes	   molecules	   called	   cerberus	   and	   dickkopf,	   which	  antagonize	  the	  posteriorizing	  effect	  of	  molecules	  expressed	  by	  the	  neural	  plate,	  such	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as	  Wnt,	  Fgfs	   family	  members	  and	  retinoic	  acid	  (RA)	  (Altmann	  and	  Brivanlou,	  2001;	  Sasai	  and	  De	  Robertis,	  1997).	  Then,	  after	  the	  anterior	  neural	  induction,	  the	  secondary	  organizer,	   the	   Anterior	   Neural	   Ridge	   (ANR),	   is	   in	   charge	   to	   promote	   telencephalic	  development.	  ANR	  triggers	  the	  expression	  of	  Foxg1	  via	  Fgf8	  secretion	  (Houart	  et	  al.,	  1998;	  Shimamura	  and	  Rubenstein,	  1997).	   In	   fact,	  when	  ANR	   is	  ablated	   in	  mice,	   the	  expression	  of	   the	   telencephalic	  markers	  Foxg1	  and	  Emx1	   is	  prevented	   (Shimamura	  and	  Rubenstein,	  1997).	  	  Furthermore,	   Hedgehog	   signaling	   induces	   Foxg1	   expression	   (Danesin	   et	   al.,	  2009).	   Thus,	   the	   coordinated	   stimulation	   by	   Fgf8	   from	   ANR	   and	   Shh	   from	   the	  prechordal	   plate,	   allow	   a	   graded	   Foxg1	   expression:high	   ventral/anterior	   to	   low	  dorsal/posterior.	  	  As	   for	   the	  dorso/ventral	   specification	  of	   telencephalon,	   there	   is	   a	  balance	  of	  Gli3	   and	   Shh	   expression,	   which	   show	   dorsalizing	   and	   ventralizing	   effects,	  respectively	   (Grove	   et	   al.,	   1998;	   Kuschel	   et	   al.,	   2003).	   In	   this	   scenario,	   Foxg1	  cooperates	  with	  Fgf	  as	  ventralizing	  signal,	  downstream	  to	  Shh,	   in	  order	  to	  generate	  ventral	  cell	  types	  (Rallu	  et	  al.,	  2002).	  This	  is	  confirmed	  by	  the	  evidence	  that	  in	  Foxg1-­‐/-­‐	   the	   formation	   of	   the	   subpallium	   is	   strongly	   impaired	   (Xuan	   et	   al.,	   1995).	  Telencephalon	  is	  completely	  lost	  in	  Foxg1/Gli3	  double	  mutants,	  suggesting	  that	  these	  two	   factors	  are	  essential	   to	  generate	  and	  maintain	   telencephalic	  dorsal	   and	  ventral	  subdivision,	   respectively	   (Hanashima	  et	   al.,	   2007).	   	  Noticeably,	   Fgf	   signaling	   is	   also	  crucial	  for	  the	  generation	  of	  the	  ventral	  cell	  types	  (Gutin	  et	  al.,	  2006).	  In	  this	  respect,	  Foxg1	   is	   required	   for	   Fgf8	   expression	   from	   ANR	   	   (Martynoga	   et	   al.,	   2005)	   and	  conversely,	   Foxg1	   expression	   is	   itself	   regulated	   by	   Fgf	   signaling	   forming	   a	   positive	  feedback	  loop	  ((Shimamura	  and	  Rubenstein,	  1997;	  Storm	  et	  al.,	  2006)).	  Beside	  its	  key	  centralizing	   role,	   Foxg1	   is	   also	   required	   to	   restrict	   dorsal	   fates	   by	   limiting	   Wnt	  expression.	   Indeed,	   Foxg1	   represses	  Wnt8b	   transcription,	   by	  directly	  binding	   to	   its	  promoter	  (Danesin	  et	  al.,	  2009).	  In	  summary,	  Foxg1	  takes	  part	  to	  a	  complex	  network	  of	  signaling	  pathways:	  it	  promotes	   ventral	   identity	   downstream	   of	   Shh	   and	   concomitantly	   controls	   the	  extension	  of	  the	  dorsal	  territory	  via	  a	  direct	  Wnt	  ligands’	  repression.	  
	  Moreover,	   Foxg1	   plays	   a	   key	   task	   in	   the	   process	   of	   cortical	   arealization:	   it	   has	   an	  extremely	  important	  function	  during	  the	  subdivision	  of	  the	  cerebral	  cortex	  in	  distinct	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anatomical	   and	   functional	   areas.	   	   Patterning	   centres	   imimplicated	   in	   cortical	  arealization	  are	  listed	  below:	  	  (1)	  rostrally,	  the	  commissural	  plate	  (CoP)	  secretes	  Fgfs	  (Fgf3,8,17	  and	  18);	  	  (2)	  dorsocaudally,	  the	  cortical	  hem	  secretes	  the	  class	  of	  bone	  morphogenetic	  proteins	  (Bmp2,4,5,6,7)	  and	  Wnts	  (Wnt2b,	  3a,	  5a,	  tb	  8b);	  	  (3)	  lateroventrally,	  the	  cortical	  antihem	  secretes	  the	  Epidermal	  growth	  factor	  family	  members	  (Tgfα,	  Nrg1	  and	  Nrg3),	  Fgf7,	  and	  the	  Wnt	  signaling	  inhibitor,	  Sfrp2.	  As	   stated	   before,	   Foxg1	   is	   expressed	   in	   progenitor	   cells	   along	   a	  caudo/medial(low)	  to	  	  rostro/lateral(high)	  gradient.	  In	  Foxg1-­‐/-­‐	  mutants,	  cortical	  field	  is	   abnormally	   specified	   as	   a	   hippocampal	   anlage	   and	   the	  neocortical	   as	  well	   as	   the	  paleocortical	  programs	  are	  fully	  aborted	  (Muzio	  et	  al.,	  2005).	  Furthermore,	  there	  is	  a	  dramatic	  excess	  of	  Cajal	  Retzius	  neurons	  production(Hanashima	  et	  al.,	  2004;	  Muzio	  et	  al.,	  2005).	  	  	  
1.4.3	   Foxg1	  in	  neural	  precursors	  kinetics	  Foxg1	   is	   implicated	   in	   the	   intricate	   regulation	   of	   the	   balance	   between	  proliferation	  and	  differentiation	  of	  neural	  precursors.	  	  At	  this	  level,	  the	  control	  of	  cell	  cycle	  progression	  and	  governing	  is	  crucial.	  In	  fact,	  during	  the	  neurogenesis,	  cell	  cycle	  duration	   is	   progressively	   prolonged,	   thanks	   to	   the	   lengthening	   of	   the	   G1	   phase.	   In	  addition,	   an	   increasing	  number	  of	   cells	   exit	   from	  cell	   cycle	   (Takahashi	   et	   al.,	   1995)	  and	   cells	   start	   undergoing	   asymmetrical	   differentiate	   divisions,	   instead	   of	   self-­‐renewing	   symmetrical	   ones	   (Calegari	   and	  Huttner,	   2003;	   Götz	   and	  Huttner,	   2005).	  These	  processes	  are	  finely	  regulated	  by	  Cdk-­‐Cyclin	  complex	  inhibitors	  of	  the	  Kip/Cip	  family,	  as	  shown	  in	  Fig.	  I.19.	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Figure	  I.19.	  Structure	  and	  regulation	  of	  the	  cell	  cycle.	  (Adapted	  from	  (Dehay	  and	  Kennedy,	  2007))	  	  	  
Foxg1	   mantains	   a	   telencephalic	   progenitor	   status	   and	   ensures	   that	   such	  progenitors	  maintain	  appropriate	  cell	  cycle	  kinetics.	  Foxg1	  expression	  is	  high	  in	  the	  proliferating	   cells	   of	   the	   neuroepithelium	   during	   neocortical	   development,	   while	   it	  declines	  in	  the	  postmitotic	  cells.	  Foxg1-­‐/-­‐	  mice	  show	  a	  reduced	  hemispheres	  size	  and	  a	  severely	   affected	   ventral	   telencephalic	   development.	   Overall,	   they	   exhibit	   reduced	  proliferation	  and	  increased	  differentiation	  (Hanashima	  et	  al.,	  2002;	  Martynoga	  et	  al.,	  2005;	  Xuan	  et	  al.,	  1995).	  	  
Foxg1	   pro-­‐proliferative	   activity	  depends	  on	   its	   capability	   to	  bind	  and	   inhibit	  the	  FoxO-­‐Smad	  transcriptional	  complex,	  and	  in	  thus	  to	  obstruct	  p21	  (Cip1)	  induction	  by	  Tgfb.	  In	  this	  way,	  p21	  cannot	  mediate	  the	  cell	  cycle	  arrest	  at	  G1	  phase	  (Dou	  et	  al.,	  1999;	  Seoane	  et	  al.,	  2004).	  Furthermore,	  Foxg1	  acts	   together	  with	  Polycomb	  factor	  Bmi-­‐1,	  repressor	  of	   the	  cell	  cycle	   inhibitors	  p16,	  p19	  and	  p21.	  Bmi-­‐1	  overexpression	  in	  turn	  upregulates	  Foxg1,	  which	  is	  crucial	  to	  mediate	  promotion	  of	  neural	  progenitor	  cells	  self-­‐renewal	  (Fasano	  et	  al.,	  2009).	  	  Finally,	   Foxg1	   overexpression	   in	   neural	   stem	   cells	   induces	   the	   expansion	   of	  their	   compartment,	  perhaps	  by	   increasing	  NSCs	  self-­‐renewal,	  promoting	  progenitor	  survival	  and	  delaying	  neurogenesis	  (Brancaccio	  et	  al.,	  2010).	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1.4.4	   Foxg1	  in	  neuronal	  differentiation	  and	  migration	  Early	   during	   development,	   pyramidal	   neurons	   are	   born	   within	   the	  proliferative	   layers	   of	   the	   cerebral	   cortex	   and	   then	   migrate	   to	   their	   appropriate	  laminar	  position.	  This	  is	  performed	  thanks	  to	  both	  radial	  (through	  radial	  glial	  fibers)	  and	   tangential	   migration	   (Götz	   and	   Huttner,	   2005).	   When	   pyramidal	   neuron	  precursors	   lie	   within	   the	   intermediate	   zone,	   they	   transiently	   acquire	   a	   multipolar	  morphology,	   then	   they	   detach	   from	   the	   radial	   glia	   and	   initiate	   axonal	   outgrowth,	  before	  entering	  the	  cortical	  plate	  ((Barnes	  et	  al.,	  2007;	  Noctor	  et	  al.,	  2004)).	  During	  these	   migratory	   phases,	   Foxg1	   is	   expressed	   in	   a	   dynamic	   fashion.	   It	   is	   transiently	  down	   regulated	   in	   nascent	   pyramidal	   neuron	   precursors,	   allowing	   NeuroD1	   and	  Unc5d	   expression,	   critical	   for	   the	   transition	   to	   the	   late	   multipolar	   phase.	  Subsequently,	  Foxg1	  is	  specifically	  unregulated	  in	  order	  to	  induce	  the	  cells’	  exit	  from	  the	  multipolar	  phase	  and	  ingress	  into	  the	  cortical	  plate.	  	  
Foxg1	  is	  also	  crucial	  for	  the	  proper	  lamination	  of	  cortical	  progenitor	  cells.	  The	  process	   of	   neocortico-­‐genesis	   needs	   the	   early	   specification	   of	   Cajal-­‐Retziuspioneer	  neurons,	   then	   the	   subsequent	  differentiation	  of	  deep	   layer	  neurons	   first	   and	  upper	  layer	  neurons	  after,	  as	  shown	  in	  figure	  (Fig.	  I.20).	  	  	  
Figure	   I.20.	   	   Mechanisms	   of	   neuronal	   subtype	   transitions	   and	   integration	   in	   the	  




First,	   Foxg1	   and	   Lhx2	   instruct	   the	   cessation	   of	   the	   Cajal-­‐Retzius	   cells’	  production,	  thus	  inducing	  progenitors	  to	  give	  rise	  to	  deep	  layer	  neurons	  (Hanashima	  et	   al.,	   2007;	   Kumamoto	   et	   al.,	   2013).	   As	   stated	   before,	   Foxg1	   is	   induced	   by	   Fgf8	  expressed	   in	   the	   anterior	   neural	   ridge	   (Shimamura	   and	   Rubenstein,	   1997)	   and	  subsequently	  expands	  caudally.	   	  Therefore,	   the	  onset	  of	  Foxg1	  expression	  represses	  several	  transcription	  factors	  in	  an	  opposing	  rostral-­‐to-­‐caudal	  gradient	  and	  regulates	  the	   transition	   from	   CR	   cell	   to	   DL	   neuron	   identity	   in	   a	   spatio-­‐temporaldependent	  manner	  (Kumamoto	  et	  al.,	  2013).	  Moreover,	  Foxg1	  is	  responsible	  for	  Tbr1	  repression,	  which	  preceeds	  the	  onset	  of	  Ctip2	  and	  Fezf2,	  which	  mostly	  regulate	  deep	  layer	  specification.	  This	  suggest	  that	  
Tbr1	  repression	  by	  Foxg1	  regulate	  the	  correct	  sequence	  of	  deep	  layer	  and	  upper	  layer	  neurons	  generation,	  by	  establishing	  the	  initial	  bias	  to	  deep	  layer	  identity	  (Toma	  et	  al.,	  2014).	  Intriguingly,	   Foxg1	   is	   present	   in	   both	   the	   nucleus	   and	   the	   cytoplasm:	   it	   is	  predominantly	   confined	   in	   the	   nucleus	   in	   areas	   of	   active	   neurogenesis,	   while	   it	   is	  translocated	   to	   the	   cytoplasm	   in	  early	  neuronal	  differentiation	  areas	   (Seoane	  et	   al.,	  2004).	   Recently,	   a	   Foxg1	   fraction	   localized	   in	   mitochondria	   has	   been	   illustrated,	  suggesting	   a	   possible	   mechanisms	   for	   mitochondria	   in	   neuronal	   differentiation	  (Pancrazi	  et	  al.,	  2015).	  	  
Foxg1	   is	  still	  expressed	  in	  post-­‐mitotic	  neurons,	  suggesting	  that	  it	  could	  have	  an	  essential	  role	  in	  that	  compartment	  too.	  	  




2.	   AIM	  OF	  THE	  WORK	  
	   Aim	   of	   my	   study	   was	   to	   investigate	   the	   role	   of	   Foxg1	   and	   Emx2	   in	   the	  regulation	   of	   corticocerebral	   astrogenesis.	   In	   detail,	   I	   studied	   the	   involvement	   of	  






3.	   MATERIALS	  AND	  METHODS	  
	  
3.1	  	   Lentiviral	  Vectors	  Packaging	  and	  Titration	  	   Third	   generation	   self-­‐inactivating	   (SIN)	   lentiviral	   vectors	   (LVs)	   were	  generated	   as	   previously	   described	   (Follenzi	   and	   Naldini,	   2002)	   with	   some	  adjustments.	   In	   brief,	   HEK293T	   cells	   were	   co-­‐transfected	   with	   the	   transfer	   vector	  plasmid	  plus	  three	  auxiliary	  plasmids	  (pMD2	  VSV.G;	  pMDLg/pRRE;	   pRSV-­‐REV),	   in	   the	   presence	   of	   LipoD293TM	   (SigmaGen).	   The	  conditioned	   medium	   was	   collected	   after	   24	   and	   48	   hours,	   filtered	   and	  ultracentrifuged	  at	  50000	  RCF	  on	  a	  fixed	  angle	  rotor	  (JA25.50	  Beckmann	  Coulter)	  for	  150	   min	   at	   4°C.	   Lentiviral	   pellets	   were	   then	   resuspended	   in	   PBS	   1X	   without	   BSA	  (Gibco).	  	  LVs	  were	   titrated	  by	  Real	  Time	  quantitative	  PCR	  after	   infection	  of	  HEK293T	  cells,	  as	  previously	  reported	  (Sastry	  et	  al.,	  2002).	  One	  end	  point	  fluorescence	  titrated	  LV	   was	   included	   in	   each	   PCR	   titration	   session	   and	   PCR-­‐titers	   were	   adjusted	   to	  fluorescence-­‐equivalent	  titers	  throughout	  the	  study.	  	  Where	   necessary,	   specific	   lentiviral	   plasmids	   were	   constructed	   with	   basic	  cloning	   techniques.	   DNA	   manipulations	   (extraction,	   purification	   and	   ligation),	  bacterial	   cultures	   and	   transformations	   were	   performed	   according	   to	   standard	  methods.	   Restriction	   and	   modification	   enzymes	   were	   obtained	   from	   New	   England	  Biolabs	  and	  Promega;	  DNA	  fragments	  were	  purified	  from	  agarose	  gel	  by	  QIAquick	  Gel	  Extraction	   Kit	   (Qiagen);	   plasmid	   preparations	   were	   done	   by	   DN	   PLASMID	  PURIFICATION	   KIT	   (Qiagen).	   Plasmids	   were	   grown	   in	   E.	   Coli,	   Xl1-­‐blue	   or	  ElectroMAX™	  Stbl4™	  Competent	  Cells	  (Invitrogen).	  	  LVs	  used	  for	  this	  study	  were	  referred	  to	  throughout	  the	  thesis	  according	  to	  the	  standard	  nomenclature:	  LV:pX-­‐GOI,	  where	  pX	  is	  the	  promoter	  and	  GOI	  is	  the	  gene	  of	  interest.	  They	  were:	  	  LV_pPgk1-­‐rtTA2S-­‐M2-­‐WPRE	  (Spigoni	  et	  al.,	  2010),	  LV_Pgk1p-­‐tTA-­‐WPRE,	   obtained	   by	   transferring	   the	   BamHI/XhoI-­‐cut	   tTA-­‐cds	  fragment	  from	  LV:pTYF-­‐1xSYN-­‐tTA	  (Addgene	  #19980)	  [12]	  into	  the	  BamHI/SalI-­‐cut	  LV_pPgk1-­‐EGFP-­‐WPRE,	  in	  place	  of	  EGFP.	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3.2	   Animal	  handling	  and	  embryo	  dissection	  	   Animal	   handling	   and	   subsequent	   procedures	   were	   done	   according	   to	  European	   laws	   [European	   Communities	   Council	   Directive	   of	   November	   24,	   1986	  (86/609/EEC)]	   and	   with	   National	   Institutes	   of	   Health	   guidelines.	   Wild	   type	   mice	  (strain	  CD1,	  purchased	   from	  Harlan-­‐Italy),	  Emx2+/-­‐mutants	  (Pellegrini	  et	  al.,	  1996)	  moved	  to	  a	  CD1	  background,	  Foxg1+/-­‐	  mutants	  (Hébert	  and	  McConnell,	  2000),	  were	  maintained	  at	  the	  SISSA	  animal	  house	  facility.	  	  All	  embryos	  and	  pups	  were	  staged	  by	  timed	   breeding	   and	   vaginal	   plug	   inspection.	   	   Were	   necessary,	   embryos	   were	  genotyped	   by	   PCR,	   as	   previously	   described	   (Brancaccio	   et	   al.,	   2010).	   Pregnant	  females	  were	  killed	  by	  cervical	  dislocation.	  Embryonic	  cortices	  were	  dissected	  out	  in	  cold	  PBS,	  under	  sterile	  conditions.	  	  
	  
3.3	   Cortico-­‐cerebral	  primary	  cultures	  	   Cortical	  primordium	  was	  dissected	  from	  E12.5	  or	  E14.5	  mouse	  embryos	  and	  mechanically	   dissociated	   to	   single	   cells	   by	   gentle	   pipetting.	   The	   number	   of	  dissociated	   cells	   was	   quantified	   in	   a	   Burker	   chamber	   and	   neural	   precursors	   were	  then	   plated	   in	   24-­‐multiwell	   plates	   (Falcon)	   at	   the	   density	   of	   1000	   cells/μL.	  When	  required,	   they	   were	   infected	   with	   a	   mix	   of	   LTVs	   with	   molteplicity	   of	   infection	  (number	   of	   viruses	   per	   cell,	   m.o.i.)	   8.	   	   As	   previously	   described	   (Brancaccio	   et	   al.,	  2010),	   this	   m.o.i.	   is	   sufficient	   to	   infect	   the	   almost	   totality	   of	   neural	   cells	   in	   these	  conditions.	  The	  dissection/infection	  day	  was	  referred	  to	  as	  “day	  in	  vitro	  1”	  (DIV1).	  As	  for	  Emx2	  or	  Foxg1	  loss	  of	  function	  mice,	  the	  cell	  cultures	  were	  not	  infected.	  Precursor	  cells	  were	  cultured	  under	  pro-­‐proliferative	  [1:1	  DMEM-­‐F12,	  1X	  Glutamax(Gibco),	  1X	  N2	   supplement	   (Invitrogen),	   1mg/ml	   BSA,	   0.6%	   Glucose,	   2	   μg/ml	   mouse	   heparin	  (Stemcell	  technologies),	  1X	  Pen/strept	  (Gibco),	  10pg/ml	  Fungizone	  (Gibco),	  20	  ng/ml	  bFGF	   (invitrogen),	   20	   ng/mL	   EGF	   (Invitrogen)].	   Where	   necessary,	   cells	   were	   then	  transferred	  to	  pro-­‐differentiative	  conditions,	  according	  to	  various	  protocols,	  in	  order	  to	   finally	   perform	   immunofluorescence	   analysis,	   extract	   RNA	   for	  mRNA	   expression	  profiling	   or	   extract	   proteins	   for	   western	   blot	   analysis.	   As	   for	   Foxg1	   set	   of	  experiments,	   prodifflrentiative	   medium	   was	   composed	   by:	   Neurobasal	   A,	   1X	  Glutamax,	   1X	   B27,	   1X	   Pen/strept	   (LifeTech).	   As	   for	   Emx2	   study,	   prodifflrentiative	  medium	  was	  made	   up	   by:	   1:1	   DMEM-­‐F12,	   1X	   Glutamax(Gibco),	   1X	  N2	   supplement	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(Invitrogen),	   1mg/ml	   BSA,	   0.6%	   Glucose,	   2	   μg/ml	   mouse	   heparin	   (Stemcell	  technologies),	   1X	   Pen/strept	   (Gibco),	   10pg/ml	   Fungizone	   (Gibco),	   1mM	   N-­‐acetylcysteine	  (sigma),	  5%	  FBS	  (Clontech).	  	  In	   particular,	   cells	   were	   cultured	   as	   floating	   neurospheres	   under	   pro-­‐proliferative	  conditions	  or	  were	  attached	  to	  200μg/ml	  poly-­‐L-­‐lysin	  coated	  coverslips	  in	  the	  pro-­‐differentiative	  conditions	  at	  appropriate	  timing.	  	  	  If	   an	   inducible	   TetON	   system	  was	   used	   to	   obtain	   the	   expression	   of	   the	   transgene,	  doxycyclin	  (Clontech)	  was	  added	  to	  the	  medium	  at	  the	  final	  concentration	  of	  2μg/ml	  in	  due	  time.	  	  In	   specific	   cases,	   medium	   was	   supplemented	   by	   0.7	   mM	   LDN193189	  (Stemgent	   #130-­‐096-­‐226),	   or	   20ng/mL	   Fgf9	   (Sigma#SRP4057-­‐10UG),	   or	   30ng/mL	  Lif	   (Millipore),	   or	   50ng/mL	   BMP4.	   	   In	   all	   differentiative	   mediums,	   FBS	   was	  tetracyclin-­‐free.	  	  
3.4	   Glioblastoma	  cell	  culture	  	   Human	  U87MG	  GBM	   cell	   line	   and	   T98G	  GBM	   cell	   line	  were	   purchased	   from	  SIGMA	   (#89081402	   and	   #92090213,	   respectively).	   Low	   passage	   criopreserved	  samples	   of	   them	  were	   employed	   to	   run	   this	   analysis.	   They	  were	   kept	   as	   adherent	  cultures	   in	  DMEM/Glutamax	  medium	  (ThermoFisher,	  #31966	  ),	  supplemented	  with	  10%	   FBS	   and	   1X	   Pencillin/Streptomycin.	   Cells	   were	   cultured	   at	   500	   cells/μl	   and	  passaged	  by	  trypsin	  on	  days	  of	  counting	  or,	  at	  most,	  every	  4	  days.	  	  GbmA-­‐E	   cells	   originate	   from	   GBM	   surgical	   samples	   collected	   at	   IRCCS	   A.O.U.	   San	  Martino-­‐IST,	   Dept	   of	   Neuroscience	   and	   Sense	   organs,	   Unit	   of	   Neurosurgery	   and	  Neurotraumatology,	   with	   patients'	   informed	   consent	   and	   in	   compliance	   with	  pertinent	  Italian	  law.	  They	   were	   derived	   in	   Antonio	   Daga	   laboratory.	   Low	   passage	   criopreserved	  samples	   of	   them	  were	   employed	   to	   run	   this	   analysis.	   GbmA	   cells	  were	   cultured	   in	  “DMEM	   /	   F12	   /	   glutamax	   /	   NeurobasalA”	   (ThermoFisher	   #10888-­‐	   022).	   GbmB-­‐E	  were	   cultured	   as	   spheres	   in	   NeuroCult™	  NS-­‐A	   Proliferation	   Kit	   (Human)	   (StemCell	  Technologies,	   Vancouver	   -­‐	   Canada,	   #05751).	   In	   both	   cases,	   mediums	   were	  supplemented	   with	   1X	   Penicillin/Streptomycin,	   2	   μg/ml	   human	   heparin	   (StemCell	  Technologies	   #07980),	   20	   ng/ml	   recombinant	   human	   EGF	   (ThermoFisher	  #PHG0311),	  20	  ng/ml	  recombinant	  human	  FGF2	  (ThermoFisher	  #PHG0261).	  All	  the	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cells	   were	   cultured	   under	   normoxic	   conditions	   (5%	   CO2,	   21%	   O2,	   74%	  N2).	   Cells	  were	   cultured	   at	   500	   cells/μl	   and	   passaged	   by	   Accutase	   (Sigma,	   Milan	   -­‐	   Italy,	  #A6964)	  on	  days	  of	  counting	  or,	  at	  most,	  every	  4	  days.	  	  When	  required,	  cells	  were	  acutely	  infected,	  at	  a	  concentration	  of	  500	  cells/μl,	  by	  a	  mix	  containing	  lentiviral	  vectors,	  each	  one	  at	  a	  multiplicity	  of	  infection	  (m.o.i)	  =	  6.	  This	  moi	   is	  sufficient	  to	   infect	  the	  almost	  totality	  of	  GBM	  cells	   in	  such	  conditions.	  Where	   required,	   they	  were	  subsequently	   transferred	   to	  polylysinated	  coverslips.	   In	  specific	   cases,	   medium	   was	   supplemented	   by	   0.7	   μM	   LDN193189	   (Stemgent,	  Lexington	   -­‐	   MA,	   #130-­‐096-­‐226),	   20	   ng/ml	   Fgf9	   (Sigma	   #SRP4057-­‐	   10UG),	   or	  10μg/ml	  BrdU.	  TetON-­‐controlled	  transgenes	  were	  switched	  on	  by	  2	  μg/ml	  doxycyclin	  (Sigma	  #D9891-­‐	  10G).	  	  
3.5	   GBM	  cell	  growth	  curves	  	  After	  sphere	  dissociation,	  2x105	  GBM	  cells/well	  were	  seeded	  in	  a	  24-­‐well	  plate	  and	   infected	   with	   LV_	   Pgk1p-­‐rtTA-­‐M2-­‐WPRE	   and	   LV_TREt-­‐IRES-­‐EGFP-­‐WPRE	   or	  LV_TREt-­‐Emx2-­‐IRES-­‐EGFP-­‐WPRE,	   each	   at	   m.o.i.	   6.	   Viable	   cells	   (trypan	   blue-­‐excluding)	  were	   counted	   at	   fixed	  days	   on	   a	   hemocytometer.	   After	   every	   cell	   count,	  differently	   engineered	   cells	   were	   plated	   at	   the	   same	   concentration	   (2	   .	   105	   GBM	  cells/well).	  Cell	  counting	  was	  performed	  on	  1/200	  of	  each	  biological	  sample	  (in	  case	  of	  Figure	  1,	  3	  and	  5	  data,	  at	  t=0,	  each	  sample	  included	  200,000	  cells).	  Growth	  curves	  were	  interrupted	  when	  Emx2-­‐GOF	  cell	  cultures	  had	  collapsed.	  	  




3.7	   Neural	  precursor	  cell	  transplantation	  	  	   As	  for	  Foxg1-­‐GOF	  and-­‐	  LOF	  in	  vivo	  experiments,	  P0	  pups	  were	  anaesthetized	  on	  ice	  for	  40-­‐60s.	  2.0	  μl	  of	  a	  solution	  containing	  400,000	  cells	  (200,000	  Foxg1-­‐GOF-­‐Egfp+	   and	   200,000	   control-­‐mCherry+	   cells;	   or	   200,000	   Foxg1-­‐GOF-­‐mCherry+	   and	  200,000	   control-­‐Egfp+cells;	   or	   200,000	   αFoxg1-­‐shRNA/Egfp+	   and	   200,000	   control-­‐
shRNA/mCherry+	  cells,	  pre-­‐engineered	  by	   lentiviral	   transduction	  7	  days	  and	  4	  days	  before,	   respectively),	   mixed	   with	   0.02%	   fast-­‐green	   dye	   in	   DMEMF12/Glutamax	  Proliferation	   medium,	   were	   injected	   through	   the	   skull	   into	   the	   corticocerebral	  parenchyma,	   by	   free	   hands,	   using	   a	   sharp	   pulled	   micropipette	   (hole	   external	  diameter	  about	  40	  μm)	  with	  the	  help	  of	  light	  fibers.	  Animals	  were	  left	  to	  recover	  in	  a	  warm	   clean	   cage.	   Then	   they	   were	   transferred	   to	   their	   mother	   and	   were	   finally	  sacrificed	  4	  days	  later.	  	  	  
3.8	   GBM	  short	  term	  in	  vivo	  experiments	  	   P4	  pups	  were	  anaesthetized	  on	  ice	  for	  40-­‐60s.	  2.0	  μl	  of	  a	  solution	  containing	  200,000	   cells	   (100,000	  Emx2-­‐	  GOF-­‐Egfp+	   and	  100,000	   control-­‐mCherry+	   cells,	   pre-­‐engineered	   by	   lentiviral	   transduction	   1	  week	   before	   at	  MOI=6),	  mixed	  with	   0.02%	  fast-­‐green	   dye	   in	   NeuroCult™	   NS-­‐A	   Proliferation	   (Human)	   medium	   (StemCell	  Technologies	   #05751),	   were	   injected	   through	   the	   skull	   into	   the	   corticocerebral	  parenchyma,	   by	   free	   hands,	   using	   a	   sharp	   pulled	   micropipette	   (hole	   external	  diameter	  about	  40	  μm)	  with	  the	  help	  of	  light	  fibers.	  Animals	  were	  left	  to	  recover	  in	  a	  warm	   clean	   cage.	   Then	   they	   were	   transferred	   to	   their	   mother	   and	   were	   finally	  sacrificed	  7	  days	  later.	  	  
3.9	   GBM	  survival	  experiments	  	   For	  this	  study,	  nude	  (strain:	  Hsd:AthymicNude-­‐Foxn1nu)	  	  mice	  were	  used.	  	  6-­‐weeks-­‐old	   females	  were	   anaesthetized	  with	  Ketamine-­‐Xylazine	   solution.	   5.0	   μl	   of	   a	  solution	  containing	  300,000	  cells	  (300,000	  Emx2-­‐GOF-­‐Egfp+	  cells	  in	  some	  mice,	  and	  300,000	   control-­‐Egfp+	   cells	   in	   the	   others;	   cells	   pre-­‐engineered	   with	   lentiviral	  transaction	   1	  week	   before,	   at	  MOI=16),	   in	  DMEM-­‐Glutamax	  medium,	  were	   injected	  through	   the	   skull	   into	   the	   striatum,	   by	   Hamilton	   syringe	   (Hamilton	   #7105KH),	  following	  the	  stereotaxic	  coordinates:	  AP	  +0.5;	  L	  -­‐1.8;	  	  	  V	  -­‐2.8.	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Animals	  were	  left	  to	  recover	  in	  a	  warm	  clean	  cage.	  Then,	  they	  were	  checked	  each	  day	  and	  sacrificed	  when	  they	  showed	  clear	  symptoms	  of	  suffering.	  Survival	  curves	  were	  drawn.	  	  	  
3.10	   Immunofluorescence	  sample	  preparation	  
	   Brains	  were	  fixed	  by	  immersion	  in	  4%	  PFA	  overnight	  at	  4C,	  washed	  by	  1XPBS	  three	  times,	  equilibrated	  in	  30%sucrose-­‐1XPBS	  at	  4°C,	  included	  into	  OCT	  (Killik),	  and	  frozen	  at	  280C.	  Finally	  they	  were	  coronally	  sliced	  at	  16	  μm,	  by	  a	  Microm	  cryostat.	  As	  for	  Emx2	  protein	  quantification,	  neocortices	  collected	  from	  10	  E12.5	  embryos	  and	  5	  P0	  neonates	  were	  pooled	  by	  age,	  mechanically	  dissociated	  to	  single	  cells,	  allowed	  to	  acutely	  attach	  on	  polilysin-­‐coated	  SuperFrost	  N1	  slides	  and	   fixed	   for	  15	  min	   in	  4%	  PFA	  at	  RT.	  As	   for	   immunofluorescence	  on	   in	  vitro	  experiments,	  cells	  were	  blocked	  at	  due	   time	  and	  fixed	  for	  15	  min	  in	  4%	  PFA	  at	  RT.	  	  	  
3.11	   Immunofluorescence	  	   Immunocytofluorescence	   was	   performed	   as	   previously	   described	   (Puzzolo	  and	   Mallamaci,	   2010;	   Brancaccio	   et	   al.,	   2010).	   As	   for	   BrdU,	   its	   unmasking	   was	  performed	   by	   0.2	   M	   HCl	   for	   150	   at	   RT.	   In	   case	   of	   immunos	   with	   polyclonal	   anti-­‐Aldolase	  C,	  anti-­‐Emx2,	  and	  anti-­‐Ki67	  and	  monoclonal	  anti-­‐S100b	  antibodies,	  antigen	  retrieval	  was	  performed	  by	  baking	  samples	  in	  10	  mM	  citrate	  buffer	  (pH56.0),	  at	  700	  W	   for	   5,	   5,	   3,	   and	   5	   min,	   respectively.	   The	   following	   antibodies	   were	   used:	   anti-­‐Aldolase	   C,	   rabbit	   polyclonal	   (Abcam	   #ab87122),	   at	   1:50;	   anti-­‐BrdU,	   mouse	  monoclonal,	  B44	  antibody	  (Becton-­‐Dickinson	  #347580),	  at	  1:50;	  anti-­‐CNPase,	  mouse	  monoclonal,	   clone	   11-­‐5B	   antibody	   (Abcam	   #ab6319),	   at	   1:200;	   anti-­‐Emx2	   mouse	  monoclonal	   M06-­‐4F7	   antibody	   (Abnova#H00002018-­‐M06),	   at	   1:200	   ;	   anti-­‐p(Tyr1284)ErbB4	   rabbit	   polyclonal	   (Abcam	   #61059),	   at	   1:200;	   anti-­‐Emx2,	   rabbit	  polyclonal	   (Mallamaci	   et	   al.,	   1998),	   at	   1:700;	   anti-­‐GFAP	   rabbit	   polyclonal	  (DAKO#Z0334),	   at	   1:600;	   anti-­‐GFP	   chicken	   polyclonal	   (Abcam	   #13970),	   at	   1:400;	  anti-­‐Ki67,	  mouse	  monoclonal	  (BD	  Pharmingen	  #550609),	  at	  1:50;;	  anti-­‐NCoR,	  rabbit	  polyclonal	   (Abcam	   #3482)	   at	   1:200;	   anti-­‐Pax6,	   rabbit	   polyclonal	   (Covance	   #PRB-­‐278P),	   at	   1:150;	   anti-­‐RFP	   rat	   monoclonal	   5F8	   (Chromotek	   #5f8-­‐20),	   at	   1:500;	  antiS100b,	  mouse	  monoclonal,	   clone	   4C4.9	   (Abcam	   #ab4066),	   at	   1:50;	   anti-­‐S100b,	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rabbit	   polyclonal	   (DAKO	   #Z0311),	   at	   1:800–1:300;	   anti-­‐Sox2	   rabbit	   polyclonal	  (Abcam	  #97959),	  1:1,000;	  anti-­‐Tubb3	  (TUJ1),	  mouse	  monoclonal(Biolegend	  #MMS-­‐	  435P),	  at	  1:1000.	  The	  following	  secondary	  antibodies	  were	  used:	  Alexa408	  Goat	  Anti-­‐Rabbit;	  Alexa594	  	  Goat	  Anti-­‐Rabbit;	  Alexa594	  Goat	  Anti-­‐Mouse,	  Alexa408	  Goat	  Anti-­‐Mouse,	  Alexa488	  Goat	  Anti-­‐Chicken,	  Alexa594	  Donkey	  Anti-­‐Rat.	  	  Immunos	  were	  photographed	  on	  a	  Nikon	  Eclipse	  TI	  microscope	  equipped	  with	  a	  20X	  objective	  and	  a	  Hamamatsu	  camera.	  Images	  were	   imported	   and	   analyzed	   by	   Photoshop	  CS2	   (Adobe)	   and	   ImageI	  softwares.	   In	   case	   of	   Emx2	   immunodetection	   in	   vivo	   (by	   an	   Alexa	   594	   secondary	  antibody),	   tissue	   autofluorescence	  was	   assayed	   by	   inspecting	   emission	   at	   520	   nm,	  where	  no	  specific	  signal	  was	  expected.	  Where	   not	   otherwise	   stated,	   each	   experiment	   was	   performed	   at	   least	   in	  biological	   triplicate.	   For	   each	   experimental	   condition	   and	   each	   biological	   replicate,	  >200	   cells	   and	   2,000–6,000	   cells	   (from	   20	   randomly	   assorted	   photographic	   fields)	  were	   scored,	   as	   for	   in	   vivo	   and	   in	   vitro	   assays,	   respectively.	   Cell	   countings	   were	  performed	   by	   being	   blind	   of	   sample	   identity.	   Frequencies	   of	   immunoreactive	   cells	  were	   averaged	   and	   s.e.m.’s	   were	   calculated.	   Results	   were	   normalized	   against	  controls.	  Their	  statistical	  significance	  was	  evaluated	  by	  the	  t	  test	  (one-­‐tail;	  unpaired).	  “n5x,y”	  refers	  to	  the	  number	  of	  samples	  scored	  for	  each	  genotype.	  In	  the	  case	  of	  Emx2	  protein	  quantification	  (Fig.	  R.10	  D,E),	  photos	  were	  taken	  from	  4	  slides	  per	  age.	  Sox2+cell-­‐containing	  fields	  were	  selected	  by	  an	  operator	  blind	  of	  Emx2-­‐fluorescence	  and	  sample	  age.	  30–40	  randomly	  picked	  Sox2+	  cells	  per	  slide	  were	  analyzed.	  Emx2-­‐levels	  were	  evaluated	  by	  Photoshop-­‐Histogram	  plugin,	  per	  each	  single	  cell.	  Data	  were	  analyzed	  by	  Excel	  and	  their	  significance	  was	  evaluated	  by	  the	  t	  test	   (one-­‐tail;	  unpaired).	   “n”	   is	   the	  number	  of	   samples.	   In	   the	  case	  of	  Sox2	   (Fig.	  R.9	  
B,C),	  immunofluorescence	  quantification	  was	  made	  similarly	  to	  Emx2,	  but	  on	  batches	  of	  about	  300	  cells	  per	  experimental	  condition	  and	  biological	  replicate.	  
	  
3.12	   Cytofluorometry	  	   To	   prepare	   fluorescence	   activated	   cell	   sorting	   (FACS)	   analysis,	   cells	   were	  labeled	   as	   follows.	   Dissociated	   cortico-­‐cerebral	   precursors,	   obtained	   as	   described	  above,	  were	  acutely	  infected	  with	  the	  following	  lentiviruses:	  LV:pNes/hsp68-­‐rtTA2S-­‐M2;	   LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	   (or,	   alternatively,	   LV:TREt-­‐Luc-­‐IRES2-­‐EGFP,	   as	   a	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control);	   LV:pTa1-­‐mCherry.	   96	   hr	   prior	   to	   analysis,	   transgenes	   were	   activated	   by	  doxycyclin	  addition.	  Moreover,	  72	  hr	  prior	  to	  analysis,	  standard	  Egf	  was	  replaced	  by	  biotinylated,	   Alexa	   Fluor	   555	   streptavidin-­‐complexed	   Egf	   (equally	   concentrated),	  which	  was	  refreshed	  48	  hr	  later.	  Finally,	  just	  prior	  to	  fluorimetric	  profiling,	  cells	  were	  mechanically	   dissociated	   and	   further	   labeled	   with	   anti-­‐A2B5	   mouse	   monoclonal	  antibody,	   APC	   conjugated	   (MACS	   Miltenyi),	   at	   1:10	   concentration,	   according	   to	  manufacturer	  instructions.	  Labeled	  cells	  were	  analyzed	  on	  a	  Cyan	  ADP	  flow	  cytometer	  (Dakocytomation,	  Denmark).	  Forward	  scatter	  (FSC)	  and	  side	  scatter	  (SSC)	  were	  used	  to	  exclude	  debris	  and	   cell	   aggregates	   (live	   gate).	   Cells	   belonging	   to	   the	   live	   gate	   were	   evaluated	   for	  their	   EGFP6/	   mCherry6/Egf-­‐Alexa5556/A2B5-­‐APC6	   fluorescence	   profile.	   Data	  analysis	  was	  performed	  by	  FlowjoTM	  software	  (Tree	  Star,	  Ashland).	  This	  experiment	  was	  performed	   in	  biological	   septuplicate.	  For	  each	  experimental	  condition,	   samples	  of	  80,000	  cells	  were	  scored.	  Frequencies	  of	  immunoreactive	  cells	  were	  averaged	  and	  s.e.m.’s	  were	  calculated.	  Statistical	  significance	  of	  results	  was	  evaluated	  by	  the	  t	  test	  (one-­‐tail;	   unpaired).	   “n=x,y”	   refers	   to	   the	   number	   of	   samples	   scored	   for	   each	  genotype.	  	  
3.13	   mRNA	  profiling	  	  	   Total	   RNA	   was	   extracted	   from	   cells	   using	   Trizol™	   (ThermoFisher	   #15596-­‐026),	  according	  to	  Manufacturer’s	  instructions	  and	  resuspended	  in	  sterile	  deionized	  water.	   Agarose	   gel	   electrophoresis	   and	   spectrophotometric	   measurements	  (NanoDrop	  ND-­‐1000)	  were	  employed	  to	  estimate	  quantity,	  quality	  and	  purity	  of	  the	  resulting	  RNA.	   Prior	   to	   analysis,	   samples	  were	   processed	   by	   the	   TurboDNAfree	   kit	  (Ambion™),	   for	   1	   hour	   at	   37°C.	   At	   least	   1.0	   μg	   RNA	   from	   each	   sample	   was	  retrotranscribed	  by	   SuperScriptIII™	   (ThermoFisher	  #18080044)	   in	   the	  presence	   of	  random	  hexamers,	  according	  to	  manufacturer's	  instructions.	  RT-­‐minus	  samples	  were	  scored	  as	  controls,	  in	  the	  case	  of	  intronless	  transcripts.	  	  1/50	   of	   the	   resulting	   cDNA	  was	   used	   as	   substrate	   of	   any	   subsequent	   qPCR	  reaction.	  PCR	  reactions	  were	  performed	  by	   the	  SsoAdvanced	  SybrGreen™	  Supermix	  platform	  (Biorad),	  according	  to	  manufacturer’s	  instructions.	  Each	  biological	  replicate	  was	   scored	   at	   least	   in	   technical	   triplicate	   and	  data	  were	   normalized	   against	  Gapdh	  and	  GAPDH	  for	  murine	  and	  human	  cell	  samples,	  respectively.	  Results	  were	  averaged	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and	  further	  normalized	  on	  their	  controls.	  Averages	  ±	  s.e.m.'s	  were	  reported	  in	  Table	  1.	   Statistical	   significance	  of	   results	  was	   evaluated	  by	   the	   t-­‐test	   (one-­‐tail;	   unpaired).	  “n”	  is	  the	  number	  of	  samples.	  Oligo	  were	  as	  follows:	  Murine	  oligos:	  -­‐	  Brn2,	  mBrn2/F1,	  5’	  CAA	  CAA	  CAG	  CGA	  CCG	  CCA	  CATCTG	  GTG	  3’,	  and	  mBrn2/R1,	  5’	  GTG	  AAG	  CTC	  GGC	  TGC	  GAA	  TAG	  AGC	  AAA	  C	  3’;	  -­‐	  EgfR,	  EgfR/F,	  5’	  AGA	  CCC	  ACA	  GCG	  CTA	  CCT	  TGT	  TATCCA	  3’,	  and	  EgfR/R,	  5’	  CAA	  CTA	  CAT	  CCT	  CCA	  TGT	  CCT	  CTT	  CAT	  CCA	  3’;	  -­‐	  Emx2,	  E2S/N2F,	  5’	  GGA	  AAG	  GAA	  GCA	  GCT	  GGC	  TCACAG	  TCT	  CAG	  TCT	  TAC	  3’,	  and	  E2S/N2R,	  5’	  GTG	  GTG	  TGT	  CCC	  TTT	  TTT	  CTT	  CTG	  TTG	  AGA	  ATC	  TGA	  GCCTTC	  3’;	  -­‐	  Fgf9,	   Fgf9/F4,	   5’	   CGA	  GAA	  GGG	  GGA	  GCT	  GTA	  TGG	  ATCAGA	  A	  3’,	   and	  Fgf9/R4,	  5’	  AGA	  GGT	  TGG	  AAG	  AGT	  AGG	  TGT	  TGT	  ACC	  AGT	  3’;	  -­‐	  Gapdh,	  Gapdh5/F,	  5’	  ATC	  TTC	  TTG	  TGC	  AGT	  GCC	  AGCCTC	  GTC	  3’,	  and	  Gapdh5/R,	  5’	  GAA	  CAT	  GTA	  GAC	  CAT	  GTA	  GTT	  GAG	  GTC	  AAT	  GAA	  GG	  3’;	  -­‐	  Gfap,	  Gfap/F,	  5’	  GCA	  GAT	  GAA	  GCC	  ACC	  CTG	  GCT	  C	  3’,	  and	  Gfap/R,	  5’	  CCA	  GAT	  CGC	  AGG	  TCA	  AGG	  CCT	  GCA	  G	  3’;	  	  -­‐	  Hes5,	  Hes5/F,	  5’	  GCT	  CAG	  TCC	  CAA	  GGA	  GAA	  AAA	  CCG	  ACT	  GCG	  3’,	  and	  Hes5/R,	  5’	  CGC	  GGC	  GAA	  GGC	  TTT	  GCT	  GTG	  TTT	  CAG	  3’;	  	  -­‐	  Id3,	   Id3/F1,	  5’	  CGG	  TCC	  GCA	  TCT	  CCC	  GAT	  CCA	  GAC	  A	  3’,	  and	  Id3/R1,	  5’	  CGG	  GCG	  CCA	  GCA	  CCT	  GCG	  TTC	  3’;	  	  -­‐	  Msx1,	  Msx1/F1,	  5’	  GAC	  TCC	  TCA	  AGC	  TGC	  CAG	  AAG	  ATG	  CTC	  3’,	  and	  Msx1/R,	  5’	  GTC	  CTG	  GGC	  TTG	  CGG	  TTG	  GTC	  TTG	  TG	  3’;	  -­‐	  Ncor1,	  Ncor1/F,	  5’	  CCA	  GCA	  CCT	  CAG	  TGG	  TGA	  CGA	  GCA	  3’,	  and	  Ncor1/R	  5’	  GCC	  TTT	  CAG	  TTC	  CTA	  AAT	  AGC	  TTT	  GCC	  C	  3’;	  
-­‐	  Pax6,	  Pax6/ForM,	  5’	  CCA	  AGG	  GCG	  GTG	  AGC	  AGA	  TGT	  GTG	  AGA	  TCT	  TCT	  ATT	  CTA	  G	  3’,	  and	  Pax6/RevM,	  5’	  CCC	  GTT	  GAC	  AAA	  GAC	  ACC	  ACC	  AAG	  CTG	  ATT	  CAC	  TC	  3’;	  	  -­‐	  Sip1,	  mZeb2/F2,	  5’	  CGA	  GAG	  GCA	  TAT	  GGT	  GAC	  GCA	  CAA	  G	  3’,	  and	  mZeb2/R1,	  5’	  CAC	  TGT	  GAA	  TTC	  TCA	  GGT	  GTT	  CTT	  TCA	  GGT	  3’;	  	  -­‐	  Sox2,	  Sox2/FEXT,	  5’	  CGG	  CAC	  GGC	  CAT	  TAA	  CGG	  CAC	  ACT	  G	  3’,	  and	  Sox2/REXT,	  5’	  GAG	  CAT	  TAT	  CAG	  ATT	  TTT	  CCT	  ACT	  CTC	  CTC	  TTT	  TTG	  3’;	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Human	  oligos:	  -­‐	  GAPDH,	  hGAPDH/Fw,	  5’	  CAT	  CAC	  CAT	  CTT	  CCA	  GGA	  GCG	  AGA	  TCC	  3’,	  and	  hGAPDH/	  Rv,	  5’	  CAA	  ATG	  AGC	  CCC	  AGC	  CTT	  CTC	  CAT	  GG	  3’;	  -­‐	  EGFR,	  hEGFR/Fw,	  5’	  GAG	  ACC	  CCC	  AGC	  GCT	  ACC	  TTG	  TCA	  TTC	  A	  3’,	  and	  hEGFR/Rv,	  5’	  CCA	  CCA	  CGT	  CGT	  CCA	  TGT	  CTT	  CTT	  CAT	  CCA	  3’;	  -­‐	  PDGF,	  hPDGF/Fw,	  5’	  CCT	  GCC	  CAT	  TCG	  GAG	  GAA	  GAG	  AAG	  CA	  3’,	  and	  hPDGF/Rv,	  5’	  GGT	  GCA	  GCG	  TTT	  CAC	  CTC	  CAC	  GCA	  CG	  3’;	  	  -­‐	  PDGFR,	  hPDGFR/Fw,	  5’	  ACA	  CTT	  GCT	  ATT	  ACA	  ACC	  ACA	  CTC	  AGA	  CAG	  AAG	  3’,	  and	  hPDGFR/Rv,	  5’	  TCC	  TCC	  ACG	  ATG	  ACT	  AAA	  TAA	  TCC	  GTC	  ATT	  CCT	  A	  3’;	  	  -­‐	   PTEN,	  hPTEN/Fw,	   5’	   GTT	   TGT	   GGT	   CTG	   CCA	   GCT	   AAA	   GGT	   GAA	   GAT	   A	   3’,	   and	  hPTEN/	  Rv,	  5’	  CAC	  AGG	  TAA	  CGG	  CTG	  AGG	  GAA	  CTC	  AAA	  G	  3’;	  -­‐	  NF1,	  hNF1/Fw,	  5’	  AGG	  ACC	  TGA	  AGG	  TAT	  TCC	  ACA	  ATG	  CTC	  TCA	  A	  3’,	  and	  hNF1/Rv,	  5’	  CTG	  AAG	  TTA	  CTT	  GGA	  CAG	  CAG	  TAG	  AAC	  CAA	  C	  3’;	  	  -­‐	  MYC,	  hMYC/Fw,	  5’	  CCC	  TGG	  TGC	  TCC	  ATG	  AGG	  AGA	  CAC	  3’,	  and	  hMYC/Rv,	  5’	  AGG	  AGC	  CTG	  CCT	  CTT	  TTC	  CAC	  AGA	  AAC	  A	  3’;	  -­‐	  MYCN,	  hMYCN/Fw,	  5’	  GAG	  AGG	  ACA	  CCC	  TGA	  GCG	  ATT	  CAG	  ATG	  3’,	  and	  hMYCN/	  Rv,	  5’	  TGG	  TGA	  ATG	  TGG	  TGA	  CAG	  CCT	  TGG	  TGT	  TG	  3’;	  	  -­‐	   RB1,	   hRB1/Fw,	   5’	   GAG	   GGA	   ACA	   TCT	   ATA	   TTT	   CAC	   CCC	   TGA	   AGA	   GTC	   3’,	   and	  hRB1/Rv,	  5’	  CAG	  AAG	  TCC	  CGA	  ATG	  ATT	  CAC	  CAA	  TTG	  ATA	  CTA	  AGA	  3’;	  	  -­‐	   CDKN2a/b,	   hCDKN2a/b/Fw,	   5’	   CTC	   CAC	   GGC	   GCG	   GAG	   CCC	   AAC	   T	   3’,	   and	  hCDKN2a/b/	  Rv,	  5’	  GCA	  GCA	  CCA	  CCA	  GCG	  TGT	  CCA	  GGA	  A	  3’;	  	  -­‐	  CDK4,	  hCDK4/Fw,	  5’	  GCA	  TCC	  CAA	  TGT	  TGT	  CCG	  GCT	  GAT	  GGA	  3’,	  and	  hCDK4/Rv,	  5’	  GGT	  CTA	  CAT	  GCT	  CAA	  ACA	  CCA	  GGG	  TTA	  CC	  3’;	  	  -­‐	   CDK6,	   hCDK6/Fw,	   5’	   GCA	   CCC	   CAA	   CGT	   GGT	   CAG	   GTT	   GTT	   TGA	   TG	   3’,	   and	  hCDK6/Rv,	  5’	  GGT	  CAA	  GTC	  TTG	  ATC	  GAC	  ATG	  TTC	  AAA	  CAC	  TAA	  A	  3’;	  	  -­‐	  CCND2,	  hCCND2/Fw,	  5’	  CCT	  GCA	  GCA	  GTA	  CCG	  TCA	  GGA	  CCA	  A	  3’,	  and	  hCCND2/Rv,	  5’	  TCA	  CAG	  GTC	  GAT	  ATC	  CCG	  CAC	  GTC	  TGT	  A	  3’;	  	  -­‐	  SOX2,	  hSOX2/Fw,	  5’	  CGG	  CAC	  GGC	  CAT	  TAA	  CGG	  CAC	  ACT	  G	  3’,	   and	  hSOX2/Rv,	  5’	  GTT	  TTC	  TCC	  ATG	  CTG	  TTT	  CTT	  ACT	  CTC	  CTC	  TTT	  TG	  3’;	  -­‐	   TRP53,	   hTRP53/Fw,	   5’	   CCT	   CCT	   CAG	   CAT	   CTT	   ATC	   CGA	   GTG	   GAA	   G	   3’,	   and	  hTRP53/Rv,	  5’	  CAT	  AGG	  GCAC	  CAC	  CAC	  ACT	  ATG	  TCG	  AAA	  AG	  3’;	  -­‐	   MDM2,	   hMDM2/Fw,	   5’	   GTA	   TAA	   GTG	   TCT	   TTT	   TGT	   GCA	   CCA	   ACA	   G	   3’,	   and	  hMDM2/Rv,	  5’	  TGT	  ACC	  TAC	  TGA	  TGG	  TGC	  TGT	  AAC	  CAC	  C	  3’;	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-­‐	  GLI1,	  hGLI1/Fw,	  5’	  GGA	  GGA	  AAG	  CAG	  ACT	  GAC	  TGT	  GCC	  AGA	  3’,	  and	  hGLI1/Rv,	  5’	  CAG	  ACC	  AGT	  GCC	  AGC	  AAT	  GCA	  AGG	  TCC	  3’;	  	  -­‐	  HES1,	  hHES1/Fw,	   5’	   CCA	   AAG	   ACA	   GCA	   TCT	   GAG	   CAC	   AGA	   AAG	   TCA	   TC	   3’,	   and	  hHES1/	  Rv,	  5’	  GCG	  AGC	  TAT	  CTT	  TCT	  TCA	  GAG	  CAT	  CCA	  AAA	  TC	  3’;	  	  -­‐	  VEGF,	  hVEGF/Fw,	  5’	  GAA	  GAT	  GTA	  CTC	  GAT	  CTC	  ATC	  AGG	  GTA	  C	  3’,	  and	  hVEGF/Rv,	  5’	  CAG	  AAG	  GAG	  GAG	  GGC	  AGA	  ATC	  ATC	  AC	  3’.	  	  
3.14	   Western	  blots	  	  Western	   analysis	   was	   performed	   according	   to	   standard	   methods.	   Total	   cell	  lysates	   in	   CHAPS	   buffer	   were	   quantified	   by	   BCA	   protein	   assay	   kit	   (ThermoFisher	  #10678484)	  and	  denatured	  at	  95°C	  for	  5	  min,	  prior	  to	  loading.	  Thirty	  micrograms	  of	  proteins	  were	  loaded	  per	  each	  lane	  and	  run	  on	  a	  12%	  acrylamide	  −	  0.1%	  SDS	  gel.	  Full	  details	   about	   antibodies	   employed	   are	   reported	   in	   Supplementary	   Materials	   and	  Methods.	  Different	  antigens	  and	  bACT	  were	  sequentially	  revealed	  by	  an	  ECL	  kit	  (GE	  Healthcare,	  Milan	   -­‐	   Italy,	  #GERPN2109).	   Images	  were	  acquired	  by	  an	  Alliance	  LD2–77.WL	   apparatus	   (Uvitec,	   Cambridge)	   and	   analyzed	   by	   Adobe	   Photoshop	   CS2	  software™	  and	  Microsoft	  Excel	  11	  software™.	  	  The	  following	  primary	  antibodies	  were	  used:	  anti-­‐	  Emx2,	  mouse	  monoclonal,	  M06-­‐4F7	   antibody	   (Abnova	   #H00002018-­‐M06),	   at	   1:300;	   anti-­‐p(Thr202/Tyr204)Erk1/2,	   rabbit	   monoclonal	   (Cell	   Signaling	   Technology,	   Leiden	   -­‐	  The	   Netherlands,	   #4370),	   at	   1:2000;	   anti-­‐p(Ser463/465)Smad1/5/8,	   rabbit	  polyclonal	   (Merck-­‐Millipore,	   Vimodrone	   -­‐	   Italy,	   #ab3848),	   at	   1:500;	   anti-­‐p(Tyr705)Stat3,	   rabbit	   monoclonal	   (Cell	   Signaling	   Technology	   #9145),	   at	   1:1000;	  anti-­‐p(Ser727)	  Stat3,	  rabbit	  polyclonal	  (Santa	  Cruz,	  Dallas	  -­‐	  TX,	  sc-­‐	  8001-­‐R),	  at	  1:800.	  	  A	  secondary	  HRP-­‐conjugated	  anti-­‐rabbit	  antibody	  (ThermoFisher	  #32260)	  was	  used	  at	   1:2000.	   bACT	   was	   straightly	   detected	   by	   a	   peroxydase	   C-­‐conjugated	   mouse	  monoclonal	  antibody	  (Sigma	  #A3854),	  used	  at	  1:10,000.	  	  	  
3.15	   Statistical	  analysis	  of	  results	  	   Where	  it	  not	  otherwise	  stated,	  each	  experiment	  was	  performed	  at	  least	  in	  biological	  triplicate.	  For	  each	  experimental	  condition,	  2,000-­‐3,000	  cells	  (from	  20	  photographic	  fields)were	  scored,	  by	  an	  operator	  (the	  candidate)	  blind	  of	  sample	  identity.	  Frequencies	  of	   immunoreactive	  cells	  were	  averaged	  and	  s.e.m.'s	  were	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calculated.	   Results	   were	   normalized	   against	   controls.	   Their	   statistical	  significance	  was	  evaluated	  by	  the	  t-­‐test	  (one-­‐tail;	  unpaired).	  As	   for	   the	   RT-­‐PCR	   results,	   upon	   normalization	   of	   each	   gene	   of	   interest	  with	  a	  housekeeping	  gene,	  a	  t-­‐test	  (one-­‐tail;	  unpaired)	  was	  performed	  in	  order	  to	  acknowledge	  statistical	  significance.	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4.	   RESULTS	  
	  
4.1	   Foxg1	  regulation	  of	  astrogenesis	  
	  
4.1.1	   Foxg1	  inhibits	  astrogenesis	  both	  in	  vivo	  and	  in	  vitro	  Previous	   investigations	   in	   our	   lab	   gave	   evidence	   for	  both	   an	   enlargement	  of	  the	   NSCs	   compartment	   and	   reduction	   of	   astroglial	   output	   following	   Foxg1	  overexpression	  in	  NSCs.	  These	  studies	  also	  reported	  a	  defective	  progression	  of	  NSCs	  to	   early	   glia	   committed	   progenitors.	   However,	   these	   phenomena	   were	   only	  documented	   in	   vitro,	   as	   well	   as	   in	   a	   temporal	   frame	   delayed	   as	   compared	   to	   the	  physiological	   astrogliogenic	   schedule	   (Brancaccio	   et	   al.,	   2010).	   On	   the	   basis	   of	   this	  research	   study,	   we	   hypothesized	   that	   Foxg1	   might	   also	   control	   the	   developmental	  commitment	   of	   neural	   stem	   cells	   towards	   glial	   fates,	   so	   constrainin	   the	   astrogenic	  volume	  within	  the	  developing	  cerebral	  cortex.	  	  To	  test	  this	  hypothesis,	  we	  decided	  to	  assess	  if	  Foxg1	  overexpression	  impacts	  the	   in	  vivo	  astroglial	  output	  of	  genetically	  manipulated	  NSCs,	   transplanted	   into	  wild	  type	   recipient	   brains,	   according	   to	   a	   developmentally	   plausible	   schedule.	   For	   this	  purpose,	   we	   engineered	   dissociated	   E12.5	   cortico-­‐cerebral	   precursors	   for	  conditional,	   TetON-­‐driven	   Foxg1	   overexpression,	   under	   the	   control	   of	   a	   synthetic,	  Nestin	  gene-­‐derivative	  promoter,	  selectively	  firing	  in	  NSCs.	  We	  acutely	  activated	  the	  transgene	  via	  doxycyclin	  administration	  and	  we	  maintained	  cells	  in	  pro-­‐proliferative	  medium	  for	  seven	  days.	  Then,	  we	  transplanted	  cells	  into	  the	  parietal	  cortico-­‐cerebral	  parenchyma	  of	  P0	  isochronic	  mouse	  pups.	  Specifically,	  we	  injected	  a	  1:1	  mix	  of	  cells,	  made	   alternatively	   gain-­‐of-­‐function	   for	   Foxg1	  or	   a	   control,	   and	   labelled	  with	   EGFP	  and	  mCherry,	   respectively.	  Four	  days	   later,	  we	  sacrificed	   the	  pups	  and	  scored	   their	  brains	   for	   the	   	   astroglial	  outputs	  of	   the	   two	  different,	   transplanted	  precursor	   types	  (Fig.	  R.1	  A-­‐A’).	  Remarkably,	  each	  pool	  of	  Foxg1-­‐GOF	  cells	  could	  be	  referred	  to	  the	  pool	  of	   control	   cells	   in	   the	   same	   brain.	   	   We	   found	   that,	   compared	   to	   controls,	   s100β+	  derivatives	  of	  Foxg1-­‐GOF	  precursors	  were	  reduced	  by	  19.25	  ±	  6.94%	  (	  p<	  9.60x10^-­‐6,	  n=8,8,	  paired	  t-­‐test)	  (Fig.	  R.1	  C).	  Brancaccio	  et	  al.	  showed	  that	  Foxg1	  also	  promotes	  NSCs	  self-­‐renewal	   (Brancaccio	  et	  al.,	  2010).	  We	  reasoned	   that	   this	  might	   lead	  us	   to	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underestimate	   the	   real	   impact	  of	  Foxg1	  overexpression	  on	   the	  astrogenic	  power	  of	  NSCs	  in	  vivo.	  To	  compensate	  for	  such	  an	  effect,	  we	  evaluated	  the	  frequency	  of	  Nestin+	  NSCs	   within	   each	   precursor	   pool,	   just	   before	   transplantation	   (at	   day	   0),	   and	  normalized	  the	  pool’s	  astroglial	  output	  against	  such	  frequency.	  As	  expected,	  we	  found	  that	   Foxg1	   overexpression	   induced	   a	   2.5-­‐folds	   increase	   of	   Nestin+	   cell	   frequency	  (+149.76	   ±6.34,	  p<	  4.37x10^-­‐12,	  n=3,3)	   in	   respect	   to	   the	   controls	   (Fig.	  R.1	  B).	   This	  means	  that	  the	  same	  manipulation	  elicited	  a	  decrease	  of	  the	  NSCs-­‐normalized	  	  s100β+	  astrocytic	  output	  by	  67.67%.	  	  Then,	   to	   rule	   out	   a	   possible	   a	   dominant	   negative	   effect	   on	   our	   result,	   we	  performed	   a	   specular	   loss-­‐of-­‐function	   assay,	   with	   neural	   precursors	   alternatively	  engineered	   cells	   by	   an	  αFoxg1-­‐shRNA-­‐expressing-­‐LV	   or	   a	   control	   (Fig.	  R.1	  D-­‐D’).	   To	  increase	  the	  sensitivity	  of	  the	  assay,	  we	  anticipated	  precursors’	  transplantation	  by	  3	  days,	   so	   interrogating	   cells	   which	   display	   huigher	   levels	   of	   Foxg1-­‐mRNA	   (our	  unpublished	   observations).	   Specifically,	   we	   engineered	   E12.5	   corticocerebral	  precursors,	  we	  maintained	  them	  in	  culture	  for	  only	  4	  days	  and	  we	  co-­‐transplanted	  a	  1:1	  mix	  of	  them	  into	  heterochronic	  P0	  pups.	  Then,	  we	  assessed	  the	  final	  glial	  output	  at	  P4.	  The	  s100β+	  cells	   frequency	  did	  not	  change	  upon	  Foxg1	  manipulation	  (n=4,4)	  (Fig.	   R.1	   F).	   However,	   on	   the	   day	   of	   transplantation,	   the	   frequency	   of	   Nestin+	  precursors	  was	   decreased	   by	   32.14±3.26%	   in	   αFoxg1-­‐shRNA	   samples	   compared	   to	  controls	   (Fig.	  R.1	  E).	   	  This	  means	   that	  Foxg1	  downregulation	  upregulated	   the	  NSCs-­‐
normalized	   astrogenic	  output	  by	  39.75	  %.	  All	   together	   these	   last	  data	   confirm	   that,	  when	  overexpressed	  in	  NSCs,	  Foxg1	  exerts	  a	  genuine	  anti-­‐astrogenic	  effect..	  Interestingly,	  such	  Foxg1	  antiastrogenic	  activity	  was	  robustly	  confirmed	  when	  consequences	   of	  Foxg1	  mis-­‐expression	  were	   re-­‐evaluated	   in	   vitro,	  within	   the	   same	  temporal	   framework.	   That	   is	   very	   important,	   as	   it	   suggests	   that	   molecular	  mechanisms	  leading	  to	  this	  phenotype	  may	  be	  largely	  dissected	  in	  this	  simplified	  in	  vitro	  set-­‐up.	  	  In	   a	   first	   assay,	   we	   acutely	   engineered	   dissociated	   E12.5	   cortico-­‐cerebral	  precursors	   for	   conditional	   Foxg1	   overexpression,	   as	   described	   above	   for	  transplantation	   assays.	   We	   maintained	   cells	   in	   a	   pro-­‐proliferative	   medium	  supplemented	  with	  doxycyclin	  for	  seven	  days.	  Next,	  we	  transferred	  cells	  to	  a	  poli-­‐L-­‐lysin-­‐coated	   coverslips	   and	   kept	   them	   under	   pro-­‐differentiative	   medium,	  supplemented	   with	   doxycyclin,	   for	   four	   additional	   days.	   Finally,	   we	   performed	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cultures	   immunolabeling.	   We	   found	   a	   pronounced	   loss	   of	   S100β+	   astrocytes	   (-­‐	  63.89±9.14%,	  p<0.003,	  n=4,4)	  (Fig.	  R.2	  C),	  as	  well	  as	  a	  consistent	  reduction	  of	  Gfap+	  cells	   (-­‐37.32±20.10%,	  p<0.002,	  n=3,3,)	   (Fig.	  R.2	  D)	   upon	  Foxg1	   overactivation.	   In	   a	  second	   assay,	   astroglial	   cultures	   prepared	   from	   Foxg1+/-­‐	   mice-­‐derived	   cortico-­‐cerebral	   precursors	  displayed	  no	   significant	  difference	   in	   the	   s100β+	  cell	   frequency	  compared	  to	  the	  wild	  type	  controls	  (Fig.	  R.2	  G).	  	  Finally,	   we	   also	   evaluated	   the	   frequencies	   of	   presumptive	   NSCs	   in	   Foxg1-­‐mutant	   cultures	   and	   normalized	   the	   number	   of	   their	   S100β+	   	   and	   Gfap+	   in	   vitro	  progenies	   against	   such	   frequencies.	   At	   DIV4,	   NSCs,	   expressing	   Sox2	   but	   not	   an	  mCherry	  reporter	  under	  the	  control	  of	  the	  Tubulin-­‐α1	  promoter	  (selectively	  firing	  in	  the	   whole	   neuronogenic	   lineage),	   were	   augmented	   by	   89.64±10.67%	   (p<0.0001,	  
n=4,4)	   in	  Foxg1-­‐GOF	  cultures	   	  and	  decreased	  by	  26.95%	   in	  Foxg1-­‐LOF	  cultures(Fig.	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Figure	  R.1	   Reduced	   astrocytogenesis	   upon	   Foxg1	   manipulation,	   in	   vivo.	   Experimental	  strategy	  and	  lentiviral	  vectors	  employed	  for	  its	  implementation	  are	  shown	  in	  (A,A’,C,C’).	  (B)	  Frequencies	   of	   Nestin+	   derivatives	   of	   neocortical	   (ncx)	   precursors,	   acutely	   infected	   with	  LV:pNes/hsp68-­‐rtTA2S-­‐M2	   and,	   alternatively,	   LV:TREt-­‐IRES2-­‐PLAP	   (NC)	   and	  LV:TREt-­‐Foxg1-­‐
IRES2	   (Foxg1-­‐GOF).	   Cells	   kept	   for	   7	   days	   under	   pro-­‐proliferative	   medium	   and	   acutely	  attached	   on	   poli-­‐L-­‐lysin-­‐coated	   coverslips;	   doxycyclin	   administered	   at	   DIV-­‐7–0.	   Data	  normalized	  against	   sample	   (ctr);	   absolute	   frequency	  of	  Nestin+	   cells	   in	   (ctr),	  10.38±0.39%.	  Scale	   bar=s.e.m.	   (B’-­‐B’’)	   Examples	   of	   Nestin+	   	   cells	   referred	   to	   in	   (B).	   (D)	   Frequencies	   of	  Nestin+	  derivatives	  of	  cortical	  precursors,	  acutely	  infected	  with	  LV:U6-­‐ctr-­‐shRNA	  (ctr-­‐shRNA)	  and,	   alternatively,	   LV:U6-­‐αFoxg1-­‐shRNA	   (αFoxg1-­‐shRNA).	   Cells	   kept	   for	   4	   days	   under	   pro-­‐proliferative	   medium	   and	   acutely	   attached	   on	   poli-­‐L-­‐lysin-­‐coated	   coverslips;	   doxycyclin	  administered	   at	   DIV-­‐4–0.	   Data	   normalized	   against	   sample	   (ctr);	   absolute	   frequency	   of	  Nestin+	   cells	   in	   (ctr),	   22.45±1.21%.	   Scale	   bar=s.e.m.	   (D’-­‐D’’)	   Examples	   of	   Nestin+	   	   cells	  referred	  to	  in	  (D).	  (E)	  Frequencies	  of	  S100β+	  astrocytes,	  evaluated	  within	  the	  parietal	  cortex	  of	   P4	   pups	   among	   derivatives	   of	   cells	   engineered	   as	   in	   (A,A’),	   further	   labeled	   with	   either	  
LV:Pgk1-­‐EGFP	  (for	  ctr)	  or	  LV:Pgk1-­‐mCherry	  (for	  Foxg1-­‐GOF)	  and	  co-­‐transplanted	  as	  a	  1:1	  mix	  into	  the	  cortical	  parietal	  parenchyma	  of	  isochronic	  P0	  pups.	  Data	  normalized	  against	  sample	  (ctr);	   absolute	   frequencies	   of	   S100β+	   (ctr),	   30.38±2.24	   cells.	   Scale	   bar=s.e.m.	   (E’-­‐E’’)	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Figure	  R.2.	  Reduced	  astrocytogenesis	  upon	  Foxg1	  manipulation,	  in	  vitro.	   	  Experimental	  strategy	  and	  lentiviral	  vectors	  employed	  for	  its	  implementation	  are	  shown	  in	  (A,A’,C,C’).	  (B)	  Frequencies	  of	   Sox2+-­‐mCherry-­‐	  derivatives	  of	  neocortical	   (ncx)	  precursors,	   acutely	   infected	  with	   LV:pNes/hsp68-­‐rtTA2S-­‐M2,	   LV:ptα1-­‐mCherry,	   and,	   alternatively,	   LV:TREt-­‐IRES2-­‐PLAP	  (ctr)	   or	   LV:TREt-­‐Foxg1-­‐IRES2	   (Foxg1-­‐GOF).	   Cells	   kept	   for	   4	   days	   under	   pro-­‐proliferative	  medium	   and	   acutely	   attached	   on	   poly-­‐L-­‐lysin-­‐coated	   coverslips	   at	   DIV4;	   doxycycline	  administered	  at	  DIV0-­‐4.	  Cells	  immunoprofiled	  at	  DIV	  4	  (analysis	  1,	  referred	  to	  in	   	  (A)).	  Data	  normalized	   against	   sample	   (ctr);	   absolute	   frequency	   of	   Sox2+-­‐mCherry-­‐	   cells	   in	   (ctr),	  
68 
 
15.05±0.79%.	   Scale	   bar=s.e.m.	   (B’,B’’)	   Examples	   of	   Sox2+-­‐mCherry-­‐	   cells	   referred	   to	   in	   (B).	  
(D)	   	   Frequencies	   of	   Sox2+-­‐mCherry-­‐	   cells	   derived	   from	   cortical	   precursors	   alternatively	  dissected	  from	  wild	  type	  (wt)	  and	  Foxg1+/-­‐	  littermate	  mice	  (Foxg1-­‐LOF),	  and	  acutely	  infected	  with	  LV:ptα1-­‐mCherry.	  Cells	  kept	  for	  7	  days	  under	  pro-­‐proliferative	  medium	  and	  4	  more	  days	  under	  pro-­‐differentiative	  medium.	  Cells	   immunoprofiled	   at	  DIV	  4	   (analysis	  1,	   as	   showed	   in	  	  (C)).	   Data	   normalized	   against	   sample	   (wt);	   absolute	   frequency	   of	   Sox2+-­‐mCherry-­‐	   cells	   in	  (ctr),	  14.36±0.10%.	  Scale	  bar=s.e.m.	  (D’,D’’)	  Examples	  of	  Sox2+-­‐mCherry-­‐	  cells	  referred	  to	  in	  (D).	   	  (E,F)	  Frequencies	  of	  S100β+(E)	  and	  Gfap+(F)	  derivatives	  of	  cortical	  precursors,	  acutely	  infected	   with	   LV:pNes/hsp68-­‐rtTA2S-­‐M2,	   and,	   alternatively,	   LV:TREt-­‐IRES2-­‐PLAP	   (ctr)	   or	  LV:TREt-­‐Foxg1-­‐IRES2	  (Foxg1-­‐GOF).	  Cells	  kept	  for	  7	  days	  under	  pro-­‐proliferative	  medium	  and	  4	  more	  days	  under	  pro-­‐differentiative	  medium;	  doxycycline	  administered	  at	  DIV0-­‐11.	  Cells	  immunoprofiled	   at	   DIV	   11	   (analysis	   2,	   as	   showed	   in	   (A)).	   Data	   normalized	   against	   sample	  (ctr);	   absolute	   frequency	   of	   S100β+	  and	   Gfap+	   cells	   in	   (ctr),	   14.95±1.27	   and	   21.67±1.03%,	  respectively.	  Scale	  bar=s.e.m.	  (E’,E’’,F’,F’’)	  Examples	  of	  S100β+	  	  and	  Gfap+	  	  cells	  referred	  to	  in	  (E),	   (F),	   respectively.	   (G)	   Frequencies	   of	   S100β+	   cells	   derived	   from	   cortical	   precursors	  alternatively	  dissected	   from	  wild	   type	   (wt)	   and	  Foxg1+/-­‐	   littermate	  mice	   (Foxg1-­‐LOF).	   Cells	  kept	   for	  7	  days	  under	  pro-­‐proliferative	  medium	  and	  4	  more	  days	  under	  pro-­‐differentiative	  medium.	   Cells	   immunoprofiled	   at	   DIV	   11	   (analysis	   2,	   referred	   to	   in	   (C)).	   Data	   normalized	  against	   sample	   (wt);	   absolute	   frequency	   of	   S100β+	   cells	   in	   (wt),	   25.36±1.70%.	   Scale	  bar=s.e.m.	  (G’-­‐G’’)	  Examples	  of	  S100β+	  	  	  cells	  referred	  to	  in	  (G).	  n	  is	  the	  number	  of	  biological	  replicates;	  p-­‐value	  calculated	  by	  t-­‐test	  (one-­‐tail,	  unpaired).	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4.1.2	   Preliminary	   dissection	   of	   molecular	   mechanisms	   underlying	   Foxg1	  
regulation	  of	  astrogenesis	  As	   far	   as	   we	   know,	   the	   key	   molecular	   pathways	   modulating	   astroglial	  differentiation	   play	   a	   prominent	   role	   in	   transcriptional	   control	   of	   glial	   genes.	  Therefore,	  we	  considered	  the	  possibility	  to	  use	  trascriptional	  regulation	  of	  glial	  genes	  as	  a	  starting	  model	  to	  dissect	  molecular	  mechanisms	  mediating	  Foxg1	  anti-­‐astrogenic	  activity.	  For	  this	  purpose,	  we	  wondered	  if,	  apart	  from	  down-­‐regulating	  the	  frequency	  of	  astroglial	  cells,	  Foxg1	   is	  able	   to	  dampen	  Gfap-­‐mRNA	  levels.	  We	  engineered	  E14.5	  cortico-­‐cerebral	   precursors	   for	   TetON-­‐controlled	   Foxg1	   overexpression,	   driven	   by	  the	  constitutive	  Pgk1	  promoter.	  We	  plated	  cells	  on	  poli-­‐ornithin/fibronectin	  treated	  coverslips,	   under	   NeurobasalA	   medium	   supplemented	   with	   B27,	   200μM	   L-­‐glutammine,	   Pen/Strept	   and	   doxyciclin.	   At	   DIV3	   we	   administered	   a	   24	   hours-­‐long	  pulse	  of	  50ng/ml	  BMP4	  and	  30ng/ml	  LIF.	  Finally,	  at	  DIV4	  we	  harvested	  cells	  for	  RNA	  extraction	  (Fig.	  R.3	  A-­‐B)	  and	  evaluated	  Gfap-­‐mRNA	  levels	  by	  qRT-­‐PCR.	  We	  found	  that	  
Gfap-­‐mRNA	   was	   decreased	   by	   49.92±13%	   upon	   Foxg1	   overactivation	   (p<0.021,	  
n=6,6)	   (Fig.	   R.3	   C).	   Remarkably,	   when	   Gfap-­‐mRNA	   levels	   were	   further	   normalized	  against	  the	  frequency	  of	  Nestin+	  cells	  (evaluated	  in	  Foxg1-­‐GOF	  cultures	  at	  the	  time	  of	  RNA	  extraction),	  this	  decrease	  was	  even	  more	  pronounced	  (-­‐64.78%).	  This	  suggests	  that,	   in	   addition	   to	   its	   general	   negative	   impact	   on	   astrogenesis	   progression,	   Foxg1	  may	  specifically	  down-­‐regulate	  Gfap	  transcription.	  	  	  
	  
Figure	   R.3.	   Foxg1	   represses	   Gfap	   transcription.	   Experimental	   strategy	   and	   lentiviral	  vectors	   employed	   for	   its	   implementation	   are	   shown	   in	   (A,A’).	   (B)	   Frequencies	   of	   Nestin+	  derivatives	   of	   neocortical	   (ncx)	   precursors,	   acutely	   infected	  with	   LV:pPgk1-­‐rtTA2S-­‐M2	   and,	  alternatively,	   LV:TREt-­‐IRES2	   (ctr)	   or	   LV:TREt-­‐Foxg1-­‐IRES2	   (Foxg1-­‐GOF).	   Cells	   acutely	  attached	  on	  poly-­‐ornithin/fibronectin-­‐coated	  coverslips,	  kept	  for	  4	  days	  under	  NeurobasalA	  medium	  supplemented	  with	  B27,	  200μM	  L-­‐glutammine,	  Pen/Strept;	  doxycyclin	  administered	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at	   DIV0–4.	   Cells	   immunoprofiled	   at	   DIV4.	   	   Data	   normalized	   against	   sample	   (ctr);	   absolute	  frequency	  of	  Nestin+	  cells	   in	  (ctr),	  8.63±0.27%.	  Scale	  bar=s.e.m.	  (B’-­‐B’’)	  Examples	  of	  Nestin+	  cells	   referred	   to	   in	   (B).	   (C)	  Gfap-­‐mRNA	   levels	   in	   derivatives	   of	   precursors	   acutely	   infected	  with	   LV:pPgk1-­‐rtTA2S-­‐M2	   and,	   alternatively,	   LV:TREt-­‐IRES2	   (ctr)	   or	   LV:TREt-­‐Foxg1-­‐IRES2	  (Foxg1-­‐GOF).	  Cells	  acutely	  attached	  on	  poly-­‐ornithin/fibronectin-­‐coated	  coverslips,	  kept	   for	  4	   days	   under	   NeurobasalA	   medium	   supplemented	   with	   B27,	   200μM	   L-­‐glutammine,	  Pen/Strept,	   GFs;	   doxycyclin	   administered	   at	   DIV0–4.	   Data	   double-­‐normalized,	   against	  endogenous	  Gapdh-­‐mRNA	  and	  (ctr)	  values.	  n	   is	   the	  number	  of	  biological	  replicates;	  p-­‐value	  calculated	  by	  t-­‐test	  (one-­‐tail,	  unpaired).	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To	   clarify	   mechanisms	   dampening	   Gfap-­‐mRNA	   levels	   in	   Foxg1-­‐GOF	  precursors,	   we	   decided	   to	   profile	   these	   precursors	   for:	   (1)	   functional	   levels	   of	  pathways	  modulating	   glial	   genes	   transcription,	   and	   (2)	   the	   epigenetic	   state	   of	  Gfap	  chromatinWe	  started	  from	  the	  first	  part,	  while	  the	  second	  one	  will	  be	  the	  focus	  of	  a	  dedicated	  follow	  up	  study.	   	  Here	  we	  provide	  partial	  results	  about	  the	  issue	  (1).	  This	  functional	  dissection	  will	  be	  completed	  in	  a	  dedicated	  follow	  up	  study.	  	  We	  preliminarily	  evaluated	  the	  global	  availability	  of	  key	  effectors	  modulating	  Gfap	  transcription	  in	  Foxg1-­‐GOF	  cultures.	  For	  this	  purpose,	  we	  overactivated	  Foxg1	  in	  E12.5	   cortico-­‐cerebral	  precursors	  and	  we	  kept	   them	   in	  pro-­‐proliferative	   conditions	  for	   seven	   days.	   Then,	   we	   harvested	   cells	   for	   protein	   extraction	   and	   Western	   Blot	  analysis	   (Fig.	   R.4	   A,D).	   We	   found	   that	   neither	   p(Tyr705)Stat3	   nor	  p(Ser463/465)Smad1,5,8	   levels	  were	  changed	  upon	  Foxg1	  manipulation	   (Fig.	  R.4	  B-­‐C).	  Interestingly,	   immunofluorescence	   profiling	   of	   the	   whole	   cell	   population	   revealed	  that	  nuclear	  ErbB4-­‐ICD	  levels	   levels	  were	  augmented	  by	  12.13±2.79%	  (Fig.	  R.4	  H,I).	  Conversely,	   nuclear	   NCoR	   immunolabeling	   displayed	   no	   significant	   difference	   (Fig.	  
R.4	  K,L).	  	  Next,	  we	   restricted	  our	  analysis	   to	   the	  Nestin+	  NSC	  compartment,	  where	   the	  histo-­‐genetic	  choice	  subject	  of	  our	  interest	  is	  taken.	  We	  limited	  Foxg1	  overexpression	  to	   this	   compartment	   and	   immunoprofiled	   nuclei	   of	   its	   cells	   for	   the	   four	   effectors	  mentioned	   above.	   As	   for	   the	   evaluation	   of	   pStat3	   and	   pSmad1,5,8,	   we	  immunolabelled	   cells	   after	   a	   1hour	   pulse	   of	   30ng/ml	   Lif	   and	   50mg/ml	   Bmp4,	  respectively.	   Intriguingly,	   we	   found	   a	   significant	   decrease	   of	   both	   pStat3	   and	  pSmad1,5,8,	   by	   58.28±1.99%	   (p<	   2.54x10^-­‐10,	   n=300,310)	   and	   52.91±2.34%	   (p<	  5.78x10^-­‐23,	  n=270,220),	   respectively,	   upon	  Foxg1	   overexpression	   (Fig	  R.5	  B,C	  and	  
Fig.	  R.5	  E,F).	   The	   average	   ErbB4-­‐ICD	   signal	   did	   not	   vary	   (Fig	  R.5	  H,I).	   Surprisingly,	  NCoR,	   which	   had	   been	   found	   unmodified	   in	   the	   whole	   cell	   population,	   was	  significantly,	   albeit	  moderately	  upregulated	   (+14.18±2.83%,	  p<	  0.0002,	  n=212,281)	  ((Fig	  R.5	  K,L).	  In	  synthesis,	  as	  many	  as	  three	  modifications	  potentially	  accounting	  for	  




Figure	  R.4.	  Immunoprofiling	  of	  Foxg1	  gain-­‐of-­‐function	  cortico-­‐cerebral	  cultures	  for	  key	  
intracellular	   signalling	   transducers,	   within	   the	   whole	   population.	   Experimental	  strategies	  and	   lentiviral	  vectors	  employed	   for	   their	   implementation	  are	  shown	   in	  (A,D,G,J).	  Western	   blot	   evaluation	   of	   (A-­‐C)	   p(Tyr705)Stat3	   and	   (D-­‐F)	   p(Ser463/Ser465)Smad1/5/8	  protein	  levels	  in	  derivatives	  of	  neocortical	  (ncx)	  precursors,	  acutely	  infected	  with	  LV:pPgk1-­‐
rtTA2S-­‐M2	   and,	   alternatively,	   LV:TREt-­‐IRES2-­‐EGFP	   (ctr)	   or	   LV:TREt-­‐Foxg1-­‐IRES2-­‐EGFP	  (Foxg1-­‐GOF).	  Cells	  kept	  for	  7	  days	  under	  pro-­‐proliferative	  medium;	  doxycyclin	  administered	  at	  DIV0–7.	  Lif	   (A-­‐C)	  and	  Bmp4	  (D-­‐F)	  added	  to	  the	  medium	  24	  hours	  prior	   to	  analysis.	  Cells	  immunoprofiled	   at	   DIV7.	   Data	   normalized	   against	   sample	   (ctr).	   Evaluation	   of	   (G-­‐H)	  p(Tyr1284)ErbB4-­‐ICD	   and	   (J-­‐K)	   NCoR	   protein	   levels	   within	   the	   nucleus	   of	   derivatives	   of	  cortical	   precursors,	   acutely	   infected	   with	   LV:pNes/hsp68-­‐rtTA2S-­‐M2,	   and,	   alternatively,	  LV:TREt-­‐IRES2-­‐PLAP	   (ctr)	  or	  LV:TREt-­‐Foxg1-­‐IRES2	   (Foxg1-­‐GOF).	  Cells	  kept	  for	  7	  days	  under	  pro-­‐proliferative	  medium	  and	  attached	  on	  poly-­‐L-­‐lysin-­‐coated	  coverslips	  at	  DIV7;	  doxycyclin	  administered	  at	  DIV0–7.	  Cells	  immunoprofiled	  at	  DIV7.	  Data	  normalized	  against	  sample	  (ctr).	  




Figure	  R.5.	  Immunoprofiling	  of	  Foxg1	  gain-­‐of-­‐function	  cortico-­‐cerebral	  cultures	  for	  key	  
intracellular	   signalling	   transducers,	   within	   the	   neural	   stem	   cell	   population.	  Experimental	  strategies	  and	  lentiviral	  vectors	  employed	  for	  thei	   implementation	  are	  shown	  in	   (A,D,G,J).	   Evaluation	   of	   (B)	   p(Tyr705)Stat3,	   (E)	   p(Ser463/Ser465)Smad1/5/8,	   (H)	  p(Tyr1284)ErbB4-­‐ICD	  and	  (K)	  NCoR	  protein	  levels	  within	  the	  nucleus	  of	  Nestin+	  derivatives	  of	  neocortical	   (ncx)	   precursors,	   acutely	   infected	   with	   LV:pNes/hsp68-­‐rtTA2S-­‐M2,	   and,	  alternatively,	  LV:TREt-­‐IRES2-­‐PLAP	   (ctr)	  or	  LV:TREt-­‐Foxg1-­‐IRES2	   (Foxg1-­‐GOF).	  Cells	  kept	   for	  7	   days	   under	   pro-­‐proliferative	   medium	   and	   attached	   on	   poly-­‐L-­‐lysin-­‐coated	   coverslips	   at	  DIV6,	   under	   Neurobasal	   A	   medium,	   supplemented	   with	   B27,	   200μM	   L-­‐glutammine,	  Pen/Strept,	  GFs;	  doxycyclin	  administered	  at	  DIV0–7;	  Lif	  (A-­‐C)	  and	  Bmp4	  (D-­‐F)	  added	  to	  the	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medium	  1	  hour	  prior	  to	  the	  analysis.	  Cells	  immunoprofiled	  at	  DIV7.	  Data	  normalized	  against	  sample	   (ctr).	  n	   is	   the	  number	   of	   biological	   replicates;	  p-­‐value	   calculated	  by	   t-­‐test	   (one-­‐tail,	  unpaired).	   (C),	   (F),	   (I)	   and	   (L)	   Examples	   of	   p(Tyr705)Stat3+/Nestin+,	  	  	  	  p(Ser463/Ser465)Smad1/5/8+/Nestin+,	  p(Tyr1284)ErbB4-­‐ICD+/Nestin+	  and	  NCoR+/Nestin+	  cells	  referred	  to	  in	  (B),	  (E),	  (H)	  and	  (K),	  respectively.	  	  	  	   To	  assess	  functional	  relevance	  of	  the	  moderate	  NCoR	  upregulation	  observed,	  we	  tried	  to	  rescue	  the	  S100β+	  output	  of	  Foxg1-­‐GOF	  cultures,	  by	  knocking	  down	  Tab2,	  whose	   protein	   product	   is	   essential	   to	   anti-­‐astrogenic	   NCoR	   activity	   upon	   ErbB4	  stimulation.	   	  We	  engineered	  E12.5	  precursors	  for	  conditional	  Foxg1	  overexpression,	  in	  the	  presence	  of	  a	  short	  hairpin	  against	  Tab2	  (αTab2-­‐shRNA)	  or	  a	  control.	  	  We	  kept	  cells	   in	   pro-­‐proliferative	   conditions	   for	   seven	   days,	   and	   then	   transferred	   them	   to	  poly-­‐L-­‐lisine	  coverslips	  under	  pro-­‐differentiative	  Neurobasal	  A	  medium	  for	  four	  days.	  Finally,	  we	   immunolabeled	  cells	   for	  S100β	  marker	   (Fig.	  R.6	  A).	  Remarkably,	  αTab2-­‐shRNA	   rescued	   the	   astroglial	   output	   of	   Foxg1-­‐GOF	   samples,	   while	   not	   increasing	  S100β+	   cell	   frequency	   in	   controls	   (Fig.	   R.6	   B,C).	   This	   suggests	   that	   the	  ErbB4/Tab2/NCoR	  pathway	  is	  a	  likely	  key	  mediator	  of	  Foxg1	  antiastrogenic	  activity.	  	  However,	   to	   complete	   the	   reconstruction	   of	   the	   antigliogenic	   cascades	   ruled	  by	  Foxg1,	   further	   in	   depth	   analysis	   of	   transactive	   pathways	   and	   epigenetic	   state	   of	  chromatin	  they	  converge	  on	  will	  be	  required.	  	  
	  
	  
Figure	  R.6	   Tab2	   mediate	   antiastrogenic	   properties	   of	   Foxg1	   in	   derivatives	   of	   E12.5	  
cortico-­‐cerebral	  precursors.	  Experimental	  strategy	  and	  lentiviral	  vectors	  employed	  for	  its	  implementation	  are	  shown	  in	  (A).	  (B)	  Frequencies	  of	  S100β+	  derivatives	  of	  neocortical	  (ncx)	  precursors,	   acutely	   infected	   with	   LV:pNes/hsp68-­‐rtTA2S-­‐M2,	   and,	   alternatively,	   LV:TREt-­‐
IRES2-­‐PLAP	  (ctr)	  or	  LV:TREt-­‐Foxg1-­‐IRES2	  (Foxg1-­‐GOF)	  and	  also	  LV:U6p-­‐ctr-­‐shRNA	  or	  LV:U6p-­‐ 
αTab2-­‐shRNA.	  Cells	  kept	  for	  7	  days	  under	  pro-­‐proliferative	  medium	  and	  4	  more	  days	  under	  pro-­‐differentiative	  medium;	   doxycycline	   administered	   at	   DIV0-­‐11.	   Cells	   immunoprofiled	   at	  DIV	  11.	  Data	  normalized	  against	  PLAP+/ctr-­‐shRNA+	  control	  sample	  (ctr)	  absolute	  frequency	  of	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4.2	   Emx2	  regulation	  of	  astrogenesis	  
	  
4.2.1	   Emx2	  overexpression	  reduces	  astrogenesis	  We	  previously	   reported	   that	  prolonged	  Emx2	   overexpression	   in	   early	  pallial	  NSCs	   results	   in	   a	   substantial	   decrease	   of	   their	   ultimate	   glial	   output.	  We	   suspected	  that	  this	  could	  be	  due	  to	  a	  precocious	  shrinkage	  of	  the	  proliferating	  astrogenic	  pool	  (Brancaccio	  et	  al.,	  2010).	  These	  observations	  were	  made	  in	  vitro.	  To	  verify	  if	  this	  also	  happens	  in	  vivo,	  we	  injected	  a	  plasmid	  driving	  Emx2	  overexpression	  into	  the	  lateral	  ventricular	  cavity	  of	  P0	  brains	  and	  electroporated	  it	   into	  periventricular	  precursors	  of	   the	   posterior	   parietal	   wall.	   Four	   days	   later,	   we	   sacrificed	   pups	   and	   inspected	  heavily	  electroporated	  regions	  of	  their	  neocortices	  for	  distribution	  of	  astroglial	  cells.	  As	   expected,	   we	   found	   that	   S100β+	   astrocytes	   and	   S100β+Ki67+	   astroglial	  proliferating	   progenitors	   laying	   above	   a	   periventricular	   border	   of	   defined	   length	  were	  down	  regulated	  by	  27.87±6.90%	  (p<0.049,	  n=5,5)	  and	  47.85±5.97%	  (p<0.006,	  
n=5,5),	  respectively,	  compared	  to	  controls	  (Fig.	  R.7	  A,B,E).	  To	  rule	  out	  that	  this	  result	  was	  due	  to	  a	  dominant	  negative	  effect,	  astrogenesis	  was	  also	  scored	  in	  the	  posterior	  cortex	   of	   E17.5	   Emx2-­‐/+	   embryos.	   Here,	   frequencies	   of	   S100β+	   astrocytes	   and	  S100β+Ki67+	  astroglial	  proliferating	  progenitors	  were	  upregulated	  by	  33.24±11.03%	  (p<0.040,	   n=5.5)	   and	   129.61±6.74%	   (p<0.063,	   n=3.3),	   respectively	   (Fig.	   R.7	   C,D,F),	  suggesting	  that	  dampening	  of	  astrogenesis	  is	  a	  genuine	  function	  exerted	  by	  Emx2	  in	  vivo.	   Then,	   in	   order	   to	   set	   up	   an	   in	   vitro	   model	   suitable	   to	   dissect	   molecular	  mechanisms	   underlying	   Emx2	   antiastrogenic	   activity,	   we	   engineered	   dissociated	  E12.5	  cortico-­‐cerebral	  precursors	  for	  conditional	  Emx2	  overexpression.	  We	  activated	  the	   transgene	   at	   in	   vitro	   equivalent	   of	   perinatal	   age	   and	   finally	   evaluated	   the	  astroglial	   output.	   Immunoprofiling	   of	   engineered	   cultures	   at	   DIV21	   revealed	   that,	  similarly	   to	   in	   vivo,	   S100β+	   cells	   were	   reduced	   by	   31.88±7.10%	   (p<0.007,	   n=3,3),	  compared	   to	   controls	   (Fig.	   R8	   A).	   Interestingly,	   the	   decrease	   of	   these	   cells	   was	  preceded	  by	  a	  shrinkage	  of	  the	  astrogenic	  proliferating	  pool,	  -­‐66.78±10.31%	  at	  DIV13	  compared	  to	  controls	  (p<0.003,	  n=3,3)	  (Fig.	  R8	  B,C).	  Consistently,	  BrdU	  uptake	  within	  the	   astrogenic	   lineage	   was	   also	   diminished	   (Suppl.	   Fig.	   S.3).	   Noticeably,	   in	   both	  controls	   and	   Emx2-­‐GOF	   cultures,	   almost	   9/10	   of	   S100β+	   cells	   (87.14±2.69%	   and	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89.72±0.83%,	   respectively,	  with	  p<0.205	   and	  n=3,3)	  were	   also	   immunoreactive	   for	  the	  established	  Aldolase	  C	  (AldoC)	  pan-­‐astrocytic	  marker	  (Suppl.	  Fig.	  S.1	  A,B).	  	  	  	  
	  
Figure	  R.7.	   Reduced	   astrocytogenesis	   upon	  Emx2	  manipulation,	   in	   vivo.	  (A,	   B)	  Linear	  densities	   of	   S100β+	   astrocytes	   and	   S100β+Ki67+	   astroglial	   proliferating	   progenitors	   in	   the	  posterior	   parietal	   cortex	   of	   P4	   pups	   electroporated	   at	   P0	  with	   a	   pCMVIRES2-­‐EGFP	   control	  (NC)	   and,	   alternatively,	   a	   constitutive	   pCMV-­‐Emx2-­‐IRES2-­‐EGFP	   expressor	   plasmid	   (Emx2-­‐GOF).	  Data	  normalized	  against	  sample	  (NC);	  absolute	  frequencies	  of	  S100β+	  and	  S100β+Ki67+	  cells	   in	   (NC),	   40.9±5.4	   cells/100	   mm	   and	   11.7±1.6	   cells/100	   mm,	   respectively.	   Scale	  bar=s.e.m.	   (C,	   D)	   Linear	   densities	   of	   S100β+	   astrocytes	   and	   S100β+Ki67+	   astroglial	  proliferating	  progenitors	  in	  the	  posterior	  parietal	  cortex	  of	  E17.5	  embryos	  heterozygous	  for	  an	  Emx2	  null	  allele	  and	  their	   littermate	  wild	   type	  controls.	  Data	  normalized	  against	  sample	  (NC);	   absolute	   frequencies	   of	   S100β+	   and	   S100β+Ki67+	   cells	   in	   (NC),	   9.6±0.8	   cells/100	  mm	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Figure	   R.8.	   Reduced	   astrocytogenesis	   upon	   Emx2	   overexpression,	   in	   vitro.	   (A)	  Frequencies	   of	   S100β+	   derivatives	   of	   cortical	   precursors,	   acutely	   infected	   with	  LV:pNes/hsp68-­‐rtTA2S-­‐M2	   and,	   alternatively,	   LV:TREt-­‐IRES2-­‐EGFP	   (NC)	   and	   LV:TREt-­‐Emx2-­‐
IRES2-­‐EGFP	   (Emx2-­‐GOF).	   Cells	   kept	   for	   2	   weeks	   under	   anti-­‐differentiative	   medium	   and	   1	  more	   week	   under	   pro-­‐differentiative	   medium;	   doxycyclin	   administered	   at	   DIV8–14.	   Data	  normalized	  against	   sample	   (NC);	   absolute	   frequency	  of	  S100β+	  cells	   in	   (NC),	  17.52±0.54%.	  Scale	   bar=s.e.m.	   (B)	   Frequencies	   of	   S100β+Ki67+	   derivatives	   of	   cortical	   precursors,	   acutely	  infected	  as	  in	  (A).	  Cells	  kept	  for	  11	  days	  under	  antidifferentiative	  medium	  and	  2	  more	  days	  under	   GF-­‐supplemented	   pro-­‐differentiative	   medium;	   doxycyclin	   administered	   at	   DIV8–11.	  Data	   normalized	   against	   sample	   (NC);	   absolute	   frequency	   of	   NC	   S100β+Ki67+	   cells,	  10.48±0.72%.	  Scale	  bar=s.e.m.	  (C)	  Examples	  of	  S100β+Ki67+	  cells	  (arrowheads)	  referred	  to	  in	  (B).	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4.2.2	   Molecular	  mechanisms	  mediating	  antiastrogenic	  properties	  of	  Emx2	  To	  get	  hints	  on	  molecular	  mechanisms	  mediating	  such	  astrogenesis	  reduction,	  we	   monitored	   a	   few	   established	   genes	   promoting	   the	   expansion	   of	   the	   astrogenic	  proliferating	  pool:	  EgfR	  ((Mayer	  et	  al.,	  2009;	  Viti	  et	  al.,	  2003)),	  Fgf9	  (Lum	  et	  al.,	  2009)	  and	  Sip1	  (Seuntjens	  et	  al.,	  2009).	   Interestingly,	  Emx2	  downregulated	  EgfR	   and	  Fgf9	  by	  31.10±6.74%	  (p<0.008,	  n=3)	  and	  49.24±8.23%	  (p<0.025;	  n=3),	  respectively,	  while	  not	   affecting	   Sip1	   (Fig.	   R.9	   A).	   Consistently,	   EgfR-­‐mRNA	   and	   Fgf9-­‐mRNA	   were	  upregulated	  in	  isochronic	  Emx2+/-­‐	  cultures,	  by	  circa	  74.60±31.21%	  (p<0.07,	  n=3)	  and	  29.78±1.18%	  (p<0.069,	  n=2),	  respectively	  (Fig.	  R.9	  B).	  Intriguingly,	   FACS	   profiling	   of	   NSC-­‐restricted-­‐Emx2-­‐GOF	   cultures	   revealed	   no	  significant	  change	  in	  frequencies	  of	  EgfR+	  NSCs.	  Conversely,	  it	  showed	  a	  delayed	  and	  pronounced	   reduction	   of	   EgfR	   levels	   within	   the	   astrogenic	   compartment	   (Fig.	   R.9	  
C,D),	  pointing	  to	  an	  indirect	  regulation	  of	  EgfR	  by	  Emx2.	  To	   assay	   functional	   relevance	   of	   EgfR	   and	   Fgf9	   down	   regulation	   to	   Emx2	  depression	   of	   astrogenesis,	   we	   delivered	   a	   lentivector	   driving	   constitutive	   EgfR	  expression	  to	  Emx2-­‐GOF	  cultures	  at	  DIV8	  and,	  alternatively,	  we	  supplemented	  these	  cultures	  with	  exogenous	  Fgf9.	  Both	  treatments	  rescued	  the	  normal	  astroglial	  output.	  When	  they	  were	  administered	  to	  Emx2-­‐wt	  cultures,	  this	  parameter	  was	  not	  affected	  (Fig.	   R.9	   E,F).	   Remarkably,	   both	   EgfR	   and	   Fgf9	   also	   rescued	   the	   shrinkage	   of	   the	  astrogenic	  proliferating	  pool	  induced	  by	  Emx2	  (Fig.	  R.9	  G,H).	  Finally,	  the	  amplitude	  of	  astrogenesis	  reduction	  elicited	  by	  either	  Emx2	  overexpression	  in	  NSCs	  or	  Egf	  removal	  from	   the	   culturing	  medium	  at	   astrocytogenesis	  peak	   time	  were	   comparable	   (Suppl.	  




Figure	  R.9.	  EgfR	  and	  Fgf9	  mediate	  antiastrogenic	  properties	  of	  Emx2	   in	  derivatives	  of	  
E12.5	  cortico-­‐cerebral	  precursors.	  (A)	  EgfR-­‐,	  Fgf9-­‐,	  and	  Sip1-­‐mRNA	  levels	  in	  derivatives	  of	  precursors	   acutely	   infected	   with	   LV:pPgk1-­‐rtTA2S-­‐M2	   and,	   alternatively,	   LV:TREt-­‐IRES2-­‐
EGFP(NC)	   or	   LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	   (Emx2-­‐GOF).	   Cells	   kept	   for	   11	   days	   under	   anti-­‐differentiative	   medium;	   doxycyclin	   administered	   at	   DIV8–11.	   Data	   double-­‐normalized,	  against	   endogenous	   Gapdh-­‐mRNA	   and	   (NC)	   values.	   (B)	   EgfR-­‐	   and	   Fgf9-­‐mRNA	   levels	   in	  derivatives	   of	   wild	   type	   (NC)	   and	   Emx2+/-­‐	   (Emx2-­‐LOF)	   precursors.	   Culture	   conditions	   and	  data	  normalization	  as	   in	   (A).	  (C)	  Frequencies	  of	  EgfR	  expressing	  elements	   in	  derivatives	  of	  precursors	   acutely	   infected	   with	   LV:pNes/hsp68-­‐rtTA2S-­‐M2,	   LV:pTa1-­‐mCherry	   and,	  alternatively,	   LV:TREt-­‐IRES2-­‐EGFP	   (NC)	   or	   LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	   (Emx2-­‐GOFNSC).	  Culture	   conditions	   as	   in	   (A),	   standard	   Egf	   replaced	   by	   Alexa	   555-­‐tagged	   Egf	   at	   DIV9–11.	  FACS-­‐profiling	   after	   terminal	   anti-­‐A2B5-­‐APC	   labeling.	   Frequencies	   of	   EgfR-­‐expressing	   cells	  evaluated	  within	   the	   neural	   stem	   cells	   (NSCs),	   early	   glial	   progenitors	   (eGPs),	   and	   late	   glial	  progenitors	  (lGPs)	  compartments.	  (D)	  EgfR	  cytofluorescence	  levels	  in	  EgfR+	  glial	  progenitors,	  normalized	   against	   eGPs.	   In	   (C,	   D),	   different	   precursor	   types	   recognized	   according	   to	   the	  following	   profiles:	   NCS=pNes-­‐EGFP+/antiA2B5-­‐APC-­‐/pTa1-­‐mCherry-­‐;	   eGPs=pNes-­‐EGFP+/antiA2B5-­‐APC+/pTa1-­‐mCherry-­‐;	   lGPs=pNes-­‐EGFP-­‐/antiA2B5-­‐APC+/pTa1-­‐mCherry-­‐).	  
(E)	   Frequencies	   of	   S100β+	   derivatives	   of	   cortical	   precursors,	   acutely	   infected	   with	  LV:pNes/hsp68-­‐rtTA2S-­‐M2	   (a-­‐d),	   LV:TREt-­‐IRES2-­‐EGFP	   (a,	   b)	   and	   LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	  (c,	  d),	  and	  subsequently	  (DIV8)	  superinfected	  with	  LV:TREt-­‐luc	  (a,	  c)	  and	  LV:pPgk1-­‐EgfR	  (b,	  d).	   Cells	   kept	   for	   2	   weeks	   under	   anti-­‐differentiaive	  medium	   and	   1	  more	  week	   under	   pro-­‐differentiative	   medium;	   doxycyclin	   administered	   at	   DIV8–14.	   Data	   normalized	   against	  sample	  (a);	  absolute	  frequency	  of	  S100β+	  cells	  in	  (a),	  19.95±1.72%.	  p(Emx2/EgfR	  interaction,	  2-­‐ways	  ANOVA)<	  0.10.	  (F)	  Frequencies	  of	  S100β+	  derivatives	  of	  cortical	  precursors,	  acutely	  infected	  with	  LV:pNes/hsp68-­‐rtTA2S-­‐M2	  (a-­‐d),	  LV:TREt-­‐IRES2-­‐EGFP	  (a,	  b)	  and	  LV:TREt-­‐Emx2-­‐
IRES2-­‐EGFP	   (c,	   d),	   and	   subsequently	   (DIV8)	   exposed	   to	   Fgf9	   (b,	   d).	   Cells	   kept	   for	   2	  weeks	  under	   anti-­‐differentiative	   medium	   and	   1	   more	   week	   under	   pro-­‐differentiative	   medium;	  doxycyclin	  administered	  at	  DIV8–14.	  Data	  normalized	  against	  sample	  (a);	  absolute	  frequency	  of	   S100β+	   cells	   in	   (a),	   17.07±0.45%.	   p(Emx2/Fgf9	   interaction,	   2-­‐ways	   ANOVA)<0.002.	   (G)	  Frequencies	  of	  S100β+Ki67+	  derivatives	  of	  cortical	  precursors,	  acutely	  infected	  as	  in	  (E)	  and	  superinfected	  at	  DIV8	  with	  LV:pPgk1-­‐EgfR	  (c)	  and	  LV:TREt-­‐EGFP	  (a,	  b).	  Cells	  kept	  for	  11	  days	  under	   anti-­‐differentiative	  medium,	   supplemented	  with	   doxycyclin	   at	   DIV8–11,	   and	   2	  more	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days	   under	   GF-­‐supplemented	   pro-­‐differentiative	  medium.	   Data	   normalized	   against	   sample	  (NC);	   absolute	   frequency	   of	   (NC)	   S100β+Ki67+	   cells,	   9.81±0.54%.	   Scale	   bar=s.e.m.	   (H)	  Frequencies	  of	  S100β+Ki67+	  derivatives	  of	  cortical	  precursors,	  acutely	  infected	  as	  in	  (F)	  and	  supplemented	  with	  Fgf9	  at	  DIV8	  (c).	  Cells	  kept	  for	  11	  days	  under	  anti-­‐differentiative	  medium,	  supplemented	  with	   doxycyclin	   at	   DIV8–11,	   and	   2	  more	   days	   under	   GF-­‐supplemented	   pro-­‐differentiative	   medium.	   Data	   normalized	   against	   sample	   (NC);	   absolute	   frequency	   of	   (NC)	  S100β+Ki67+	  cells,	  10.32±0.61%.	  Scale	  bar=s.e.m.	  	  	  	   As	   for	  Emx2-­‐dependent	  EgfR	  regulation,	  we	  speculated	   that	  a	  key	  role	  might	  be	  played	  by	  Bmp	  signaling.	  In	  fact,	  Emx2	  promotes	  this	  signaling,	  by	  downregulating	  its	   established	   inhibitors	  Noggin	   and	  Fgf8	   ((Bilican	   et	   al.,	   2008;	   Fukuchi-­‐Shimogori	  and	   Grove,	   2003;	   Shimogori	   et	   al.,	   2004)),	   while	   Bmps,	   in	   turn,	   inhibit	   EgfR	  expression	  (Lillien	  and	  Raphael,	  2000).	  We	  confirmed	  the	  Emx2	  capability	  to	  enhance	  Bmp	   signaling	   in	   our	   system,	   by	   assessing	   the	   up	   regulation	   of	   two	   well-­‐known	  endogenous	   reporters	   of	   Bmp	   signaling,	   Id3	   and	  Msx1	   (Hollnagel	   et	   al.,	   1999)	   (Fig.	  
R.10	  A).	  Then,	   as	   expected,	   we	   found	   that	   Bmp	   inhibition	   by	   LDN193189	   restored	   EgfR	  expression	  levels	  in	  an	  Emx2-­‐	  GOF	  environment,	  while	  not	  affecting	  them	  in	  controls	  (Fig.	  R.10	  D).	  Concerning	   Fgf9,	   its	   expression	   might	   rely	   on	   Sox2,	   which	   is	   specifically	  promoted	  by	   signals	   triggering	   astrocytic	   proliferation	   (Bani-­‐Yaghoub	   et	   al.,	   2006).	  Emx2	  might	   down	   regulate	   Fgf9	   by	   inhibiting	   the	   Sox2	   activation	   elicited	   by	   Brn2	  (Mariani	   et	   al.,	   2012),	  which	   is	   expressed	   in	   a	   variety	   of	   neural	   cells	   including	   the	  astrogenic	   lineage	   (Abe	   et	   al.,	   2012).	   We	   found	   that	   Emx2	   overexpression	   almost	  silenced	  Sox2	  in	  cortico-­‐cerebral	  precursors	  at	  astrogenesis	  peak	  time	  (Fig.	  R.10	  B,C).	  Furthermore,	  Sox2	  overexpression	  rescued	  Fgf9	  levels	  in	  an	  Emx2-­‐GOF	  environment	  (Fig.	   R.10	   E).	   This	   confirms	   that	   Sox2	   is	   implicated	   as	   a	   key	   mediator	   of	   Emx2-­‐	  dependent	   Fgf9	   regulation.	   As	   expected,	   we	   also	   found	   that	   Brn2	   overexpression	  rescued	  Fgf9	  levels	  in	  an	  Emx2-­‐GOF	  environment,	  while	  not	  affecting	  them	  in	  controls	  (Suppl.	  Fig.	  S.6).	  Finally,	   we	   wondered	   if	   Bmp	   signaling	   and	   Sox2	   are	   also	   implicated	   in	   the	  regulation	  of	  Fgf9	  and	  EgfR,	  respectively.	  Interestingly,	  we	  observed	  that	  both	  Bmp	  inhibition	  by	  LDN193189	  and	  Sox2	  overexpression	  were	  able	  to	  rescue	  the	  inhibition	  of	  these	  two	  genes	  elicited	  by	  Emx2	  (Fig.	   R.10	   F,G).	   Intriguingly,	   however,	   Bmp	   inhibition	   in	   the	   absence	   of	   Emx2	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overexpression	  did	  not	  affect	  Fgf9	   (Fig.	  R.10	  F,	  compare	  a	  and	  b).	  On	   the	  other	  side,	  while	  Emx2	  downregulated	  Fgf9	  in	  control	  conditions	  (Fig.	  R.10	  F,	  compare	  a	  and	  c),	  it	  increased	  Fgf9-­‐	  mRNA	  levels	  by	  >2.25-­‐folds	  upon	  Bmp	  signaling	  inhibition	  (Fig.	  R.10	  
F,	  compare	  b	  and	  d).	  This	  suggests	   that	  Bmp	  signaling	  might	   inhibit	  Fgf9	  expression	  by	   antagonizing	   a	   hypothetical,	  Emx2-­‐dependent	   stimulatory	   pathway	   (Fig.	  R.10	  H,	  
question	  mark).	  	  	  
	  
Figure	  R.10.	  Emx2	  represses	  EgfR	  and	  Fgf9	  by	  enhancing	  Bmp	  signaling	  and	  inhibiting	  
Sox2.	   (A)	   Upregulation	   of	   the	  Bmp	   targets	   Id3	   and	  Msx1	   in	   preparations	   of	   E12.5	   cortico-­‐cerebral	   precursors,	   acutely	   infected	  with	   LV:pPgk1p-­‐rtTA2S-­‐M2	   (Emx2-­‐GOF,	  NC),	   LV:TREt-­‐
IRES2-­‐EGFP	   (NC)	   and	   LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	   (Emx2-­‐GOF),	   grown	   in	   anti-­‐differentiative	  medium	   and	   subsequently	   (DIV8)	   exposed	   to	   doxycyclin.	   Data	   double-­‐normalized	   against	  Gapdh	  and	  NC.	  (B)	  Sox2	  levels	  in	  cultures	  of	  cortico-­‐cerebral	  precursors	  prepared	  as	  in	  (A),	  evaluated	   by	   immunofluorescence.	   Data	   normalized	   against	   NC.	   (C)	   Distribution	   of	   Sox2	  immunoreactivity	  and	  EGFP	  fluorescence	  in	  cells	  referred	  to	  in	  (B).	  Circles	  delineate	  heavily	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infected	   cells	   displaying	   residual	   EGFP	   fluorescence	   despite	   of	   PFA	   fixation,	   while	   arrows	  point	  to	  Sox2-­‐negative	  cells.	  (D)	  EgfR-­‐mRNA	  levels	  in	  preparations	  of	  E12.5	  cortico-­‐cerebral	  precursors,	  acutely	   infected	  with	  LV:Pgk1prtTA2	  S-­‐M2	   (a-­‐d),	  LV:TREt-­‐IRES2-­‐EGFP	   (a,	  b)	  and	  LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	   (c,	   d),	   grown	   in	   anti-­‐differentiative	   medium	   and	   subsequently	  (DIV8)	   exposed	   to	   doxycyclin	   (a-­‐d)	   and	   the	   Bmp-­‐inhibitor	   LDN193189	   (b,	   d).	  p(Emx2/LDN193189	   interaction,	   2-­‐ways	   ANOVA)<	   0.01.	   (E)	   Fgf9-­‐mRNA	   levels	   in	  preparations	  of	  E12.5	  cortico-­‐cerebral	  precursors,	  acutely	  infected	  with	  LV:Pgk1p-­‐rtTA2S-­‐M2	  (a-­‐d),	  LV:TREt-­‐IRES2-­‐EGFP	   (a,	  b),	   LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	   (c,	  d)	   and	  LV:TREt-­‐Sox2	   (b,	  d),	  grown	  in	  anti-­‐differentiative	  medium	  and	  subsequently	  (DIV8)	  exposed	  to	  doxycyclin	  (a–d).	  p(Emx2/Sox2	   interaction,	   2-­‐ways	   ANOVA)	   <	   0.04.	   (F,	   G)	   Fgf9-­‐	   and	   EgfR-­‐mRNA	   levels	   in	  reparations	   of	   cortico-­‐cerebral	   precursors	   described	   in	   (D)	   and	   (E),	   respectively.	  p(Emx2/LDN193189	   interaction,	   2-­‐ways	  ANOVA)	  <	  0.001	   and	  p(Emx2/Sox2	   interaction,	   2-­‐ways	   ANOVA)<	   0.5.	   In	   (D–G),	   data	   double-­‐normalized	   against	   Gapdh	   and	   samples	   (a).	   (H)	  Synopsis	  of	  epistatic	  relationships	  among	  Emx2	  and	  mediators	  of	   its	  antiastrogenic	  activity,	  inferred	  from	  data	  reported	  in	  (A–G).	  The	  question	  mark	  highlights	  a	  hypothetical	  regulatory	  branch	  possibly	  accounting	  for	  data	  in	  (Fbd).	  In	  (A,	  B,	  D–G),	  Scale	  bar=	  s.e.m.	  	  
	  
	  
4.2.3	   Relevance	  of	  Emx2	  dynamics	  to	  perinatal	  burst	  of	  astrogenesis	  Since	   neuronogenesis	   peak	   time,	   cortico-­‐cerebral	   precursors	   can	   sense	  exogenous	  gliogenic	  signals	  and	  relay	  them	  to	  the	  nucleus,	  where	  chromatin	  of	  glial	  genes	   is	   already	   prone	   to	   transcription	   (Barnabé-­‐Heider	   et	   al.,	   2005;	  Hatada	   et	   al.,	  2008).	  Nevertheless,	   astrogenesis	  mounts	   only	   4–5	  days	   later,after	   neuronogenesis	  completion.	  Late-­‐embryonic	  arousal	  of	  astrogenic	  cytokines	  has	  been	  shown	  to	  be	  a	  main	   determinant	   of	   this	   schedule	   (Barnabé-­‐Heider	   et	   al.,	   2005).	  We	   hypothesized	  that	  high	  Emx2	  levels	  displayed	  by	  multipotent	  precursors	  within	  the	  neuronogenic	  time	  window	  (Gulisano	  et	  al.,	  1996)	  could	  contribute	  to	  such	  schedule,	  by	  shrinking	  the	  embryonic	  astrogenic	  pool	  and	  limiting	  its	  eventual	  output.	  To	   test	   this	   prediction,	   first,	   we	   compared	   Emx2	   expression	   levels	   in	  embryonic	  and	  perinatal	  neural	  precursors.	  As	  expected,	  we	  found	  that	  Emx2-­‐mRNA,	  normalized	   against	   three	   genes	  mainly	   active	  within	  multipotent	   precursors	   of	   the	  apical	   domain,	   Sox2,	   Pax6,	   and	   Hes5	   (http://developingmouse.	   brain-­‐map.org),	  progressively	   decreased	   from	   E14.5	   to	   E18.5,	   concomitantly	   with	   the	   arousal	   of	  astrogenesis	   (Fig.	  R.11	  A–C).	  Then,	   to	   corroborate	   this	   result,	  we	   scored	  expression	  levels	  of	  the	  Emx2	  protein,	  using	  two	  antibodies.	  First,	  we	  evaluated	  Sox2-­‐normalized	  Emx2	  immunofluorescence	  levels	  in	  acutely	  dissociated,	  single	  Sox2+	  precursors,	  by	  means	   of	   a	   mouse	   monoclonal	   antibody.	   Interestingly,	   such	   levels	   resulted	   almost	  halved	   in	   precursors	   originating	   from	   P0	   neocortices	   compared	   to	   their	   E12.5	  counterparts	   (Fig.	   R.11	   D,E).	   Moreover,	   we	   immunoprofiled	   coronal	   sections	   from	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E12.5	   and	   E18.5	   brains	   with	   a	   rabbit	   polyclonal	   antibody.	   Here,	   we	   observed	   that	  Emx2	  immunoreactivity	  was	  extremely	  high	  in	  the	  E12.5	  pallium,	  while	  being	  barely	  detectable	  in	  periventricular	  layers	  of	  the	  E18.5	  neocortex	  (Fig.	  R.11	  F).	  Finally,	   to	   assess	   the	   effects	   elicited	   by	   short	   term	   Emx2	   overexpression	   in	  embryonic	  NSCs,	  we	   challenged	   embryonic	   precursors	   by	   a	   Lif-­‐supplemented,	   pro-­‐differentiative	  medium.	  Wild	   type	  precursors	  kept	  under	  Lif	   for	  4	  days	  generated	  GFAP+	  and	  S100β+	  cells	   at	   frequencies	   far	   above	   untreated	   controls	   (not	   shown).	   Remarkably,	   Emx2	  overexpression	   reduced	   these	   frequencies	   by	   76.22±4.07%	   (p<0.0004,	   n=3)	   and	  40.16±9.17%	  (p<0.02,	  n=3),	  respectively	  (Fig.	  R.11	  G,H).	  Consistently,	  neural	  cultures	  heterozygous	   for	   an	  Emx2-­‐null	  mutation,	   kept	   under	   Lif	   for	   2	   days,	   gave	   rise	   to	   an	  almost	   double	   S100β+	   	   cell	   output	   compared	   to	   controls	   (191.85±22.81%,	   with	  




Figure	  R.11.	  High	  Emx2	  expression	  in	  embryonic	  cortical	  NSCs	  dampens	  astrogenesis.	  
(A–C)	   Time	   course	   profile	   of	   Emx2-­‐mRNA	   in	   the	   embryonic	   neocortex.	   qRT-­‐PCR	   results	  normalized	   against	   two	   genes	   highly	   expressed	   in	   apical	  multipotent	   precursors,	   Sox2	   and	  
Pax6,	   and	   the	  NSC	  marker	  Hes5,	   and	   further	  normalized	  against	  E12.5	   (A)	  and	  E14.5	   (B,	  C)	  data.	   (D)	   Distribution	   of	   Sox2-­‐normalized	   Emx2	   immunofluorescence	   levels	   in	   acutely	  dissociated,	  single	  Sox2+	  precursors	  originating	  from	  E12.5	  and	  P0	  neocortices.	  For	  each	  box-­‐plot,	  bars	  represent	  1st	  decile,	  1st	  quartile,	  median,	  3rd	  quartile	  and	  9th	  decile,	  respectively.	  (E)	  Example	  of	  Sox2+	  cells	  referred	   to	   in	  (D).	   (F)	  Distribution	  of	  Emx2	   immunoreactivity	   in	  frontal	   sections	   of	   E12.5	   and	   E18.5	   telencephala.	   Emx2	   immunoreactivity	   (1st	   row)	   is	  compared	  to	  endogenous	  autofluorescence	  (2nd	  row)	  and	  DAPI	  staining	  (3rd	  row)	  from	  the	  same	   E12.5	   and	   E18.5	   sections,	   as	   well	   as	   with	   Sox2	   (4th	   row)	   and	   Pax6	   (5th	   row)	  immunoreactivities	   from	   adjacent	   sections.	   Emx2	   immunoreactivity	   is	   very	   strong	   in	   the	  ventricular	  zone	  of	  E12.5	  cortex	  (1st	  row,	  1st	  column).	  It	  is	  absent	  in	  the	  same	  layer	  of	  E12.5	  basal	   ganglia	   (1st	   row,	   3rd	   column),	   shown	   here	   as	   an	   internal,	   tissuematched,	   negative	  control.	   Arrowheads	   point	   to	   E18.5	   periventricular	   cells	  weakly	   immunoreactive	   for	   Emx2	  (1st	  row,	  2nd	  column).	  Arrows	  indicate	  Emx2+	  Cajal-­‐Retzius	  cells	  within	  the	  marginal	  zone,	  shown	  here	  as	  an	  internal	  positive	  control	  (1st	  row,	  4th	  column).	  Abbreviations:	  cx,	  cortex;	  bg,	   basal	   ganglia;	   vz,	   ventricular	   zone;	   svz,	   subventricular	   zone;	   iz,	   intermediate	   zone;	   cp,	  cortical	   plate;	   mz,	   marginal	   zone.	   (G,	   H)	   Frequencies	   of	   GFAP+	   and	   S100β+	   elements	  originating	   from	   E12.5	   cortico-­‐cerebral	   precursors,	   acutely	   infected	   with	   LV:pNes/hsp68-­‐
rtTA2S-­‐M2	  and,	  alternatively,	  LV:TREt-­‐IRES2-­‐EGFP	  (NC)	  or	  LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	  (Emx2-­‐GOFNSC).	   Cells	   kept	   under	   anti-­‐differentiative	   medium	   at	   DIV1-­‐2	   and	   under	   Neurobasal	  A/B27/glutamax	   at	   DIV3–6;	   Lif	   and	   doxycyclin	   administered	   at	   DIV3–6.	   Data	   normalized	  against	  NC	  samples;	  absolute	  frequencies	  of	  GFAP+	  and	  S100β+	  cells	  in	  (NCs),	  36.55±62.62%	  and	   46.32±64.86%,	   respectively.	   Scale	   bar = s.e.m.	   (I)	   Frequencies	   of	   S100β+	   elements	  originating	  from	  E12.5	  cortico-­‐cerebral	  precursors,	  wild	  type	  and	  heterozygous	  for	  an	  Emx2-­‐null	  mutation.	  Cells	  kept	  under	  anti-­‐differentiative	  medium	  at	  DIV1-­‐3	  and	  under	  Neurobasal	  A/B27/glutamax	   at	   DIV4–6;	   Lif	   administered	   at	   DIV4–6.	   Data	   normalized	   against	   (NC)	  samples;	  absolute	  frequencies	  of	  S100β+	  cells	  in	  (NCs),	  17.29 ± 62.74%.	  Scale	  bar=s.e.m.	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4.3	  	   Emx2	   overexpression	   in	   glioblastoma	   multiforme:	   a	  
therapeutical	  application	  	  
	  
4.3.1	  	   Emx2	  overexpression	  kills	  glioblastoma	  cells	  in	  vitro	  	  To	  assess	  if	  Emx2	  can	  antagonize	  glioblastoma	  multiforme,	  we	  overexpressed	  its	  coding	  sequence	  in	  2	  GBM	  lines	  (U87MG	  and	  T98G)	  as	  well	  as	  in	  GBM	  cell	  cultures	  originating	   from	   5	   different	   patients	   (GbmA,	   GbmB,	   GbmC,	   GbmD	   and	   GbmE),	   via	  lentiviral	  vectors	  and	  TetON	  technology.	  As	  controls,	  we	  employed	  the	  corresponding	  GBM	   cultures,	   infected	   by	   Egfp-­‐	   or	   Emx2-­‐encoding	   lentiviruses	   and	   kept	   in	   the	  presence	  or	  absence	  of	  doxycycline,	   respectively	  (Fig.	  R.12	  A,B	  and	  Suppl.Fig.	  S7).	   In	  all	  cases,	  the	  activation	  of	  the	  Emx2	  transgene	  arrested	  the	  expansion	  of	  the	  culture	  and	  led	  to	  its	  collapse,	  usually	  within	  7-­‐8	  days,	  never	  beyond	  the	  22nd	  day	  (Fig.	  	  R.12	  




Figure	   R.12.	   Population	   dynamics	   of	   Emx2	   gain-­‐of-­‐function	   GBM	   cultures.	   In	   vitro	  kinetic	  progression	  of	  U87MG,	  T98G,	  GbmA,	  GbmB,	  GbmC,	  GbmD	  and	  GbmE	  GBM	  lines	  C-­‐I.,	  engineered	  by	  lentiviral	  vectors	  and	  TetON	  technology	  as	  in	  A,	  B.,	  and	  kept	  as	  adherent	  C,	  D.	  or	  floating	  cultures	  E-­‐I.,	  under	  Fgf2	  and	  Egf.	  Ki67+	  proliferating	  L,	  M.	  and	  activated-­‐Casp3+	  apoptotic	  N,	  O.	  fractions	  of	  GbmA,	  GbmB	  and	  GbmC	  glioblastoma	  cells,	  engineered	  by	  control	  (J.,	  a-­‐b1)	  and	  Emx2-­‐GOF	  (J,	  a-­‐b2)	  lentiviral	  sets,	  and	  kept	  as	  floating	  cultures	  according	  to	  the	  timetable	  in	  K.	  Cell	  numbers	  were	  normalized	  against	  t=0	  values	  (C-­‐I),	  or	  control	  values	  L,	  N.	  [As	  for	  (L,	  N),	  absolute	  average	  control	  cell	  frequencies	  were:	  0.207,	  0.155	  and	  0.131	  (Ki67+,	  in	   GbmA,	   GbmB	   and	   GbmC	   cultures,	   respectively);	   0.001,	   0.012	   and	   0.012	   (actCasp3+,	   in	  GbmA,	  GbmB	  and	  GbmC	  cultures,	   respectively)].	  n	  is	   the	  number	  of	  biological	   replicates.	  p-­‐value	   was	   calculated	   by	   t-­‐test	   (one-­‐tail,	   unpaired):	   *p<0.05,	   **p<0.01,	   ***p<0.001,	  ****p<0.0001,	  *****p<0.00001.	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Table	   R.1.	  mRNA	   levels	   of	   presumptive	  mediators	   of	  Emx2	  anti-­‐oncogenic	   activity	   in	  GBM	  cells	   engineered	   as	   in	   Figure	   1A.	   Seven	   days	   after	   lentiviral	   transduction,	   doxycyclin	   was	  added	  at	  2	  μg/ml.	  RNA	  samples	  were	  collected	  at	  time	  “t”	  after	  doxycyclin	  addition.	  qRT-­‐PCR	  results,	   normalized	   against	   GAPDH	   and	   further	   normalized	   against	   their	   own	   negative	  controls,	  are	  shown	  as	  average	  ±	  s.e.m.	  Values	  possibly	  accounting	   for	  Emx2	  anti-­‐oncogenic	  activity	  are	  highlighted	  in	  blue.	  ns,	  not	  significant.	  n	  is	  the	  number	  of	  biological	  replicates.	  p-­‐value	  was	  calculated	  by	  t-­‐test	  (one-­‐tail,	  unpaired).	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4.3.2	   Emx2	  antagonizes	   glioblastoma	  by	   a	  pleiotropic	   impact	   on	  malignancy-­‐
related	  processes	  	  To	   cast	   light	   on	   molecular	   mechanisms	   underlying	   Emx2	   impact	   on	   GBM	  kinetics,	  we	  overexpressed	  its	  coding	  sequence	  in	  5	  GBM	  samples	  and	  scored	  mRNA	  levels	  of	  selected	  genes	  involved	  in	  their	  malignancy.	  These	  genes	  include:	  (a)	  a	  group	  implicated	   in	   relaying	  mitogenic	   signals	   along	  RTK	   cascades	   (EGFR,	  PDGF,	  PDGFRA,	  
PTEN,	  NF1),	  (b)	  a	  group	  involved	  in	  the	  control	  of	  early	  G1/late	  G1	  checkpoint	  (MYC,	  
MYCN,	  RB1,	  CDKN2A,	  CDKN2B,	  CDK4,	  CDK6,	  CCND2),	   and	   (c)	   a	  more	   heterogeneous	  group	   dealing	   with	   a	   variety	   of	   malignancy-­‐related	   processes,	   such	   as	   stemness,	  apoptosis,	  neovasculogenesis	  (SOX2,	  HES1,	  GLI1,	  TRP53,	  MDM2,	  VEGF).	  In	  all	  samples	  analyzed,	  Emx2	  significantly	   altered	   the	   expression	  of	   group	   (a)	   genes,	   consistently	  with	   its	   antioncogenic	   activity.	   It	   downregulated	   EGFR	   in	   all	   cases.	   In	   addition,	   it	  decreased	  PDGF	  and	  PDGFRA	  in	  1	  and	  4	  cases,	  respectively,	  and	  increased	  PTEN,	  in	  1	  case	  (Table	  R.1).	   In	  a	   large	  subset	  of	  samples,	  Emx2	  also	  modulated	  mRNA	   levels	  of	  group	  (b)	  genes,	  again	  in	  agreement	  with	  its	  antioncogenic	  activity	  (Table	  R.1).	  These	  genes	   include	   -­‐	   in	   particular	   -­‐	   CDK4	  and	   CDK6,	   mastering	   the	   early	   G1	   checkpoint	  (decreased	   in	   3	   and	   2	   cases,	   respectively).	   Finally,	  Emx2	  downregulated	   SOX2	   in	   4	  samples	  and	  increased	  TRP53	  and	  HES1	  expression,	  in	  2	  and	  5	  samples,	  respectively	  (Table	  R.1).	  	  To	  complement	  mRNA	  profiling,	  we	  also	  monitored	  Emx2	  overexpressing	  GBM	  cells	   for	   key	   phospho-­‐proteins	   involved	   in	   malignancy-­‐related,	   intracellular	   signal	  transduction	   (Fig.	   R.13	   and	   Suppl.	   Fig.	   S.9).	   We	   found	   a	   significant	   decrease	   of	  p(Thr202/Tyr204)Erk1/2	  (-­‐40.3±6.3%,	  p<0.005,	  see	  Figure	  2C,	  2D).	  This	  may	  stem	  from	  depressed	  EGF	  and	  PDGF	  signalling.	  It	  may	  be	  a	  key	  determinant	  of	  the	  kinetic	  behaviour	  of	  Emx2-­‐	  GOF	  GBM	  cells	   (Veliz	   et	   al.,	   2015).	   Furthermore,	  we	  detected	  a	  robust	  increase	  of	  p(Ser463/465)Smad1,5,8	  (+100%,	  p<0.003,	  see	  Fig.	  R.13	  E,F).	  This	  is	   an	   index	   of	   enhanced	   Bmp	   signalling,	   which	   was	   shown	   to	   be	   instrumental	   to	  
Emx2-­‐	  dependent	  inhibition	  of	  astroblast	  proliferation	  (Falcone	  et	  al.,	  2015).	  Finally,	  we	   found	   that	   Stat3	   phosphorylation	   levels	   in	   Tyr705	   and	   Ser727,	   crucial	   to	   self-­‐renewing	  abilities	  of	  GBM	  cells	  (Park	  et	  al.,	  2013),	  were	  unchanged	  (Fig.	  R.13	  G-­‐J).	  	  Next,	   we	   tested	   the	   functional	   relevance	   of	   selected	  mRNA/protein	   changes	  described	  above	  to	  the	  Emx2	  antioncogenic	  activity.	  For	  this	  purpose,	  we	  chose	  a	  few	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“X”	   agents	   neutralizing	   such	   changes	   and	   evaluated	   their	   capability	   to	   rescue	   the	  original	  GBM	  kinetic	  profiles	  (Fig.	  R.14	  A-­‐C).	  	  First,	  we	  tried	  to	  restore	  the	  basic	  expansion	  rate	  of	  GbmA	  and	  GbmC	  cultures,	  previously	   made	   gain-­‐of-­‐function	   for	   Emx2,	   by	   transducing	   them	   with	   an	   EGFR-­‐expressing	   transgene	   (Fig.	   R.14	   A,	   rescue	   X1).	   This	   manipulation	   slowed	   down	   the	  decline	  of	  these	  cultures,	  however	  only	  in	  a	  partial	  and	  temporary	  fashion	  (Fig.	  R.14	  
D,G).	  A	  similar	  effect	  was	  elicited	  by	  overexpression	  of	  the	  stemness-­‐factor	  SOX2	  (Fig.	  
R.14	  A,	  rescue	  X2)	  in	  Emx2-­‐	  GOF	  GbmA	  and	  GbmC	  (Fig.	  R.14	  E,H).	  Noticeably,	  neither	  
EGFR	  nor	   SOX2	  overexpression	   perturbed	   GBM	   kinetics	   in	   control	   conditions	   (Fig.	  
R.14	  D,E,G,H).	  	  Moreover,	   we	   tried	   to	   counteract	   HES1,	   one	   of	   the	   main	   Emx2-­‐responders,	  whose	   overexpression	  was	   previously	   linked	   to	   proliferation	   arrest	   in	   a	   variety	   of	  contexts	  [19–21].	  To	  this	  aim,	  we	  delivered	  its	  established	  functional	  antagonist	  HES6	  (Gratton	  et	  al.,	  2003)	  to	  GBM	  cells	  (Fig.	  R.14	  A,	  rescue	  X3).	  This	  manipulation	  slowed	  down	  the	  collapse	  of	  GbmA	  and	  GbmC	  cultures	  overexpressing	  Emx2,	  while	  not	  fully	  preventing	   it	   (Fig.	  R.14	  F,I).	  Conversely,	  HES6	  overexpression	  did	  not	  promote	  GBM	  expansion	  in	  control	  conditions	  (Fig.	  R.14	  F,I).	  	  Next,	   we	   tried	   to	   restore	   RTK	   signalling	   defects	   evoked	   by	   Emx2	   (Fig.	   R.13	  
C,D),	  providing	  GBM	  cultures	  with	  an	  excess	  of	  Fgf9	  (Fig.	  R.14	  A,	  rescue	  X4).	  This	  is	  a	  key	   ligand	   down-­‐regulated	   by	   Emx2	   (Falcone	   et	   al.,	   2015)	  and	   proven	   to	   promote	  proliferation	  within	  the	  astrocytic	   lineage	  (Seuntjens	  et	  al.,	  2009).	  Also,	  we	  silenced	  BMP	   signalling	   (Fig.	  R.14	  A,	   rescue	  X5),	   already	   proposed	   as	   a	   key	   therapeutic	   tool	  against	  GBM	  (Li	  et	  al.,	  2014;	  Piccirillo	  et	  al.,	  2006).	  Both	  manipulations	  slowed	  down	  the	  decline	  of	  Emx2-­‐GOF	  GbmA	  cultures,	  however	  only	   to	  a	  partial	  extent	   (Fig.	  R.14	  
J,K).	   Neither	   Fgf9	   nor	   BMP-­‐inhibitor	   delivery	   promoted	   an	   expansion	   of	   control	  GbmA	  cells	  (Fig.	  R.14	  J,K).	  	  Finally,	   in	   addition	   to	   Emx2	   impact	   on	   transcription,	   we	   considered	   the	  possibility	  that	  the	  anti-­‐oncogenic	  activity	  of	  this	  protein	  could	  be	  strenghtened	  by	  its	  capability	  to	  chelate	  the	  translational	  factor	  Eif4e	  (Nédélec	  et	  al.,	  2004).	  In	  agreement	  with	  this	  prediction,	  Eif4e	  overexpression	  in	  Emx2-­‐GOF	  U87MG	  cultures	  (Fig.	  R.14	  A,	  
rescue	  X6)	  delayed	  their	  decline,	  while	  not	  affecting	  U87MG	  controls	  (Fig.	  R.14	  L).	  	  All	   that	   suggests	   that	   Emx2	  may	   act	   by	   perturbing	   a	   number	   of	   genes	   and	  metabolic	   nodes	   crucial	   to	   GBM	   aggressiveness.	   It	   points	   at	   Emx2	   as	   a	   promising	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Figure	   R.13.	   Immunoprofiling	   of	   Emx2	   gain-­‐of-­‐function	   GBM	   cultures	   for	   key	  
intracellular	  signaling	  transducers.	  Western	  blot	  evaluation	  of	  p(Thr202/Tyr204)Erk1/2	  (C,	  






Figure	  R.14.	  Rescue	  of	  Emx2	  antioncogenic	  activity	  via	  modulation	  of	   its	  presumptive	  
mediators.	  GBM	   cells	  were	   engineered	   and	   cultured	   as	   in	   (A-­‐C)	   In	   particular,	   lentiviruses	  harboring	  an	  IRES-­‐EGFP	  or	  a	  PLAP	  module	  under	  the	  control	  of	  a	  TREt	  promoter	  were	  used	  as	  controls	   for	   “b”	  and	  “X1,	  X2,	  X3,	  X6”,	   respectively.	  Cells	  were	  scored	   for	   the	  capability	  of	  selected	   “X”	   agents	   (restoring	   presumptive	   mediators	   of	   Emx2	   anti-­‐oncogenic	   activity)	   to	  rescue	  their	  control	  kinetic	  profiles	  (D-­‐L)	  n	  is	  the	  number	  of	  biological	  replicates.	  p-­‐value	  was	  calculated	  by	  t-­‐test	  (one-­‐tail,	  unpaired).	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4.3.3	   Emx2	  overexpression	  is	  suitable	  to	  antagonize	  GBM	  in	  vivo	  To	  assess	  the	  portability	  of	  Emx2	  antioncogenic	  activity	  in	  vivo,	  we	  transplanted	  engineered	   GBM	   cells	   (U87MG,	   GbmA,	   GbmC	   and	   GbmD)	   into	   the	   neocortical	  parenchyma	  of	  P4	  wild-­‐type	  mouse	  pups.	  Specifically,	  we	  injected	  a	  1:1	  mix	  of	  cells,	  made	  alternatively	  gain-­‐of-­‐function	  for	  Emx2	  or	  a	  control,	  and	  labelled	  with	  Egfp	  and	  mCherry,	   respectively.	   One	   week	   later,	   we	   sacrificed	   the	   animals	   and	   scored	   each	  brain	  for	  the	  ratio	  between	  the	  number	  of	  Emx2-­‐GOF	  cells	  (Egfp+)	  and	  the	  number	  of	  control	  cells	  (mCherry+).	  This	  ratio	  was	  equal	  to	  0.40±0.05	  (p<0.099,	  n=3),	  0.44±0.13	  (p<0.049,	  n=4),	  0.34±0.12	  (p<0.025,	  n=4)	  and	  0.29±0.04	  (p<0.006,	  n=4),	  for	  U87MG,	  GbmA,	  GbmC	   and	  GbmD,	   respectively	   (Fig.	  R.15).	   (In	   a	   previous	   pilot	   test	   run	  with	  Egfp+	   and	  mCherry+	  GBM	   cells	   not	   harboring	   additional	   transgenes,	   this	   ratio	  was	  close	  to	  1)	  (Suppl.	  Fig.	  	  S.10).	  	  To	   complement	   this	   analysis,	   we	   investigated	   if	   Emx2	   overexpression	   may	  increase	   the	   survival	   time	  of	  GBM-­‐transplanted	  mice	   in	   a	   classical	   long-­‐term	  assay.	  	  To	  this	  aim,	  we	  transplanted	  engineered,	  EGFP-­‐labeled	  GBM	  cells	   (U87MG)	   into	   the	  striatum	  of	  	  5	  weeks	  old	  nude	  mice.	  In	  particular,	  we	  injected	  300,000	  Emx2-­‐GOF	  cells	  to	   a	   former	   group	   and	   300,000	   control	   cells	   to	   the	   other	   group.	   Remarkably,	   we	  found	  that	  mice	  transplanted	  with	  Emx2-­‐GOF	  GBM	  cells	  displayed	  a	  median	  survival	  of	   55	  days	   against	   the	  35	  days	   of	   the	   control	   group	   (p<0.001,	  n=14,14)	   (Fig.	  R.16).	  Together	   with	   the	   previous	   set	   of	   in	   vivo	   experiments,	   these	   results	   indicate	   that	  
Emx2	  exerts	  a	  robust	  antioncogenic	  activity	  even	  in	  vivo.	  	  	  Disappontingly,	  Emx2	  overexpression	  in	  pyramidal	  neurons	  is	  highly	  toxic	  (our	  unpublished	   data).	   Therefore,	   generalized	   Emx2	   delivery	   to	   the	   diseased	   brain	   of	  GBM	  patients	  would	  not	  be	  a	  suitable	  approach.	  To	  circumvent	  this	  issue,	  we	  thought	  to	   restrict	   therapeutic	  Emx2	  overexpression	   to	   tumor	   precursor	   cells,	   by	   putting	   it	  under	   the	  control	  of	   a	   cis-­‐active	  element	   selectively	   firing	   in	  neural	   stem	  cells	   (Fig.	  
R.17	  A,	  “Nes-­‐p”;	  Suppl.	  Fig.	  S.11).	  Remarkably,	  this	  design	  turned	  out	  to	  be	  feasible,	  as	  it	   successfully	   replicated	   the	   kinetic	   outcome	   elicited	   upon	   generalized	   Emx2	  overexpression	  (compare	  Fig.	  R.17	  C,D	  and	  Fig.	  R.12	  E,F).	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Figure	  R.17.	   Persisting	   antioncogenic	   efficacy	   of	  Emx2	  upon	   neural	   nestin	   enhancer-­‐
restricted	   overexpression.	   In	   vitro	   kinetic	   progression	   of	   GbmA	   and	   GbmB	   lines	   (C,D),	  engineered	   by	   lentiviral	   vectors	   and	   TetON	   technology	   as	   in	   (A,B),	   and	   kept	   as	   floating	  cultures,	   under	   Fgf2	   and	   Egf.	   Cell	   numbers	   were	   normalized	   against	   t=0	   values.	   n	   is	   the	  number	   of	   biological	   replicates.	   p-­‐value	   was	   calculated	   by	   t-­‐test	   (one-­‐tail,	   unpaired):	  ***p<0.001,	  ****p<0.0001.	  	  	  	  
Figures	  from	  R.7	  	  to	  R.11	  	  were	  adapted	  from	  (Falcone	  et	  al.,	  2015)	  and	  Figures	  from	  
R.12	  to	  R.17	  were	  adapted	  from	  (Falcone	  et	  al.,	  2016).	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5.	   DISCUSSION	  
	  	   In	  this	  study,	  I	  investigated	  the	  neurodevelopmental	  role	  of	  two	  transcription	  factors	  involved	  in	  the	  inhibition	  of	  astrogenesis	  and	  the	  exploitability	  of	  one	  of	  them	  for	  gene	  therapy	  of	  glioblastoma	  multiforme	  tumor.	  	  Astrocytes	   generation	   within	   the	   developing	   cerebral	   cortex	   is	   a	   finely	  regulated	  process.	  Astrogenesis	  begins	   in	   the	  middle	  of	   the	  neuronogenic	   temporal	  window,	   it	   spreads	   as	   soon	   as	   neurogenesis	   reaches	   its	   end	   and	   it	   peaks	   up	   after	  neuronogenesis	   completion.	   The	   astrocytic	   output	  mainly	   depends	   on	   two	   factors:	  commitment	   of	   multipotent	   precursors	   toward	   astroglial	   fates	   and	   kinetic-­‐differentiative	  progression	  of	   the	  astrogenic	  proliferating	  pool.	  The	  proper	  sizing	  of	  the	   astrocytic	   compartment	   is	   crucial	   for	   the	   adult	  brain	   functions.	  A	  deficit	   of	   this	  compartment	   may	   alter	   excitability	   and	   information	   processing	   abilities	   of	   neural	  tissues.	  An	  uncontrolled	  proliferation	  of	  astroglial	  cells	   in	  the	  adult	  may	  give	  rise	  to	  severe	   pathologies,	   among	   which	   GBM,	   representing	   one	   of	   the	   most	   aggressive	  malignant	  brain	  tumors	  in	  humans.	  Our	  research	  study	  gave	  robust	  evidence	  for	  Foxg1	  and	  Emx2	   limiting	  mouse	  cortico-­‐cerebral	  astrogenesis.	  This	  antiastrogenic	  activity	  is	  upheld	  by	  the	  outcomes	  of	   a	   variety	   of	   experimental	   manipulations	   we	   performed,	   in	   vivo	   and	   in	   vitro.	  Specifically,	  we	  found	  that	  Foxg1	  inhibits	  the	  commitment	  of	  early	  neural	  precursors	  to	   astroglial	   fates,	   while	   Emx2	   antagonizes	   astroblast	   proliferation.	   Moreover,	   we	  proved	  that	  Emx2	  may	  be	  employed	  as	  a	  therapeutical	  tool	  to	  counteract	  GBM.	  	  	   ******	  	  	   In	   the	   first	  part	  of	   this	  work,	  we	   showed	   that	  Foxg1	  overexpression	   in	  early	  neural	   stem	   cells	   inhibits	   cortico-­‐cerebral	   astrogenesis,	   both	   in	   vitro	   and	   in	   vivo	  (Fig.R.	  1	  and	  Fig.	  R.2).	  Therefore,	  we	  investigated	  the	  molecular	  mechanisms	  leading	  to	   such	  outcome,	   referring	   to	   the	   regulation	  of	   the	  well-­‐known	  Gfap	   glial	   gene	  as	   a	  model.	  We	  found	  that	  Foxg1	  inhibits	  Gfap	  transcription.	  We	  reasoned	  that	  this	  may	  be	  due	   to	   a	   mis-­‐regulation	   of	   the	   transactive	   pathways	   impinging	   on	   Gfap	   promoter	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and/or	  an	  altered	  accessibility	  of	  its	  chromatin.	  We	  focused	  our	  attention	  on	  the	  first	  issue.	  To	  have	  an	  overall	   comprehension	  of	   the	  underlying	  molecular	  dynamics,	  we	  straightly	  monitored	   the	  ultimate,	  nuclear	   transactive	  effectors	  which	   regulate	  glial	  genes	  transcription.	  We	  detected	  a	  decrease	  of	  both	  pStat3	  and	  pSmad1,5,8	  as	  well	  as	  a	  concomitant	  increase	  of	  NCoR	  levels	  in	  neural	  stem	  cells	  overexpressing	  Foxg1	  (Fig.	  
R.5).	  Moreover,	  we	   found	   that	  suppression	  of	  Tab2,	  a	  NCoR	  cofactor	  crucial	   to	  Gfap	  transrepression,	  restored	  wild	  type	  astrogenic	  rates	  in	  Foxg1-­‐GOF	  cultures	  (Fig.	  R.6).	  All	   together,	   these	  results	  strongly	  suggest	   that	  Foxg1	  antagonizes	  NSC-­‐to-­‐astrocyte	  progenitor	   progression,	   due	   to	   its	   pleiotropic	   impact	   on	   transactive	   pathways	  modulating	  such	  progression.	  	  Cortico-­‐cerebral	  astrogenesis	  is	  sharply	  regulated	  thanks	  to	  the	  integration	  of	  signals	   provided	  by	   several	   regulatory	  pathways	   and	   the	   controlled	   accessibility	   of	  glial	  chromatin.	  The	  regulation	  of	  glial	  genes	  transcription	  (mostly	  Gfap	  and	  s100β)	  is	  a	  milestone	  for	  the	  study	  of	  pro-­‐	  and	  anti-­‐gliogenic	  programs.	  Therefore,	  we	  started	  to	   investigate	   Foxg1	   activity	   by	   measuring	   its	   impact	   on	   Gfap	   transcription.	   Once	  demonstrated	   that	   Foxg1	   down-­‐regulates	   Gfap	   mRNA	   levels,	   we	   wanted	   to	  understand	  if	  this	  effect	  is	  due	  to	  its	  impact	  on	  the	  transducing	  pathways,	  to	  a	  direct	  induction	   of	   chromatin	   closure,	   or	   both.	   We	   started	   from	   the	   first	   issue.	   In	  preliminary	   tests,	  we	  quantified	   the	   final	  molecular	  effectors	  of	   the	  most	   important	  pathways	  involved	  in	  astrogenesis	  regulation,	  within	  the	  whole	  Foxg1-­‐GOF	  neural	  cell	  population.	   Results	   of	   these	   tests	   led	   us	   to	   the	   provisional	   conclusion	   that	   ErbB4-­‐intracellular	  domain	  (ErbB4-­‐ICD)	  could	  be	  the	  key	  mediator	  of	  Foxg1	  antiastrogenic	  activity.	   	   	  Strikingly,	  when	  the	  analysis	  was	  restricted	  to	  the	  stem	  cell	  compartment	  (upon	   Foxg1	   overexpression	   in	   such	   compartment),	   the	   scenario	   turned	   out	   to	   be	  radically	   different.	   We	   found	   more	   concurrent	   mechanisms,	   different	   from	   ErbB4	  misregulation,	  through	  which	  Foxg1	  could	  lead	  to	  the	  inhibition	  of	  glial	  commitment.	  	  Firstly,	  pStat3	  levels	  reduction	  suggested	  an	  impact	  of	  Foxg1	  on	  the	  main	  pro-­‐astrogenic	   cascade,	   the	   Jak/Stat	   pathway.	   Secondly,	   the	   decrease	   of	   pSmad1,5,8	  provided	  evidence	  of	  a	  dampened	  Bmp	  signaling.	  (Actually,	  relevance	  of	  both	  changes	  to	   impaired	  astrogenic	  progression	   still	  waits	   for	   functional	   validation).	  Noticeably,	  these	   results	   were	   obtained	   in	   the	   presence	   of	   saturating	   levels	   of	   Lif	   and	   Bmp4,	  respectively.	   This	   suggests	   a	   defective	   sensibility	   of	   the	   corresponding	  sensing/transducing	   pathway	   to	   relay	   information	   from	   cell	   plasmamembrane	   to	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nucleus,	   rather	   than	   a	   decreased	   ligand	   availability.	   Interestingly,	   Foxg1	   has	   been	  previously	  demonstrated	  to	  chelate	  and	  inhibit	  the	  pSmad1	  BMP4-­‐signalling	  effector	  (Rodriguez	   et	   al.,	   2001;	   Seoane	   et	   al.,	   2004;	   Vezzali	   et	   al.,	   2016).	   Next,	   pSmad1	  normally	   binds	   to	   pStat1,3	   and	   enhances	   its	   transactivating	   power	   (Fukuda	   et	   al.,	  2007;	  Onishi	  et	  al.,	  2014).	  Moreover,	  pStat1,3	  transactivates	  genes	  encoding	  for	  key	  components	  of	  its	  own	  pathway	  (Ichiba	  et	  al.,	  1998).	  Therefore,	  the	  pStat3	  decrease	  triggered	   by	  Foxg1	   overexpression	  might	   simply	   reflect	   the	   depression	   of	   the	  Bmp	  axis.	  Alternatively,	  reduced	  NSC	  sensitivity	  to	  Lif-­‐family	  ligands	  might	  be	  induced	  by	  
other	   Foxg1-­‐dependent	   mechanisms,	   distinct	   from	   Bmp	   pathway	   depression.	   This	  issue	  has	  to	  be	  experimentally	  investigated.	  	  Finally,	  the	  well-­‐known	  NCoR	  transcriptional	  corepressor	  may	  also	  be	  crucial	  to	   	   Gfap	   transcription	   inhibition.	   In	   the	   context	   of	   ErbB4	   pathway,	   ErbB4-­‐ICD	   is	  complexed	   with	   NCoR	   thanks	   to	   a	   Tab2	   cofactor	   bridge.	   The	   resulting	   ternary	  complex	   translocates	   into	   the	   nucleus	  where	   it	   represses	   glial	   genes	   transcription.	  	  We	  measured	   both	   ErbB4	   and	   NCoR	   nuclear	   immunofluorescence	   levels	   in	   neural	  stem	  cells	   in	  culture.	  We	  found	  an	  increase	  of	  NCoR,	  while	  not	  observing	  significant	  changes	   in	   ErbB4-­‐ICD.	   Therefore,	   we	   speculated	   that	   NCoR	   could	   be	   the	   actual	  limiting	   factor,	   dictating	   the	   inhibitory	   tone	   exerted	   by	   the	   NCoR:Tab2:ErbB4-­‐ICD	  complex	   on	   the	   Gfap	   promoter	   upon	   Foxg1	   manipulation.	   To	   confirm	   that	   such	  pathway	   is	   instrumental	   to	   Foxg1	   antiastrogenic	   action,	   we	   suppressed	   Tab2	  expression,	  thanks	  to	  the	  RNAi	  technique.	  In	  the	  presence	  of	  a	  short	  hairpin	  against	  
Tab2,	  we	  observed	  a	  rescue	  of	  the	  astroglial	  output	  delivered	  by	  Foxg1-­‐GOF	  samples,	  suggesting	   that	   our	   inference	   was	   correct.	   Intriguingly,	   an	   excess	   of	  NCoR:Tab2:ErbB4-­‐IC	  complex	  could	  further	  divert	  RbpJk	  from	  interacting	  with	  Notch	  intracellular	  domain	  (NICD),	  so	  further	  dampening	  the	  Notch	  pro-­‐glial	  pathway.	  This	  aspect	  needs	  to	  be	  investigated.	  	  
Foxg1	  regulation	  of	  astrogenesis	  adds	  to	  numerous	  other	  functions	  exerted	  by	  this	   gene	   in	   the	   developing	   cerebral	   cortex	   (Hanashima	   et	   al.,	   2004;	   Fasano	   et	   al.,	  2009;	  Danesin	  et	  al.,	  2009;	  Hanashima	  et	  al.,	  2007;	  Kumamoto	  et	  al.,	  2013;	  Martynoga	  et	   al.,	   2005;	   Pancrazi	   et	   al.,	   2015)	   and	   echoes	   the	   impact	   that	   its	   Drosophila	   m.	  homolog	   Slp	   exerts	   on	   fruitfly	   gliogenesis	   (Mondal	   et	   al.,	   2007).	   Actually,	   at	   the	  moment	  we	  have	  strong	  evidences	  of	  Foxg1	  ability	  to	  antagonize	  astrogenesis,	  as	  well	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some	   interesting	  hints	  about	   the	  underying	  molecular	  mechanisms.	  However,	   three	  fundamental	  issues	  still	  remain	  to	  be	  cleared.	  First,	   we	   need	   to	   secure	   Foxg1	   physiological	   relevance	   to	   proper	   temporal	  articulation	   of	   astrogenesis.	   For	   this	   purpose,	   we	   have	   to	   rigorously	   evaluate	   the	  Foxg1	  protein	  and	  mRNA	  content	  of	   cerebral	   stem	  cells,	   at	  different	  developmental	  stages.	   	  We	   expect	   to	  detect	   higher	   Foxg1	   levels	   around	  neuronogenesis’	  midpoint,	  and	   progressively	   decreasing	   levels	   when	   astrogenesis	   is	   about	   to	   reach	   its	   peak	  level.	   Moreover,	   we	   have	   to	   perform	   in	   utero	   electroporation	   of	   Foxg1-­‐GOF	   and	  




As	   reported	   above,	   a	   key	   determinant	   of	   cortico-­‐cerebral	   astrogenic	   rates	   is	  the	  accurate	  sizing	  of	  the	  proliferating	  astrogenic	  pool.	  In	  this	  context,	  a	  special	  role	  is	  played	  by	  the	  Egf	  signaling	  axis	  and	  Fgf9,	  as	  key	  promoters	  of	  astrogenesis.	  Despite	  of	  saturating	  levels	  of	  Tgfa/Egf	  ligands	  throughout	  the	  embryonic	  life	  (Assimacopoulos	  et	   al.,	   2003;	   Burrows	   et	   al.,	   1997),	   EgfR	   expression,	   very	   low	   in	   the	   early	   pallium,	  progressively	  increases	  as	  neuronogenesis	  proceeds	  (Burrows	  et	  al.,	  1997;	  Viti	  et	  al.,	  2003)	  and	  our	  data	  not	  shown).	  This	  limits	  the	  pallial	  competence	  to	  activate	  the	  Egf	  signaling	  axis,	  at	   least	  up	  to	  birth	  (Burrows	  et	  al.,	  1997).	  Similarly,	  Fgf9	  expression,	  prominent	   after	  birth,	   is	   very	  poor	  during	  prenatal	   life,	  when	   it	   results	   limiting	   for	  glioblasts	  proliferation	  (Seuntjens	  et	  al.,	  2009).	  Here	  we	  demonstrated	  that	  Emx2	  acts	  as	  a	  master	  gene	  coordinating	  proper	  temporal	  progression	  of	  both	  EgfR	  and	  Fgf9.	  Emx2-­‐dependent	   repression	   of	   EgfR	  was	   previously	   documented	  within	   the	  developing	   urogenital	   apparatus	   (Kusaka	   et	   al.,	   2010).	   Here	   we	   found	   that	   it	   also	  occurs	  within	  the	  astrogenic	  lineage.	  Conversely,	  Emx2-­‐dependent	  repression	  of	  Fgf9	  is	  a	  fully	  novel	  finding.	  Here	  we	  provided	  evidence	  that	  both	  EgfR	  and	  Fgf9	  regulation	  rely	  on	  Emx2-­‐dependent	   increase	  of	  Bmp	  signaling	  and	  dampening	  of	  Sox2.	  Finally,	  we	   showed	   that	   time	   course	   progression	   of	   Emx2	   levels	   in	   cortico-­‐cerebral	   NSCs	  contributes	  to	  postpone	  the	  bulk	  of	  astrogenesis	  to	  postnatal	  ages.	  
Emx2	   regulation	   of	   astrogenesis	   adds	   to	   a	   number	   of	   earlier	   developmental	  processes	  mastered	  by	  this	  gene,	  including	  pancortical	  specification,	  neuronogenesis,	  arealization	  and	  lamination	  (Mallamaci	  et	  al.,	  2000a,	  2000b,	  Muzio	  et	  al.,	  2002,	  2005).	  It	  points	  to	  Emx2	  as	  a	  potential	  therapeutic	  tool	  for	  the	  control	  of	  reactive	  astrogliosis	  (Sofroniew,	  2009)	  and	  competitive	  diversion	  of	  neural	  precursors	  to	  neuronogenesis,	  for	  purposes	  of	  brain	  repair	  (Burns	  et	  al.,	  2009).	  	  Moreover,	  these	  findings	  inspired	  us	  to	   exploit	   Emx2	   as	   a	   possible	   tool	   for	   the	   treatment	   of	   glioblastoma	   multiforme	  tumor,	  which	  constitutes	  the	  third	  part	  of	  this	  work.	  	  	  
	   ******	  
 	   As	   for	   the	   last	   part	   of	   this	  work,	  we	   showed	   that	  Emx2	  overexpression	   in	   a	  number	   of	   GBM	   cultures	   forced	   them	   to	   collapse,	   by	   promoting	   cell	   death	   and	  inhibiting	   cell	   proliferation.	   Emx2	   impact	   on	   GBM	  metabolism	   was	   complex	   and	   a	  number	  of	  genes	  and	  pathways	  sensitive	  to	  its	  overexpression	  were	  co-­‐involved	  in	  its	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antitumoral	   activity.	   Remarkably,	   such	   activity	   was	   confirmed	   in	   vivo,	   upon	  transplantation	   of	   conditionally	   engineered	   tumor	   cells	   into	   the	   neocortical	  parenchyma	  of	  mouse	  neonates	  and	  juvenile	  immunotolerant	  mice.	  Last	  but	  not	  least,	  restricting	   Emx2	   overexpression	   to	   presumptive	   tumor	   stem	   cells	   replicated	   the	  outcome	  of	  generalized	  gene	  overexpression.	  	  Multiple	   bodies	   of	   correlative	   data	   suggest	   that	  EMX2	  downregulation	   could	  contribute	   to	   the	   genesis	   of	   GBMs.	   The	   COSMIC	   database	   (http://cancer.sanger	  .ac.uk/cosmic)	  reports	  two	  distinct	  homozygous	  EMX2	  deletions	  occurring	  in	  2	  out	  of	  801	  gliomas	  (data	  not	  shown).	  Analysis	  of	  Allen	  Brain	  -­‐	   Ivy	  Glioblastoma	  Atlas	  data	  showed	   us	   that	   EMX2-­‐mRNA	   levels	   are	   specifically	   reduced	   by	   ≥2-­‐folds	   in	   GBM	  tumors	  with	  respect	  to	  surrounding	  tissue	  (Suppl.	  Fig.	  S.12).	  Next,	   in	  the	  majority	  of	  glioblastoma	   cultures	   analyzed	   in	   the	   present	   study,	   endogenous	  EMX2-­‐mRNA	  was	  undetectable.	   When	   it	   was	   present,	   its	   level	   was	   lower	   than	   in	   astrogenic,	   fetal	  cortico-­‐cerebral	   NSCs	   (Suppl.	   Fig.	   S.13).	   Finally,	   a	   consistent	   scenario	  was	   found	   in	  acutely	   immunopanned	   GBM	   astrocytes,	   compared	   to	   astrocytes	   purified	   from	   the	  surrounding	  healthy	  tissue	  (Zhang	  et	  al.,	  2016).	  Albeit	  intriguing,	  all	  these	  correlative	  data	  are	  obviously	  not	   sufficient	   to	  draw	   firm	  conclusions	  about	  EMX2	  role	   in	  GBM	  etiopathogenesis,	  which	  was	  out	  of	  the	  aims	  of	  the	  present	  study.	  Nevertheless,	  our	  data	   suggest	   that,	   regardless	   of	   its	   role	   in	   the	   oncogenic	   process,	   Emx2	  may	   be	   a	  powerful	  tool	  for	  counteracting	  GBM	  tumors.	  	  Subject	  of	  this	  study	  were	  two	  established	  GBM	  cell	  lines	  (U87MG	  and	  T98G)	  and	  five	  tumor	  cultures	  derived	  from	  operated	  GBM	  patients.	  Promisingly,	  all	  of	  them	  robustly	  responded	  to	  Emx2	  and	  rapidly	  collapsed,	  because	  of	  defective	  proliferation	  and	  exaggerated	  cell	  death	  (Fig.	  R.12	  and	  Suppl..	  Fig.	  S.8).	  	  Noticeably,	   their	   molecular	   responses	   were	   complex	   and	   not	   stereotyped	  (Table	  R.1),	   possibly	   reflecting	  GBM	  etiopathogenetic	  heterogeneity	   (Brennan	  et	   al.,	  2013;	   Sturm	   et	   al.,	   2014;	   Verhaak	   et	   al.,	   2010)).	   The	   vast	   majority	   of	   molecular	  changes	  evoked	  by	  Emx2	  were	  consistent	  with	   its	  antitumor	  activity	   (Table	  R.1	  and	  
Fig.	   R.13),	   a	   selection	   of	   them	   was	   proven	   to	   be	   instrumental	   to	   it	   (Fig.	   R.14).	  However,	  in	  no	  case,	  counteracting	  each	  of	  these	  changes	  could	  fully	  restore	  original	  kinetic	  properties	  of	  the	  cultures	  (Fig.	  R.14).	  All	  this	  means	  that	  Emx2	  antioncogenic	  efficacy	  may	  emerge	  as	   a	   consequence	  of	   its	   ability	   to	   attack	  a	  variety	  of	  metabolic	  nodes	  crucial	  to	  malignancy.	  In	  addition	  to	  a	  robust	  inhibition	  of	  GBM	  expansion,	  this	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ability	   might	   help	   preventing	   selection	   of	   drug-­‐resistant	   clones	   and	   recurrencies.	  Intriguingly,	  a	  number	  of	  Emx2-­‐repressed	  and	  -­‐stimulated	  genes	  reported	  above	  are	  the	   very	   same	   affected	   by	   duplications	   and	   deletions	   in	   late	   stage	   glioma	   cancers,	  respectively	  (Brennan	  et	  al.,	  2013).	  This	  further	  suggests	  that	  our	  manipulation	  could	  be	   therapeutically	   effective	   on	   a	   variety	   of	   high	   grade	   gliomas,	   regardless	   of	   their	  primary	  molecular	  origin.	  	  Remarkably,	   Emx2	   overexpression	   elicited	   a	   pronounced	   anti-­‐GBM	   activity	  even	  in	  vivo	  (Fig.	  R.15	  and	  Fig.	  R.16).	  This	  was	  found	  by	  cotransplanting	  conditionally	  engineered	  tumor	  cells,	  alternatively	  expressing	  Emx2	  or	  a	  control	  transgene,	  into	  the	  cortical	   parenchyma	   of	   wild	   type	   mouse	   pups	   and	   scoring	   the	   outcome	   one	   week	  later.	   This	   is	   a	   novel	   experimental	   setup,	   allowing	   to	   preliminarly	   assess	  antioncogenic	   power	   in	  vivo,	   quickly,	   in	   an	   immunocompetent	   environment,	   and	   in	  the	   presence	   of	   strong	   progliogenic	   cues.	   	   Consistently,	   juvenile	   immunotolerant	  mice,	   transplanted	   by	   engineered	   human	   U87MG	   cells	   according	   to	   the	   classical	  orthotopic	  approach	  (Higgins	  et	  al.,	  2013),	  underwent	  a	  pronounced	  increase	  of	  their	  average	   survival	   time	   upon	  Emx2	   overexpression.	   Finally,	   of	   particular	   therapeutic	  interest	   is	   the	   fact	   that	   a	   collapse	   of	   engineered	   GBM	   cultures	   also	   occurred	  when	  
Emx2	  overexpression	  was	  restricted	  to	  Nes-­‐p+	  precursor	  cells	  (Fig.	  R.17).	  These	  cells,	  in	   fact,	   are	   likely	   to	   include	   tumor	   initiating	   cells	   (TICs),	   from	   which	   tumor	  recurrencies	  are	  supposed	  to	  originate.	  Such	  cells	  may	  escape	  even	  the	  attack	  by	  the	  most	  advanced	  oncolytic	  vectors	  developed	  against	  GBM.	  	  All	   these	   results	   point	   to	  Emx2	  as	   a	   novel,	   promising	   tool	   for	   GBM	   therapy.	  However,	  for	  this	  purpose,	  the	  study	  of	  interaction	  of	  Emx2	  overexpression	  with	  the	  standard	   therapy	   for	   GBM,	   as	   well	   as	   the	   selection	   of	   a	   more	   appropriate,	   not-­‐genotoxic	   vectors	   for	   gene	   delivery,	   are	   mandatory.	   Moreover,	   an	   in	   depth	  exploration	  of	  mechanisms	  mediating	  Emx2	  activity,	  by	  unbiased	  GBM	  transcriptome	  profiling,	   is	   also	   due.	   These	   issues	   are	   the	   subject	   of	   a	   dedicated	   follow-­‐up	   study,	  currently	  running	  in	  our	  lab.	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6.	  SUPPLEMENTARY	  MATERIAL	  
	  
	  
6.1	   SUPPLEMENTARY	  RESULTS	  AND	  DISCUSSION	  
	  
Evaluating	   the	   Emx2	   expression	   gain	   elicited	   in	   cortico-­‐cerebral	   multipotent	  
neural	  precursors	  at	  astrogenesis	  peak	  times.	  	  	   To	  compare	  the	  outcome	  of	  our	  artificial	  manipulation	  of	  Emx2	  levels	  with	  the	  physiological	  dynamics	  of	  this	  gene	  in	  ageing	  neural	  precursors,	  we	  coinfected	  E12.5	  cortico-­‐cerebral	   precursors	   with	   constitutively	   active	   LV:pPgk1p-­‐rtTA2S-­‐M2	   and	  LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP.	   We	   kept	   them	   in	   culture	   for	   7	   days	   under	   GFs	   plus	  additional	  4	  days	  under	  GFs	  and	  doxycyclin,	  and	  finally	  compared	  them	  with	  controls	  by	   qRTPCR.	  Emx2-­‐mRNA,	   normalized	   against	  Gapdh,	   resulted	   to	   be	   upregulated	   by	  33.4±7.5	  folds	  (p<0.007;	  n=3).	  	   Remarkably,	   Emx2	   products	   are	   mainly	   confined	   to	   multipotent	   precursors	  and	   their	   immediate	   derivatives	   within	   the	   apical	   proliferative	   compartment	  (Mallamaci	  et	  al.,	  1998,	  and	  http://developingmouse.brain-­‐map.org).	  Moreover,	  such	  cells	  amount	  to	  about	  7%	  of	  primary	  cerebral	  cultures	  set	  up	  with	  a	  protocol	  similar	  to	   the	  present	  one	   (see	   (Brancaccio	   et	   al.,	   2010),	  Fig.	  R.8).	  All	   this	   suggests	   that,	   in	  control	  conditions,	  multipotent	  precursors	  within	  our	  neural	  cultures	  should	  express	  
Emx2	  at	  levels	  about	  100/7	  higher	  than	  the	  average	  level	  estimated	  for	  the	  whole	  cell	  population.	  	   Consequently,	  the	  gain	  of	  Emx2	  expression	  we	  elicited	  within	  these	  precursors	  could	  be	  approximately	  calculated	  by	  dividing	  the	  Emx2	  expression	  gain	  as	  evaluated	  over	  the	  whole	  population,	  33.4±7.5,	  by	  the	  ratio	  between	  the	  baseline	  Emx2	  level	  in	  multipotent	   precursors	   and	   the	   average	   baseline	   level	   in	   the	   whole	   population,	  100/7.	   Therefore	   it	   should	   be	   close	   to	   33.4/(100/7),	   i.e.	   2.3.	   Interestingly,	   the	  reciprocal	   of	   this	   value	   is	   similar	   to	   the	   variation	   of	  Hes5-­‐normalized	  Emx2-­‐mRNA	  levels	   we	   detected	   in	   the	   cortex	   between	   E16.5	   and	   E18.5	   (Fig.	   R.10	   A-­‐C).	   This	  suggests	  that	  our	   lentiviral/TetON	  transgene	  could	   largely	  compensate	   for	  the	  drop	  of	   Emx2	   expression	   which	   occurs	   in	   multipotent	   precursors	   at	   the	   time	   of	   the	  neuronogenic-­‐to-­‐astrogenic	  transition.	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6.2	   SUPPLEMENTARY	  FIGURES	  
	  
	  
Supplementary	   Figure	   S.1.	   Aldolase	   C	   and	   CNPase	   expression	   within	   the	   S100b+	  














Supplementary	   Figure	   S.2.	   Reduced	   astrocytogenesis	   upon	   Emx2	   overexpression,	   in	  


















Supplementary	  Figure	  S.3.	  Proliferation	  rates	  within	  the	  astrogenic	  lineage	  upon	  Emx2	  

































Supplementary	   Figure	   S.5.	   Absence	   of	   EgfR/Fgf9	   cross-­‐talk	   in	   Emx2-­‐GOF	   	   neural	  


















Supplementary	   Figure	   S.6.	  Brn2	   rescues	  Emx2-­‐dependent	  Fgf9	   downregulation.	  Fgf9-­‐mRNA	   levels	   in	   preparations	   of	   E12.5	   cortico-­‐cerebral	   precursors,	   acutely	   infected	   with	  LV:Pgk1p-­‐rtTA2S-­‐M2	   (a-­‐d),	   LV:TREt-­‐IRES2-­‐EGFP	   (a,b),	   LV:TREt-­‐Emx2-­‐IRES2-­‐EGFP	   (c,d)	   and	  LV_TREt-­‐Brn2	  (b,d),	  grown	  in	  anti-­‐differentiative	  medium	  and	  subsequently	  (DIV8)	  exposed	  to	  doxycyclin	  (a-­‐d).	  p(Emx2/Brn2	  interaction,	  2-­‐ways	  ANOVA)<0.12.	  Data	  double-­‐normalized	  against	  Gapdh	  and	  sample	  (a).	  Scalebar	  =	  s.e.m.	  	  	  
 
Supplementary	  Figure	  S.7.	  Comparison	  of	  Emx2/EMX2	  protein	  levels	  in	  U87MG	  cells	  in	  





Supplementary	   Figure	   S.8.	   Evaluation	   of	   G1-­‐to-­‐S	   phase	   progression	   of	   U87MG	   GBM	  














Supplementary	  Figure	  S.10.	  Balanced	  survival	  of	  Egfp-­‐	  and	  mCherry-­‐labelled	  GBM	  cells	  







Figure	  S.11.	  Restriction	  of	  Nes-­‐p	  promoter	  activity	  to	  embryonic	  neural	  stem	  cells	  and	  




Supplementary	   Figure	   S.12.	   Expression	   levels	   of	   EMX2	   and	   GAPDH,	   GFAP	   and	   TBP	  









Supplementary	  Figure	  S.13.	  Relationship	  between	  endogenous	  EMX2-­‐mRNA	  levels	  and	  







Supplementary	  Figure	  S.14.	   In	  silico	  prediction	  of	  EMX2-­‐binding	  sites	   in	  genes	  down-­‐
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